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“THE MICROBE is so very small
You cannot make him out at all
But many sanguine people hope
To see him through a microscope.
His jointed tongue that lies beneath
A hundred curious rows of teeth;
His seven tufted tails with lots
Of lovely pink and purple spots,
On each of which a pattern stands,
Composed of forty separate bands;
His eyebrows of a tender green;
All these have never yet been seen–
But Scientists, who ought to know,
Assure us that is must be so...
Oh! let us never, never doubt
What nobody is sure about!”
Hilaire Belloc
THE UNIVERSITY OF SHEFFIELD
Abstract
Faculty of Pure Sciences
Department of Biomedical Sciences
Doctor of Philosophy
by Guy Yealland
Mutations in parkin cause autosomal recessive Parkinsonism and mitochon-
drial defects. A recent drug screen identified a steroid like class of hydropho-
bic compounds able rescue mitochondrial function in mutant parkin fibroblasts.
These included Ursolic Acid, Ursocholanic Acid, and Ursodeoxycholic Acid.
pH-sensitive polymersomes, nanoparticles composed of amphiphilic block co-
polymer, have been shown to encapsulate hydrophobic cargoes, enter cells
without detriment to viability and release their cargoes therein. PMPC25−PDPA65
nanoparticles successfully encapsulating drugs were made by thin film rehy-
dration, and purified by hollow fibre filtration. High encapsulation efficiencies
were revealed by HPLC. Particle characterisation by and Transmission Elec-
tron Microscopy revealed a spectrum of morphologies, including spherical par-
ticles, branched tubular assemblies, and large high genus lyotropic structures.
Morphological fractionation was achieved through stepwise centrifugation, and
mass quantification showed drug encapsulation increased the relative propor-
tion of tubular assemblies. Polymersomes were found to enter into parkin mu-
tant fibroblasts without cytotoxic induction, or detriment to mitochondrial func-
tion as assessed by LDH release, mitochondrial membrane potential and cellu-
lar ATP levels. Drug loaded polymersomes of both spherical and tubular mor-
phology increased cellular ATP levels of parkin mutant fibroblasts, and were
found to deliver a fluorescent steroid at least as effectively as DMSO. The re-
sults presented here suggest PMPC-PDPA nanoparticles are suitable for use
as a therapeutic vector in parkin mutant cells. The production of spherical and
tubular nanoparticle morphologies would be of interest to in vivo applications,
each being known to show distinct properties affecting nanoparticle distribution
within the body.
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Chapter 1
Introduction
1.1 Parkinson’s Disease
Parkinson’s Disease (PD) is the second most common neurodegenerative dis-
ease, affecting 1% of the western world’s population. It most commonly occurs
in persons over 60 years of age, and subsequently its prevalence is projected
to increase as the aged population continues to grow in the western world [1].
PD is characterised by the progressive loss of voluntary movement, balance,
as well as the variable development of non-motor symptoms such as cognitive
decline, compulsions and insomnia [2]. The life expectancy of patients is similar
to those free of PD and the disease course is typically slow. As the symptoms
worsen, increasing levels of therapy and care must be given to manage the dis-
ease, which, taken with its prevalence and duration, makes PD a substantial
personal, social and economic burden. Currently therapies offer symptomatic
relief only. However progress is being made towards understanding the under-
lying aetiology and developing treatments that will target this directly, to slow or
halt the disease course.
Common to all PD is the loss of cells from the Substantia Nigra (SN) of the pa-
tient’s midbrain, most markedly, pigmented dopaminergic neurons [3, 4]. These
neurons form an important part of the basal ganglia, a series of circuits within
1
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the brain that act to permit or deny the initiation of bodily movements. Their loss
is believed to underly Parkinsonian impairment to movement. Histopathological
studies have also revealed the presence of proteinacious inclusions known as
Lewy Bodies (LB) and Lewy Fibrils within surviving neurons of the midbrain and
other brain regions [5]. The specific role these play in PD is still debated. Whilst
both loss of dopaminergic neurons and the presence of LB is necessary to the
histopathological diagnosis of PD, their severity varies greatly between patients
and may occur independently of one another. For instance, mutations in parkin
cause a familial Parkinsonism typically absent of LB [6], whilst dementia with
LB may present without Parkinsonian features [7].
1.1.1 Current clinical and experimental therapeutic
strategies for Parkinson’s Disease
Therapies in current clinical use for PD aim to replace or compensate the loss
of dopaminergic neurons, which though failing to address the ongoing neuro-
degeneration, are effective in alleviating some PD symptoms. Medication artifi-
cially raising levels of dopamine, or inducing dopamine like activity in the brain
has proven effective in relieving motor symptoms [8, 9]. However, long term ad-
ministration can lead to diminishing therapeutic effect and motor, cognitive and
systemic complications [9, 10].
Attempts have been made to replace those neurons lost in the SN. Transplants
from neural progenitors to the patient striatum have yielded some positive,
though variable results in symptomatic relief [11]. However evidence of true
neuron replacement is currently lacking. Further, there is evidence that the
existing PD pathology is able to spread from effected cells to those newly intro-
duced, leading to the eventual re-emergence of disease symptoms [12]. Whilst
work continues to resolve such issues [13], their complexity and the availability
of stem cells will continue to hold back this approach.
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Other currently experimental approaches aim to slow or prevent the on-going
neurodegeneration in PD. Neurotrophic factors are small proteins that have long
been recognised as a potential therapeutic agent for neurodegenerative disor-
ders, exerting pro-survival effects and inducing neuronal growth [14]. As neu-
rotrophic factors are unable to penetrate into the Central Nervous System (CNS)
from systemic circulation, application directly into the brain is necessary. Whilst
infusion via catheter to the striatum of PD animal models has proven effective
in preventing loss of dopaminergic cells and motor function, similar attempts
in humans have been inconsistent, possibly due to greater populations of neu-
rotrophic factor receptors, greater brain volume and/or method of administration
[15, 16]. New human trials are currently underway in which implants will be used
to improve the delivery of promising neurotrophic factors to the desired site of
action. It is hoped this will resolve previous inconsistencies in clinical trials [17].
Therapies that target the brain from routes of administration that avoid exter-
nally penetrating the brain will be both less dangerous to the individual and
easier to implement. Recombinant genes packaged within modified viruses
are being explored as a way to locally and specifically up- or down- regulate
disease-modifying proteins in vivo [18]. Though the effects of gene therapies
do vary, particularly in mitotic cells, their duration of effect and potential effi-
cacy greatly exceeds many exogenous therapies. There are however certain
safety complications associated with the use of modified viruses, including in-
creasing immunogenicity with repeated use, infection of inappropriate tissue
and cytotoxicity. Appropriate modifications and tailored dosing can limit or re-
move these and numerous human trials have proven various viral therapies to
be both safe and therapeutically effective [19, 20]. Data from an ongoing clinical
trial using lentiviral vectors loaded with three genes encoding dopamine synthe-
sising enzymes has shown both good long term safety profiles and symptomatic
improvement in PD patients, succeeding where single gene approaches have
failed [19, 21]. Though administration occurred by direct injection into patient
midbrains, benefits were seen 6 months after treatment, suggesting long term
effects of gene translation. This approach again targets the loss of dopamine in
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PD rather than the cause of neurodegeneration. Gene therapies for PD based
on neurotrophic factors have so far proved safe in clinical trials, but lack the
necessary therapeutic efficacy even following direct injection into the SN to be
of clinical use [19].
Though PD is primarily a sporadic disorder with no one clear cause, investi-
gation of environmental and genetic factors linked to the disease have brought
to light a number of molecular pathways now implicated in the pathogenesis
[22, 23]. Potential therapeutic targets that could slow or prevent the progressive
neurodegeneration seen in PD have subsequently been identified. Great efforts
have gone into finding small molecules that affect one or more of these targets,
demonstrate therapeutic action, and which are able to penetrate the brain from
systemic circulation. Whilst compounds may appear effective in disease mod-
els, they frequently fail to enter into clinical relevance. Two possible reasons
for this are (1) the models of PD used do not accurately represent the disease
in human patients, and (2) that the small molecules are unable to accumulate
within the brain at therapeutically relevant concentrations. Herein the role of
mitochondrial dysfunction in PD and the therapeutic potential of therapies that
target this are discussed.
1.1.2 The Mitochondria
Mitochondria are a semi-continuous organelle found in almost all eukaryotic
cells, whose predominant role is to enhance the cells Adenosine Triphosphate
(ATP) production capacity, the cells primary “energy currency” [24]. They also
regulate and/or take part in a number of physiological pathways. Mitochon-
dria are double membraned compartments, the outer mitochondrial membrane
(OMM) being planar and the inner mitochondrial membrane (IMM) extending
tubular protrusions into the mitochondrial lumen, also known as the matrix. At
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the µm scale, they appear throughout the cell as a highly dynamic network un-
dergoing continuos “fusion” 1 and “fission” 2 [25, 26].
Mammalian cells are able to produce ATP by glycolysis, a series of cytosolic
reactions that convert sugars such as glucose or lipid metabolites to pyruvate,
generating ATP and NADH molecules in the process [27]. Following glycolysis,
pyruvate can be transported into the mitochondrial matrix, where it, along with a
number of other metabolites, enter the citric acid cycle (also known as the Krebs
cycle) to produce NADH and FADH2. FADH2 is also produced by β oxidation of
fats. NADH and FADH2 are respectively oxidised by complexes I (also known as
NADH dehydrogenase) and II (also known as succinate dehydrogenase), pro-
tein complexes imbedded within the IMM, to NAD+ and FAD. Their freed elec-
trons are passed into the complexes initiating the mitochondrial electron trans-
port chain (ETC). The respiratory complexes undergo a number of redox reac-
tions, passing electrons along their subunits sequentially, driving the transloca-
tion of H+ ions into the inter membranous space (IMS) as they do so. Electrons
are then passed to Coenzyme Q10 (also known as ubiquinone), which in turn
transfers them to Complex III (also known as coenzyme Q oxidoreductase), and
a further series of redox reactions take place, driving more H+ ions into the IMS.
Complex III transfers electrons to cytochrome C which in turn passes them to
Complex IV (also known as cytochrome C oxidase). Finally Complex IV trans-
fers electrons to split O2 molecules, producing two water molecules and driving
the import of yet more H+ cations into the IMS. The large proton gradient gen-
erated by the ETC, the Mitochondrial Membrane Potential (MMP), is utilised by
Complex V (also known as ATP synthase) to generate ATP molecules. Pro-
tons diffuse into the IMS facing pore of Complex V and translocate through
the complex into the mitochondrial matrix, driving conformational changes that
catalyse the anabolism of Adenosine Diphosphate (ADP) and inorganic phos-
phate bound to the complex’s matrix face. This process is collectively known
as mitochondrial Oxidative Phosphorylation (OXPHOS) (summarised in figure
1Mitochondrial fusion; in which separate mitochondrial sections combine
2Mitochondrial Fissioin; in which a section of mitochondria splits and separates
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1.1), and generates ATP with great efficiency. A single glucose molecule will
for instance provides enough energy to generate 36 ATP molecules [27]. Some
heat is also generated as a by product as a result of ineffective electron trans-
fers, and electron flow back to the matrix when not through Complex V. Matrix
ATP and cytosolic ADP are then exchanged, and the ATP is used throughout the
cell where the catalysed transfer of its phosphates to various cell components
induce conformational and chemical changes that regulate many physiological
processes.
FIGURE 1.1: Mitochondrial OXPHOS and ROS generation: Orange arrows
show glycolysis, purple arrows show ROS generation and handling, pink ar-
rows show products of reactions with respiratory complexes, dashed blue line
shows flow of electrons through the ETC, and dashed green lines show the
flow of protons. Adapted from Mailloux and Harper 2012, with permission [33]
OXPHOS can be modified for specific cellular processes, for instance proteina-
cious uncouplers may be inserted into the IMS, allowing protons to leak back
into the matrix decreasing Complex V derived ATP production. Mitochondrial
uncoupling increases the mitochondrial OXPHOS kinetics, and generates more
heat than when the ETC is tightly coupled, as seen in thermogenic brown adi-
pose tissue [28]. Uncoupling may also limit the production of Reactive Oxy-
gen Species (ROS), Ca2+of which the mitochondria are the primary generators.
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Electrons transported through the respiratory complexes are capable of “leak-
ing” out of the ETC, directly to oxygen creating O·–2 [29, 30]. This typically occurs
from complexes I, III or coenzyme Q10. Mutations causing loss of OXPHOS ca-
pacity have been shown to increase mitochondrial ROS generation [31, 32].
Oxygen radicals can be converted into the less reactive H2O2 by Superoxide
Dismutase (SOD) enzymes, which in turn can be converted to water by cytoso-
lic or mitochondrial Glutathione peroxidase 1 (GPx-1). There are also a number
of free radical scavengers present within the cell such as glutathione which se-
quester excesses of free radicals. Whilst ROS generation is natural and indeed
plays important roles in signalling pathways, excesses beyond a cell’s antiox-
idant capacity can lead to cumulative damage to DNA among other cellular
components and eventually lead to cell death [33]. Certain uncoupling proteins
are activated by ROS and/or their by-products [34], inducing a proton leak that
associates decreased ROS production, however the physiological relevance of
this contentious [33, 35].
Mitochondria act as an important, though relatively small reservoir for Ca2+ ions,
a second messenger that must be kept at low concentrations in the cytosol to
correctly regulate its actions [36]. Mitochondria along with other calcium stores
have been found in close apposition to sites of high calcium flux such as neural
synapses, where its buffering role has a significant effect despite its limited
capacity and calcium uptake kinetics [37]. Calcium is also known to induce
ATP production, despite the MMP lowering effect of introducing a cation to the
matrix, allowing Ca2+ to couple regions of high energy demand to high ATP
production in the mitochondria [38]. Calcium overload in the mitochondria has,
however been observed to lead to excess ROS generation and opening of the
mitochondrial permeability transition pore (mtPTP), which allows the dissipation
of matrix ions and the MMP, as well as the release of pro-apoptotic factors
[39, 40].
Permeabilisation of the OMM results in the release of IMS proteins including
pro-apoptotic factors such as cytochrome c and Apoptotic protease activating
factor 1 (APAF1), which activate the caspase cascade that ultimately results
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in “cell suicide” [41]. Mitochondria and mitochondrial health are thus essen-
tial to cell survival, even in cells relatively independent of OXPHOS generated
ATP. Numerous proteins act as regulators of mitochondrial permeability includ-
ing Bcl-2 and Bcl-XL [42]. It is also notable that both pro- and anti- apoptotic
proteins are involved in other aspects of mitochondrial physiology [43].
During apoptosis, the mitochondrial network fragments as it undergoes exten-
sive fission [42]. Numerous proteins are involved in the fusion and fission of
the mitochondrial network, and mutations are seen to cause impaired energy
production and specific neurodegenerative diseases [25]. There are indications
mitochondrial dynamics play a part in normal energy metabolism. For instance
widespread fusion is seen under cellular stress and accompanies increased in-
tracellular ATP content, perhaps the result of improved distribution of various
respiratory components [44]. Dynamics also play an important role in the mo-
bility of mitochondria through the cell, such as in neurons where mitochondria
must present at numerous distant locations of changing energetic need [45]. It
also allows discrete sections of damaged mitochondria to be sequestered by
fission from the bulk organelle, and targeted for autopahgy in a process known
as mitophagy [44, 46].
As defective sections of the mitochondria are removed, so to are new sections
created to match the cells energetic needs. This is regulated by numerous fac-
tors and requires the concerted transport of lipids and proteins plus mtDNA
replication. The PPRγ coactivator 1 (PGC1) family of proteins are master reg-
ulators of mitochondrial biogenesis [47]. Upregulation of PGC1 -α and -β have
been shown to increase mtDNA synthesis and mitochondrial gene expression
[48], whilst inactivation results in decreased expression and mitochondrial func-
tion [49]. The PGC family regulate a number of proteins involved in the regu-
lation of mitochondrial genes including Nuclear respiratory factor (NRF) -1 and
-2, Peroxisome proliferator-activated receptor gamma (PPAR-γ) which is also
involved in lipid homeostasis and estrogen related receptors that also indirectly
stimulate mitochondrial biogenesis [50? , 51]. Numerous signalling pathways
have been shown to induce mitochondrial biogenesis in an at least partly PGC1
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dependent manner [52]. These include; the AMPK pathway triggered by low in-
tracellular ATP levels, Ca2+ signalling, cAMP signalling, nitrous oxide signalling,
and neurotrophic factors.
Though mtDNA encodes for 37 locally transcribed genes, including tRNAs and
ETC proteins, the majority of mitochondrial genes are found in the nucleus [53,
54]. These are translated either with one of several mitochondrial targetting
sequence (MTS) or close association with a chaperone protein. These are
recognised by the Translocase of the OMM (TOM) complex, which initiates their
import into the IMS, wherein further sorting occurs [55].
1.1.3 Mitochondrial dysfunction in PD
Many lines of evidence have linked mitochondrial dysfunction as a common
point in the pathogenesis of sporadic and familial PD. Early evidence came
from work that identified 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP),
a brain penetrant neurotoxin that induces atypical Parkinsonism, as an inhibitor
of Complex I of the mitochondrial ETC [56, 57]. Subsequently, a specific Com-
plex I deficiency was identified in the post mortem SN of PD patients [58].
Similar deficiencies have now also been identified in the frontal cortex, where
evidence has also been found of oxidative damage to both mitochondrial and
nuclear Complex I subunits [59, 60]. Complex I inhibitors such as MPTP and
rotenone are frequently used to induce Parkinsonian-like loss of dopaminergic
neurons in animals to model PD, as is paraquat, a compound found to increase
the production of ROS. Indeed, epidemiological links have been established
between and Parkinsonism and the environmental presence of these and other
compounds believed to impact on mitochondrial function, such as found in cer-
tain fruits and pesticides [23, 61, 62]. Evidence of mitochondrial deficiencies in
tissue other than of the CNS has also been uncovered in a proportion sporadic
cases, suggesting underlying genetic or environmental factors [63, 64].
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It is notable both that ageing is the single greatest risk factor for PD, and that
mitochondrial function declines with age as mutations accumulate within the
mitochondrial DNA (mtDNA) [24, 65]. Though there is no strong evidence that
mutations in mtDNA are causative of PD, there are indications of their involve-
ment [23]. For instance, mutations in POLG, a DNA polymerase that plays an
important role in proof reading mtDNA for replication errors, have been shown
to co-segregate with PD in some families [66]. Mutations in this gene produce
increased accumulation of mtDNA mutations over time. Post mortem analysis of
SN from patients with pathogenic mtDNA mutations found widespread deficien-
cies in complexes I and IV, but marked neuronal loss only in patients with POLG
mutations [67]. Post mortem analysis of neurons from PD patients has revealed
increases in mtDNA mutations relative to controls of dopaminergic neurons of
the SN, but not hippocampal or cortical neurons, suggesting a specific vulner-
ability and sensitivity [68, 69]. Seven of the subunits composing Complex I are
encoded in mtDNA, more than double any other complex of the ETC, and could
explain why it is more susceptible to mutations.
Mitochondria, as the primary centres for ATP anabolism, the formation and re-
sponse to ROS, calcium buffering and apoptosis [24], have proven particularly
involved in the physiology and pathogenesis of the SN’s dopaminergic neurons
[70, 71]. Firstly, like all neurons they have a high energy demand to sustain
the continuous function of these very long post mitotic cells [70]. Dopaminergic
neurons of the SN possess an atypically large and unmyelinated axonal arbor,
at least ten fold larger than other dopaminergic neurons, for which it is predicted
they have greater energetic demands [72]. It is also notable that mitochondrial
biogenesis plays an important role in the maintenance and formation of den-
dritic processes [73].
Secondly, in contrast to neighbouring dopaminergic neurons, those in the SN
are exposed to a continuous influx of calcium due to their spontaneous pace-
making activities [74, 75]. It is recognised that calcium promotes mitochondrial
oxidative phosphorylation, so may exacerbate mitochondrially related dysfunc-
tion [76]. In keeping, dopaminergic neurons of the SN have been shown to
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possess greater ROS levels than their neighbours, and that this decreases with
attenuated calcium flux [77, 78]. It is also notable that reliance on calcium chan-
nels for pace-making activity in the substantia nigra increases with age [77]
Thirdly, cytoplasmic metabolism of dopamine generates both ROS and quinones,
though this is largely prevented by transporting dopamine into vesicles [79–81].
Mice with deficient dopamine uptake into presynaptic vesicles demonstrate age
related nigrostriatal degeneration with signs of alpha-synuclein inclusions [80].
Mishandling of dopamine could also conceivably occur due to energy deficits.
Partial Complex I activity has been shown to increase the presence of its sub-
strate NADH, an inducer of dopamine biosynthesis, and increased susceptibility
to toxin induced cytosolic release of dopamine [81–83].
1.1.3.1 The genetics of Parkinson’s Disease implicate mitochondrial dys-
function
Whole genome sequencing and linkage analysis of families displaying heritable
forms of PD have identified a number of single gene mutations that cause rare
forms of PD, from which a number of physiological pathways are now been
implicated in the disease pathogenesis (figure 1.2). Roles for the mitochondria
and mitochondrial dysfunction have been implicated in almost all of these [23].
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FIGURE 1.2: Summary of pathogenic pathways in Parkinson’s disease
involving the mitochondria: Taken from Martin et al. 2011, with permission
[22].
Mutations in PTEN-induced putative kinase 1 (PINK1) cause an early onset,
autosomal recessive Parkinsonian syndrome demonstrating a clear Complex I
deficiency [84–86]. Studies have identified a role for PINK1 in maintaining the
functional health of mitochondria. PINK1 is translocated to the IMM where it is
degraded [87]. Where MMP is low, a key indicator of an ineffective ETC and
mitochondrial dysfunction, PINK1 is instead integrated into the OMM where it
plays a role in flagging the organelle for destruction by autophagy; known as
mitophagy [88, 89]. PINK1 deficiencies in mice have been shown to enhance
the susceptibility of dopaminergic neurons to death by MPTP, and that this can
be prevented by expression of parkin, DJ-1 or F-box only protein 7 (Fbxo7)
[90, 91]. Mutations in parkin [92] DJ-1 [93] and FBXO7 [94] are also known
to cause early onset, autosomal recessive Parkinsonian syndromes similar to
those of PINK1.
Tissue from parkin mutant PD patients consistently show lowered ATP levels
and altered mitochondrial morphology, as well as decreased activity of Com-
plex I and a lowered MMP [95–98]. Oxidatively damaged and misfolded Parkin
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has also been found in the brains of sporadic PD patients [99–102]. Parkin,
an E3 ubiquitin ligase, is recruited to the mitochondria by PINK1 localised to
the OMM, an event necessary for the mitophagy of damaged mitochondria, and
which PD causing mutations in parkin compromise [103–105]. However the
relevance of this to highly energetic cells is questionable. For instance it has
been shown that rat midbrain neurons exposed to a highly effective mitochon-
drial uncoupler, failed to demonstrate Parkin translocation to the mitochondria
on loss of MMP [106]. Similarly, while collapse of HeLa cell MMP lead to Parkin-
mitochondrial co-localisation in glucose media, the same is not true when incu-
bated in galactose media, an energy substrate which forces cells to depend
heavily on mitochondrial OXPHOS for their ATP supply [106, 107]. More recent
work has shown Parkin will translocate to depolarised mitochondria in mouse
cortical neurons, but only in the absence of antioxidants within the culture me-
dia, suggesting a greater mitochondrial deficit is perhaps required to initiate this
form of mitophagy in neurons [108].
Concordant to their roles in mitophagy induction, PINK1 and Parkin are also
known to alter mitochondrial transport, effecting the dissociation of a number
of transport proteins from dysfunctional mitochondria [109, 110]. Interestingly,
a role for the PINK1-Parkin pathway in the selective turnover of mitochondrial
respiratory complexes has also been described, suggesting wide roles in the
maintenance of mitochondrial health [111]. It is also notable that mitophagy
has been observed in the absence of parkin and PINK1
Though Parkin induced mitophagy is dependent on PINK1, parkin over-expression
still rescues PINK1 mutant phenotypes [23, 90, 112]. In keeping, an emerging
role for Parkin in the maintenance of mitochondria outside of mitophagy is being
uncovered. As an E3 ubiquitin ligase, it is involved in ubiquitination and subse-
quent proteosomal degradation of numerous substrates, one of which is Parkin
interacting substrate (PARIS) [113]. PARIS is a transcriptional repressor to Per-
oxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α),
a positive regulator of mitochondrial biogenesis [114]. PARIS over-expression
was shown to induce dopaminergic cell death in the SN of adult mice, and was
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mitigated by co-expression of either PGC1α or Parkin [113]. Further, mice in
whom Parkin was KO at 6-8 weeks demonstrated loss of Dopaminergic neu-
rons in a PARIS dependent manner [113].
Recent work has shown that Fbxo7 also translocates to depolarised mitochon-
dria, where it promotes mitophagy through multiple mechanisms, and that PD
causing mutations interfere with this[91]. Fbxo7 was also found to interact di-
rectly with both PINK1 and Parkin, and it’s over-expression to rescue Parkin
null, though not PINK1 null, phenotypes. F-box containing proteins are known
to recruit substrates to E3-ubiquitin ligase complexes [115], indicating a poten-
tial mechanism by which Fbxo7 may perform its roles in mitophagy, and raising
the possibility of further interactions with the Parkin pathway.
DJ-1, a protein possessing structural similarities to a stress inducible chaperone
protein, has been found to respond to and protect against oxidative stress in the
cell [116, 117]. Cells deficient of DJ-1 demonstrate fragmented mitochondrial
networks with deficient MMP, both of which are mitigated by exposure to an-
tioxidants or parkin /PINK1 over-expression, though neither has been shown to
complex with DJ-1 [118, 119]. As with parkin orPINK1, over-expression of DJ-1
protects against rotenone induced alterations to mitochondrial morphology, and
does so even in the absence of PINK1 indicating its actions are independent
[119].
Though the above mutations produce highly penetrant forms of PD, they occur
at exceptionally low frequencies within population and produce an early on-
set form of the disease, calling into question their relevance to the late onset
sporadic forms of the disease [22]. Certain polymorphisms in genes already
linked to autosomal dominant forms of PD on the other hand have also been
identified as risk factors for the disease by unbiased Genome Wide Association
Studies (GWAS) and/or association studies focussed on candidate genes.
Mutations, duplication and triplication in SNCA cause an aggressive autoso-
mal dominant PD of earlier onset [120–122]. Genetic variants have also been
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identified as risk factors [123–125]. SNCA’s protein, α-synuclein, is a nega-
tively charged protein that is able to integrate into phospholipid membranes,
and a major constituent of LBs [126, 127]. It is well expressed in the CNS,
where it is believed to have roles in transcriptional regulations, and neuro-
transmitter release [128–130]. α-Synuclein polymerises into large fibrillar ag-
gregates, intermediate structures of which are recognised as toxic to the cell
[131]. α-Synuclein fibrils or protofibrils also appear to induce further aberrant α-
Synuclein aggregation, and their transport between cells is believed to underlie
the prion like spread such aggregates through the brain [12, 132]. α-Synuclein
is found on and within mitochondria [128, 133, 134]. It is suggested to play a role
in organising membrane dynamics, and in keeping, over-expression has been
shown to induce mitochondrial fragmentation [126, 133, 134]. Models in which
excessive mitochondrial fission is present are noted to show accumulation of
mtDNA mutations, mtDNA depletion, and mitochondrial dysfunction [135]. Sim-
ilarly, α-Synuclein overexpression has been shown to induce oxidative stress,
bioenergetic defects and Complex I deficiencies [136–138].
Mutations in Leucine-rich repeat kinase 2 (LRRK2) number the most common
known cause of autosomal dominant PD, and the only mendelian form of the
disease to present with a typical age of onset and disease course [139, 140].
Like, SCNA, certain LRRK2 haplotypes are also known to increase the risk of
developing PD [123–125]. LRRK2 is a large dimerising protein which functions
as a kinase, GTPase and protein scaffold [23, 141]. While its function in health
and PD are still unknown, disease causing mutations have so far been identified
in regions relating to Kinase and GTPase activity suggesting mis-regulation of
signalling pathways. Over-expression of PD causing LRRK2 mutants causes
cellular toxicity that can be rescued using kinase inhibitors [142, 143]. Fibrob-
lasts derived from LRRK2 mutant PD patients demonstrate lowered MMP and
ETC linked ATP production [144]. LRRK2 protein has been found localised at
the mitochondria within rat brains, and links to functional roles here have been
made [145–147].
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There are also those genes that have been found to contribute toward PD in
an entirely non-mendelian manner. Cumulatively, GWAS have identified more
than 20 gene haplotypes associated with an increased risk of developing PD;
typically with odds ratios of <1.5 [148]. Though their effect is small, these mu-
tations must be present in >5% of the population to be detected by GWAS
suggesting these might play a role in the more common forms of Parkinsonism.
Gene variants of intermediate disease penetrance and population frequencies
have also been identified, however these are rarely identified by GWAS. Identi-
fication thus relies on biassed candidate gene association studies. It is widely
speculated that sporadic PD occurs as the result of one or more genetic sus-
ceptibilities, plus certain environmental factors. In this regard it is notable that
up to 30% of patients have a familial history of the disease [149].
A recent meta-analysis, in which multiple GWAS and candidate gene studies
were combined to increase statistical power, has identified 12 common genomic
loci associated with PD [125]. Of particular interest were SCNA and LRRK2, as
already discussed, MAPT, a gene implicated in other neurodegenerative dis-
eases such as Alzheimer’s Disease (AD). It is also notable that research in-
dicates other hits may interact with pathways responsible for mendelian forms
of PD. For instance SYT11/RAB25 interacts with Parkin, MCCC1/LAMP3 is es-
sential to autophagy, and STK39 is involved in stress signalling and ion home-
ostasis [150, 151]. A polymorphism in beta-glucocerebrosidase (GBA) was also
identified, a gene found by other candidate studies to be the strongest known
genetic risk factor for PD [152].
Homozygous and compound heterozygous mutations in GBA result in the lyso-
somal storage disorder Gaucher’s Disease (GD), a disease which manifests in
a heterogenous fashion, and which is known to associate with typical Parkin-
sonism among other neurological deficits [153]. GBA1 is found in the lyso-
some where it metabolises glucocerebrosidase. Decreased activity is associ-
ated with decreased lysosomal function. Post mortem analysis of sporadic and
GBA mutant PD patient brain’s revealed deficient GBA activity, most dramati-
cally in the substantia nigra [154]. In vitro studies have also shown GBA activity
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decreases with either increased α-synuclein or decreased PINK1 [154]. GBA
knock-out (KO) mice demonstrated midbrain accumulation of α-synuclein ag-
gregates, where deficient autophagic and proteosomal activity were also seen
[155]. In both -/- and -/+ GBA phenotypes, MMP and ETC efficiency were de-
creased and mitochondrial network morphology altered. Defective mitophagy
was clearly established in GBA -/- neurons and astrocytes.
With the advent of next generation sequencing, the number of genes implicated
in PD is expected to increase in the coming years.
1.1.3.2 Rectifying the mitochondrial dysfunction in Parkinson’s Disease
Correcting mitochondrial dysfunction is a promising target for neuroprotective
therapy in PD. The use of creatine in PD has received attention due to the role
this compound plays in the rapid replenishing of intracellular ATP levels, the
apparent bioenergetic deficit seen in PD, and the presence of creatine uptake
transporters in the Blood-Brain Barrier (BBB) [156, 157]. Oral administration
has been shown to protect nigrostriatal cell death in MPTP treated mice and
cells [158, 159]. Early clinical trials in which creatine was administered to PD
patients at 10g/day has proven safe, and indications of a therapeutic effect have
been seen [160]. Given these promising initial results, a five year multi-center
phase III clinical trial in which creatine will be orally administered daily to early
symptomatic PD patients is presently underway [161].
Coenzyme Q10 (CoQ10) is a cofactor of the mitochondrial ETC, accepting elec-
tron from both complexes I and II, and with a potential antioxidant role in its re-
duced form [162]. It has proven protective against MPTP induced dopaminergic
cell death in vitro, preventing the collapse of MMP and excess ROS produc-
tion otherwise seen [163]. Dietary administration of CoQ10 reduces the loss
of nigrostriatal neurons in MPTP treated mice and primates [164, 165]. While
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an initial trial demonstrated therapeutic effects following high dose oral admin-
istration to early symptomatic PD patients [166], a follow up in mid-stage pa-
tients showed no difference from placebo [167]. CoQ10 possesses a Molecular
Weight (MW) >500Da and is highly hydrophobic, both factors associated with
reduced brain penetrance from systemic circulation [168]. Poor water solubility
also leads to poor compound absorption from the gut, thus the clinical failures
of CoQ10 in PD may result from the poor brain distribution.
In an attempt to improve its mitochondrial localisation, CoQ10 has been con-
jugated with the cation triphenylphosphonium (TTP), a molecule found to seg-
regate into polarised (i.e. respiring) mitochondria [169]. Like CoQ10, this too
has proved promising in animal and cell culture models of PD [170, 171], but
has also failed to show a clinical benefits in a double blind trial with PD patients
over a year [172, 173]. Poor brain penetrance is again a probable cause for this.
Idebenone, a synthetic analogue of CoQ10 of lower MW may possess a greater
ability to penetrate the brain from oral administration. It shows highly effective
redox-cycling antioxidant activity and some promise in the treatment of Friedre-
ich’s ataxia, a rare neurological disorder, at early stages of the disease course
[174, 175]. Subsequently its use has been considered for PD, though there is
recent evidence that at µM concentrations it induces apoptosis in dopaminergic
cells, though this could be attenuated by application of antioxidants [176]. A
therapeutic dosing regime will thus require careful determination.
Pioglitazone is a specific agonist of PPAR-γ, marketed as a hypoglycaemic
agent for use in type II diabetes [177, 178]. It has demonstrated partial pro-
tection from MPTP induced cell death, and increased mitochondrial respiratory
function [179, 180]. Its use in 6OHDA treated rats was protective against loss of
dopaminergic neurons in the SN. In MPTP treated primates, Pioglitazone has
also shown clinical improvement of Parkinsonism like features, and a reduc-
tion in oxidative damage in the midbrain [181]. It was suggested Pioglitazone
may produce its therapeutic effect by enhancing glucose metabolism within af-
fected neurons, given the drugs ability to increase insulin sensitivity in other
tissues and the increase in SN glucose demand produced by MPTP treatment
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[182, 183]. Other work has shown that a separate PPAR-γ agonist increases
mitochondrial biogenesis in mouse brains [184]. As it is already in clinical use,
a randomised clinical trial testing the therapeutic effect of Pioglitazone in PD
patients receiving MAO-B inhibitor therapy has been initiated.
Methylene blue, used to treat cyanide poisoning, is able to accept electrons
from NADH and transfer them to mitochondrial cytochrome c, entirely bypass-
ing Complex I [185–187]. It has been shown to protect against rotenone in-
duced dopaminergic neuron loss in rat brains [187]. Its pharmacological pro-
file is well established, and following observations that methylene blue delays
senescence in fibroblasts [186], is currently under phase II clinical trial for AD,
another neurodegenerative disorder in which mitochondrial dysfunction is also
strongly implicated.
The female sex hormone oestrogen has been shown to increase the expression
of nuclear and mitochondrially encoded ETC enzymes, as well as induce direct
interactions between its cytosolic receptor and the mitochondria [188, 189]. Fur-
ther, it also regulates a number of genes involved in neuronal survival, includ-
ing Bcl-2, Bcl-xl and BDNF [190–192]. A recent short term clinical trial for the
safety and tolerability of oestrogen replacement in menopausal women with PD
showed a non-significant trend towards relief of motor symptoms [193]. Inter-
estingly, links have been made between steroid deficiencies and the incidence
of PD [194, 195], including oestrogen [196] and testosterone [197].
1.1.4 Ursolic acid, Ursodeoxycholic acid and Ursocholanic
acid
A recent drug screen performed in human dermal fibroblasts derived from parkin
mutant PD patients, a well characterised model of mitochondrial dysfunction in
PD [95, 96], identified a number of compounds that rescue the phenotypic de-
ficiencies in mitochondrial membrane potential and cellular ATP levels [198].
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Though PD obviously does not result from the cell death of fibroblasts, us-
ing primary patient tissue which expresses identified Parkinson’s genes and
which have experienced similar ageing to the effected regions provides advan-
tages over models in which genetic manipulation is required [199]. As primary
cells, their metabolic profile is also in closer keeping to that seen in vivo, im-
mortalised cells by contrast often demonstrate a greatly increased dependance
on glycolysis. Despite large differences in protein expression and energy utili-
sation, parkin mutant fibroblasts and dopaminergic neurons both demonstrate
similar mitochondrial deficits, such as MMP and cellular ATP deficiencies, as
well as significant alterations in mitochondrial morphology and OXPHOS respi-
ration [95, 96]. The accessibility of fibroblasts makes them well suited to high
content drug screening [198].
Two compounds in particular were selected for follow up studies owing to their
efficacy, availability and known pharmacological profile. These were Ursocholanic
Acid (UCA), a bile acid derivative and dehydro (11,12) ursolic acid lactone
(DUA), a pentacylic triterpene. Literature searches identified structural ana-
logues of these that were already under investigation for a number of medical
conditions (figure 1.3). Ursolic Acid (UA) is a pentacyclic triterpene found in
many plants. Ursodeoxycholic Acid (UDCA) is an endogenous bile acid, the use
of which is already approved for use as a treatment for liver cirrhosis [200, 201].
Both, like DUA and UCA, were found to rescue the deficient ATP levels and
MMP of parkin mutant fibroblasts to and beyond control levels, as well as in-
creasing readings from controls [198].
UA and UDCA have previously been shown to modulate Akt activity [202, 203],
and following this line UCA and DUA were found to significantly increase the
AktSer473 phosphorylation in patients but not controls fibroblasts. Inhibition of
PI3Kinase activity and Akt phosphorylation were also found to abolish the ther-
apeutic effects of DUA and UCA in both patients and control fibroblasts, impli-
cating PI3K/Akt signalling. Interestingly given their structural similarity to gluco-
corticoids, antagonisation or knockdown of the Glucocorticoid Receptor (GR) in
parkin was shown to abolish the effects UCA and DUA, of note given research
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that details interactions between the GR and PI3K signalling [204, 205]. Fi-
nally UCA and UDCA were successfully able to restore deficient ATP levels in
both parkin knockdown mouse cortical neurons, and mutant LRRK2 fibroblasts,
heightening the relevance of these compounds for possible therapeutic use in
PD. These four compounds of similar chemical structure became the primary
focus of further investigation (figure 1.3).
UA and UDCA have previously been investigated for numerous biological ac-
tions in particular; anti-oxidant, anti-inflammatory, anti-apoptotic, anti-proliferative,
anti-cancer, anti-hyperglycaemic, autophagy inducing and mild mitochondrial
uncoupling activities. These are believed to result at least in part from mod-
ulation of the Akt, ERK1/2, JNK1/2, insulin, Nrf2, PPAR-α, mTORC1, GR, and
NFκB pathways as well as direct interactions with the mitochondrial and nuclear
DNA [206–214]. Previous work also corroborates the affect of UA and UDCA
on mitochondrial physiology, and anti-apopotic effects are frequently reported
[215–220]. Literature on the therapeutic effects of DUA is comparatively sparse
as is the literature for UCA. UCA however shares strong structural similarities
with hydrophobic bile acids [209, 221].
Bile acids have been shown to bind to intracellular nuclear steroid and bile acid
receptors and an extracellular G Coupled Protein Receptor (GPCR); TGR5
[222, 223]. TGR5 is expressed throughout the body, including the CNS, En-
teric Nervous System (ENS) and skin [224–227]. It is believed to be activated
following extracellular binding, and is internalised once bound [228]. Activation
is known to induce increased oxygen consumption and energy output in tissues
co-expressing type II iododthyronine deiodinase (D2) such as human brown fat
and skeletal muscle [224, 229, 230]. Notably, human brain expresses TGR5
and D2 at levels comparable to muscle [224, 225]. Whilst UA and UCA are
both reported as TGR5 agonists [231, 232], UDCA shows only weak TGR5 ac-
tivity [223, 233, 234]. It is notable that there is evidence that GPCRs can be
activated whilst in intracellular locations [235]. Though also involved with en-
ergy metabolism, expression of intracellular bile acid receptors are restricted
to visceral organs [227], thus cannnot explain the therapeutic effects seen with
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UA, UCA and UDCA in other tissues [198]. Nuclear steroid receptors on the
other hand are expressed widely and are known to stimulate nuclear and mi-
tochondrial genes involved in OXPHOS [236, 237], therefore could account for
the effect these compounds exert in fibroblasts and neurons.
UA has been shown to directly bind cytoplasmic GR and increase its nuclear
localisation without classical Glucocorticoid Response Element (GRE) trans-
activation [238–240], as have other pentacyclic triterpenes such as avicin D
[241, 242]. Avicins have also been shown to directly interact with the mitochon-
dria and to modulate cellular oxygen consumptions [243]. UDCA is also known
to interact with the GR, though by an indirect mechanism [244–247]. Sola et al.
[246, 248] demonstrated that UDCA’s anti-apoptotic effects are dependent on
the carboxy-terminus of the GR, and that UDCA increases the presence of GR
in nucleus, which in turn mediates UDCA’s nuclear entry. The same group also
demonstrated UDCA interacts with mitochondria directly, and this is sufficient to
prevent apoptosis related permutations in the MMP [249]. Many glucocorticoid
like molecules show direct interactions with the mitochondria, and mild uncou-
pling of the ETC [207]. Lanosterol has been shown to prevent MPTP induced
cell death in dopaminergic midbrain neurons through mild mitochochondrial un-
coupling, which promoted mitophagy of damaged mitochondria [250]. Mild ETC
uncoupling and an enhanced antioxidant state are seen in cardiomycocytes fol-
lowing incubation with a UA rich plant extract, both of which were suggested
as adaptive responses to increased mitochondrial ETC kinetics and local ROS
generation [251–253]. Corticosterone has been shown to increase MMP in rat
cortical neurons, and to induce the translocation Bcl-2, an anti-apoptotic pro-
tein that prevents permeabilisation of the OMM, to the mitochondria following
complexation with the GR [254]. Overexpression of Bcl-2 has previously been
shown to enhance mitochondrial calcium capacity [255], high levels of which
induce higher ATP production [38]. Notably prolonged exposure of corticos-
terone at 1µM saw an eventual decrease in both MMP and mitochondrial Bcl-2
[254]. 1µM dexamethasone also causes GR translocation to the mitochondria
in thermocytes, as well as decreases in MMP [256]. Glucocorticoid response
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elements have been found within mtDNA, and the GR, among other steroid re-
ceptors, have been found in the mitochondria themselves underlining the coor-
dinate mechanisms by which glucocorticoids are able to stimulate both nuclear
and mitochondrial OXPHOS genes [237, 257]. Also of note, glucocorticoids are
known to directly bind many cytoplasmic proteins such as the MAPK family, po-
tentially connecting them to numerous other signalling pathways [207]. Thus
there are multiple intracellular targets by which UA, UCA and UDCA might exert
their effects in fibroblasts and neurons. One further consideration regarding the
physiological actions of these steroid like compounds would be their incorpora-
tion into lipid membranes, the effect this will have on membrane organisation
and the knock on effects to the cell [258–260].
1.1.4.1 Drug distribution to the Brain
UA, DUA, UCA and UDCA all possess therapeutic potential in PD by merit of
their ability to enhance mitochondrial function in fibroblasts and neurons. In-
deed UA and UDCA have previously been shown to exert neuroprotective ef-
fects against a range of cellular stresses. However, to treat diseases of the brain
such as PD, they must be able enter into the CNS, for which several barriers
must be traversed. A drugs pharmokinetic profile can broadly be defined by
ADME; Absorption into blood circulation, Distribution to bodily tissues and flu-
ids, potential Metabolisation of the compounds by an organism, and Excretion
from the body. Certain predictions about a compounds pharmokinetics can be
made based on its molecular properties. Lipinski et al. [261, 262] famously
established the “Rule of Five”, a set of criteria that the majority of successful
orally administered drugs adhere to. These include Octanol-Water Partition co-
efficient (Log-P)3 of <5, a MW <500Da, the possession of <5 H bond donors
and <10 H bond acceptors; note all numbers are multiples of five. Accordingly,
DUA, UA, UCA and UDCA are all likely to demonstrate poor absorption into
3LogP, determined by the relative partitioning of a compound within an immiscible mixture of
octanol and water, is a measure of a compounds water solubility, where lower values indicate
greater hydrophilicity, and higher values greater hydrophobicity
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blood circulation following oral administration, so called bioavailability, owing
to their high hydrophobicities; only UDCA possesses a predicted LogP of less
than, though close to five (figure 1.3). This can be circumvented by intravenous
administration directly into blood flow, however this requires solubilisation of the
drug either within an organic solvent or formulation within solubility enhancing
compounds collectively termed excipients. Formulation within excipients may
also be used to enhance oral bioavailability. Once in systemic circulation, brain
distribution requires penetration through the BBB [263].
FIGURE 1.3: Hexa-, Penta- and Tetra- cyclic mitochondrial therapeu-
tics: Dehydroursolic Acid Lactone (DUA), Ursolic Acid (UA), Ursocholanic acid
(UCA), Ursodeoxycholic Acid (UDCA). Molecular weights (MW) and LogPs es-
timated by XLOGP3 software (XLogP3) are indicated. Information taken from
”pubchem.com”, pictures taken from “chemspider.com”.
The BBB is a continuous endothelial layer that regulates the exchange of mate-
rial between the CNS and the micro-vessels that pass within the sub-arachnoid
space and penetrate directly through the pia mater into the brain and spinal
cord (schematised in figure 1.4) [263]. It is estimated that no neuron is further
than 8-20µm distance from a capillary, and that the BBB covers ∼20m2 surface
area [264]. Endothelial cells here are bound tightly together by tight junctions
that prevent most para-cellular extravasation between cells, requiring materi-
als to pass through the cells themselves. This may be achieved by diffusion
through the lipid membranes, facilitated transported, or receptor and/or adsorp-
tion mediated transcytosis across the cells. Foreign materials entering the BBB
may be effluxed back into circulation by P-glycoprotein and multi-drug resistant
protein [265]. The presence of intra- and extra- cellular catabolic enzymes pro-
vides a further metabolic barrier that materials must overcome in passing into
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the CNS. The high selectivity of material import and export to the CNS is es-
sential for maintaining the correct nutrient and ion composition of the Inter-stitial
Fluid (ISF) within the CNS, and is essential to brain function. Importantly it also
prevents the entry of potentially pathogenic agents such as bacteria. Endothe-
lial cells are surrounded by contractile pericytes and receive projections from
astrocytes, forming the “neurovascular unit”, which co-ordinates blood flow and
exchange of material with neural activity [263, 266]. Other routes of entry to
the CNS ISF exist, including; intranasal administration, administration into the
Cerebro Spinal Fluid (CSF) and passage through the choroid plexus, traversing
the peripheral nervous system as some viruses are known to, and direct ad-
ministration. However, the distribution to the brain from these limited to quite
specific regions. The vasculature of the brain on the other hand is fully pene-
trant, and crossing the BBB would allow for unmatched accessibility to distinct
brain regions.
To effectively and manageably treat PD, it is desirable that DUA, UA, UCA, and
UDCA cross through the BBB, something that an estimated >98% of small
molecules fail to do [267]. To diffuse through a cell membrane as must be
done in passive transit of the BBB, a molecule must be able pass through the
transitionary spaces in the fluid mosaic cell membrane, something impeded by
greater size/surface area, low lipophilicity and greater ability to hydrogen bond.
The effect of these can be quite dramatic, for instance increases in a com-
pounds MW from ∼300 to 450 Da have been shown to limit brain penetrance
by ∼100 fold [268], and a decrease of ∼10 fold is predicted each pair of hydro-
gen bonds a molecule makes [269]. Those compounds that can penetrate the
brain are generally lipophilic, possess MWs <400-500Da and make <8 hydro-
gen bonds [168, 267, 270]. Whilst DUA, UA, UCA and UDCA fall within these
hypothetical criteria, the margin by which they do so is notable. Of further con-
sideration are the strong interactions these hydrophobic compounds are likely
to make with tissues outside of the BBB and serum components, the latter of
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FIGURE 1.4: The Blood Brain Barrier: Cross section of the BBB depicting the
association between endothelial cells, basement membrane, pericytes, projec-
tions from astrocytes, neurons and glia. (a-e) Enlargement depicts routes of
crossing the BBB, and the materials that typical cross. Adapted from Abbott et
al. 2006, with permission [263].
which has been experimentally shown to hinder the brain penetrance of simi-
lar steroids [270]. Indeed it is recognised that the optimal LogP for the brain
penetration of several classes of small molecule resides between 1.5 and 2.7,
significantly lower than the those exhibited by the compounds here (figure1.3)
[168]. Further consideration must also be given to the possible effects of drug
metabolisation within the organism and potential efflux from the BBB by trans-
porters such and the P-glycoprotein. To treat diseases of the brain such as PD,
it will be essential that these compounds both cross the BBB, and distribute to
the brain in fractions large enough to provide therapeutic effects without pro-
ducing harmful off target effects.
Dietary administration of UA to mice has demonstrated poor percentage distri-
bution to the brain relative to other organs including the heart, liver, kidneys and
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colon [271]. Brain penetrance in humans is currently unknown. Oral administra-
tion of UDCA has been shown to result in accumulations within the CSF [272].
However this should not be directly attributed to penetrance of the BBB, as the
blood CSF barrier is leaky relative to the BBB, permitting entry, albeit slow en-
try, to almost all blood soluble molecules [267, 273]. Delivery from the CSF
to the brain is also relatively unfavourable due to the convection flow towards
venous circulation, and access to only ependymal surfaces [267, 274]. A sep-
arate trial in which UDCA formulated within “Yoo’s solution” was administered
orally to Amyotrophic Lateral Sclerosis (ALS) patients also reported CSF pene-
tration [275, 276]. “Yoo’s solution” is a non-covalent formulation of UDCA within
certain carbohydrates that greatly enhances its water solubility and limits its
accumulation within the liver, as typically seen with unformulated UDCA [276].
Brain penetrance of UDCA has been reported in models of stroke, [277, 278],
however permeability of the BBB is increased in this condition.
Though certainly UA has shown therapeutic effects against neurotoxicity in ani-
mal models following systemic and oral administration, whether this results from
actions in the brain or other systemic effects is not discerned, and the extent of
systemic toxicity is mostly unreported [216, 217, 279]. It is also of note that
most animal models used are of significantly smaller mass than humans, and
that even with dose adjustment by weight, the differences in endothelial surface
area and number of biological components present between the two makes dis-
tribution and toxicity studies difficult to translate. In humans, safety concerns
have been raised over the long term use and/or high dosage of both UA [280–
282] and UDCA [210, 275, 283]. It is desirable therefore that dosage be kept
to a minimum, something which can be achieved by improving the compounds
specific distribution to the brain.
Whilst the native properties of DUA, UA, UCA and UDCA may not perfectly
lend themselves to BBB penetrance from systemic circulation, appropriate for-
mulations could rectify this. By using excipients capable of carrying the com-
pounds within aqueous environments, and releasing them at the desired site(s)
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of action, inappropriate drug interactions can be limited. Indeed a number of
evolutionary designs following this paradigm exist within mammals:
 Corticosteroid-binding globulin is a liver serum protein that interacts with,
and carries ∼80% of circulating glucocorticoids, a further ∼15% associat-
ing with albumin them within systemic circulation [284]. Unbound gluco-
corticoids are cleared from the blood more rapidly. KO mice demonstrate
impaired stress induced memory retrieval, which was rescued by direct
injection of corticosterone to the brain [284]. This suggests corticosteroid-
binding globulin plays an important role in mediating the brain delivery
from blood. Corticosteroid-binding globulin is also expressed within the
CNS where it may act as a glucocorticoid vector [285, 286].
 Lipoproteins are nanoparticles assembled within the intestine and liver,
that encapsulate and transpsport cholesterol through blood and lymphatic
systems [287]. They are composed of apolipoproteins and phospholipid
encapsulating triglycerides and cholesterol, varying in composition, size
and morphology. Notably, Low Density Lipoproteins (LDL) play a signif-
icant role in transporting cholesterol to extra-hepatic tissues, particularly
adipose and adrenal tissues, which are able to utilise more cholesterol
than is synthesised locally [287, 288]. It should be noted that peripheral
cholesterol is not required by the CNS, which relies on instead on de novo
cholesterol synthesis to produce all its cholesterol [289]. However there
is evidence that other peripheral lipoproteins enter pass through the BBB,
such as apolipoprotien A-1 containing high density lipoproteins [290, 291].
Though UA, UCA and UDCA maybe able to cross the human BBB, their dis-
tribution is likely to be fairly unspecific. Thus to attain therapeutically relevant
concentrations within the CNS, high doses may be required, which may lead to
increased adverse side effects. Formulations that could increase their specific
distribution to the brain would allow for lower dosing, and a reduction in potential
side effects. In addition, formulations that could also increase the plasma circu-
lation times of these could increase their duration of effect. There are a number
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of nanoparticles in existence that are able to package hydrophobic molecules in
fashion akin to lipoproteins and cholesterol. These water soluble carriers pos-
sess surface chemistries that greatly limit their interaction with other materials.
Further their shape and size can be tuned to enhance their non-fouling proper-
ties, as well as evade clearance by the RES. Finally they may be “functionalised”
with receptor ligands, increasing their specific adherence, and initiating uptake
into- or transcytosis across- the BBB.
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1.2 Polymersomes & Drug Delivery
In the 1990s, synthetic, high MW amphiphilic block copolymers were shown
to self assemble into a number of structure when exposed to water, includ-
ing nano- and micro- scaled vesicles (figure 1.5) [292]. These later came to
be known as polymersomes (greek; body of polymer) both for meaning, and
for the analogy the name pays to liposomes, vesicles that self assemble from
naturally occurring amphiphilic lipids [293]. Like liposomes, polymersomes are
able to encapsulate hydrophilic molecules within their aqueous lumen, and am-
phiphilic and/or hydrophobic molecules within their membrane. When of ap-
propriate size, shape and chemistry, they are also capable of entering cells and
releasing their cargo therein. Unlike liposomes, polymersomes have been found
to circulate in blood for much longer durations by merit of their tougher mem-
branes and greater capacity for anti-fouling properties. Owing to their synthetic
nature, a wide range of potential customisations such as environmentally sen-
sitive drug release and variable morphologies are also available. For these rea-
sons, polymersomes and other polymeric nanoparticles are being investigated
as an alternative to liposomal drug formulation [294–296]. Indeed a number of
copolymer assemblies have proven safe in humans and are now beginning to
enter into the clinic [296–298]. Herein, the use of nanoparticles in drug delivery
is discussed, and the advantages of polymersomes highlighted with particular
consideration to brain penetrance.
FIGURE 1.5: Polymersome schematic: Cartoon of an amphiphilic diblock
copolymer membrane (left) and archetypal polymersome plus possible encap-
sulates, adornments and membrane characteristics. Adapted from Massignani
et al. 2010, with permission [401].
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1.2.1 Drug Delivery
Drug formulation within materials, collectively known as excipients, has long
been performed to improve a compounds shelf life, and distribution within the
body from a given route of administration. To take intravenous administration of
a hydrophobic or amphiphilic compound as an example, compounds are solu-
bilised prior to injection within a mixture that both solubilises the compound, and
prevents its precipitation on contact with blood, something which may otherwise
lead to potentially fatal embolisms. Typical formulation techniques include; the
use of co-solvents that are both water miscible and solubilise the drug, drug
complexation with water soluble molecules containing hydrophobic “pockets”,
packaging compounds within micelles formed of amphiphilic surfactants, emul-
sification within oils and biocompatible surfactants, and encapsulation within
vesicles composed of self-assembling amphiphiles. With the exception of co-
solvation, these all form particulate, or semi-particulate systems.
A major goal of drug formulation is to enhance therapeutic properties, either by
improving distribution to a given site, or prolonging a drugs effect. The body
presents a number of barriers that limit both. The Reticulo-endothelial Sys-
tem (RES) is the collective name for opsonising proteins, immune cells and
tissue filters, which together identify, filter and remove foreign bodies or dys-
functional plasma components from circulation [299, 300]. Except where it is
the therapeutic target, evasion of the RES is desirable. A number of properties
can help achieve this, as well as improve particle distribution to specific areas
within the body.
1.2.1.1 Hydrophilic surface chemistry
Drug adsorption to plasma components can lead to altered bio-distribution, in-
creases in particle size, and clearance from circulation. Opsonins are molecules
that bind to foreign or damaged bodies in circulation, and enhance the ability
of immune cells to target and phagocytose these. Certain opsonins are known
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complement activators, agents that induce increased immune system activity for
more effective clearance of foreign matter. As excessive complement activation
can result in reduced therapeutic efficacy and even anaphylactic shock, it is es-
sential that drug formulations are designed to limit or prevent such interactions
with the immune system [301, 302]. One effective strategy to delay adsorp-
tion by serum components is to surround a drug containing particle with a hy-
drophilic material. As interactions with water are more energetically favourable
than with larger molecules, an effective barrier of water is formed around the
particle, buffing it against further interactions. Hydrophilic compounds possess-
ing an overall charge will still readily interact with counter-ions and materials
of complementary charge so charge neutral materials have proven the most
effective [303, 304]. In this regard, non-ionic- and zwitterionic- polymers have
received a lot attention, both for their relative ease of manufacture and, given
their high MW, their large water holding capacities [305, 306].
Polyethylene oxide-poly 2-(diisopropylamino)ethyl methacrylate (PEO) (also
known as Polyethylene glycol (PEG)) [307] is a charge neutral hydrophilic poly-
mer that has famously been used to coat numerous nanoparticles, both syn-
thetic and biological in nature, resulting in greatly improved circulation times
[299, 305, 308]. Unlike many other hydrophilic polymers, PEO/PEG is also
non-immunogenic, and is now considered the gold standard anti-fouling coating
within biomedical applications [306]. A number of alternatives do however exist,
including Poly-2-methacryloyloxyethyl phosphorylcholine (PMPC), a zwitterionic
hydrophilic polymer composed of repeating phosphorylcholine groups. Phos-
phorylcholine groups are also found in the head groups of phosphatidylcholine
and sphingomyelin, major lipid components of the cell membrane. PMPC is
biocompatible, non-immunogenic, and highly resistant to adsorption by bio-
logical materials, for which it is now in use as a biocompatible coating for a
number of long term medical implants [309, 310]. PMPC is the hydrophilic
group of Poly-(2methacryloyloxy -ethylphosphorylcholine)-poly(2 -(diisopropyl -
amino)ethyl methacrylate) (PMPC-PDPA), the diblock copolymer used through-
out this thesis.
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Anti-fouling properties are most effective where access to the drug by adsorbent
material is minimised. Packaging drugs within particles totally surrounded in a
hydrophilic surface achieves this without requiring modifications to drug chem-
istry that may otherwise alter therapeutic efficacy. PEG’ylated lipids have been
used to used to package compounds, resulting in improved circulation times
[299, 308, 311]. However, the covalent attachment of a large MW hydrophilic
polymers to low MW lipids alters their self assembly properties, resulting in the
formation of lipid micelles in place of liposomes. The packing density of micelles
is markedly smaller than vesicles, resulting in a “thinned” hydrophilic “brush”
border, and subsequently reduced anti-fouling properties. Lacking a lumen,
these are also unable to encapsulate water soluble molecules. As copolymers
can be synthesised at great MW, they are able to incorporate large non-fouling
hydrophilic polymers whilst retaining their ability to form vesicles, and dense
hydrophilic “brush” borders.
1.2.1.2 Particle size
There is evidence that increasing diameter of spherical PEG’ylated polymer-
somes results in decreased circulation times [312, 313]. This is due, at least in
part, to the particulate “filters” present within systemic circulation. Blood flows
through a number of sites where anastomising capillaries lacking tight junctions
and possessing large fenestrations, known as sinusoids, allow large molecules
to pass out into tissue. These include the liver, spleen and bone marrow, all
typical sites of large nanoparticle accumulation, particularly those of larger di-
ameter [312, 314]. Spleen sinusoids have fenestrations typically 200-500nm
4, which block the passage of larger bodies. Flexible bodies larger than this
such as µm scaled erythrocytes may however still pass through by merit of their
deformability [312]. In this regard, it is notable that the supramolecular nature
of polymersomes will permit a high degree of flexibility [293].
4 = diameter
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Fenestrated endothelia are present throughout the body including the pancreas,
kidney and intestine, permitting the extravasation of material up to ∼80nm 
[315]. Endothelia elsewhere, such as along the CNS, are continuous permit-
ting only those molecules that pass through or between endothelial cells and
their basement membrane to enter the surrounding tissue. Particles <5nm are
known to clear very rapidly from blood, either by renal clearance or extravasa-
tion [316], and particles designed for extravasation should generally be<100nm
[317]. All particles should be <15µm to avoid potentially fatal occlusion of cap-
illaries [318].
1.2.1.3 Particle tensile strength and shape
To prolong circulation times, nanoparticles should be designed to withstand
the turbulent forces experienced within blood flow, something the high tensile
strengths of solid nanoparticles fair well with. However, this same characteristic
will also limit particle size owing to inflexibility and the presence of the aforemen-
tioned particulate “filters” present within mammalian systemic circulation. Their
high tensile strengths may also prove incompatible and potentially damaging to
“softer” supramolecular biological surfaces [319]. Supramolecular assemblies
on the other hand are both deformable and possess tensile strengths more akin
to those found in the body. Assemblies held together by “weak forces” do how-
ever possess tendencies to break apart under force and/or dilution, the cause
of the low circulation times of liposomes demonstrate in blood [320]. Nanoparti-
cles composed of self-assembling high MW copolymers such as polymersomes
circumvent these issues, demonstrating markedly more robust membrane prop-
erties that also retain the deformable characteristics of other supramolecular
assemblies [293, 305, 321].
The longest reported circulation time for a particulate system comes from flexi-
ble worm like micelles, or filomicelles, composed of a PEG’ylated diblock copoly-
mer [322]. These were 22-60nm  and circulated in the the blood of mice with a
half-life of up to five days, the duration of circulation scaling with particle length.
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This is roughly ten times greater than the circulation times reported for spher-
ical nanoparticles. Under flow, tubular particles have been shown to detach
from surfaces with greater ease than spherical particles, due to the greater
shear stress exerted on them [323, 324]. It has also been shown that tubes
are less likely to enter endocytic cells if presented to the plasma membrane
side-on, as a result of the slower membrane wrapping around elongated bod-
ies [325, 326]. Notably, inhibited uptake of higher aspect ratios is also seen in
phagocytes [327, 328]. Thus tubular particles of appropriate diameter appear
able to effectively navigate the various tissue filters of systemic circulation and
evade clearance by immune cells .
Nanoparticles holding cargo bound for the CNS will benefit most from those
properties that prevent their extravasation into other tissues, or clearance by
the RES. However it is also essential that they are able to interact with the en-
dothelia of the BBB, something that can be achieved by coating/functionalising
the nanoparticle with ligands against receptors/targets found on the BBB. An-
tibody functionalised nanoparticles of both spherical and elongated morpholo-
gies demonstrate enhanced endothelial binding specificity relative free antibod-
ies, where the shear stress experienced by these particles likely acts prevent
adhesion to sites of weak interaction [329–331]. Binding specificity and avidity
is greater in elongated particles relative to spherical particles, by merit of their
larger contact area to volume ratios, and greater shear forces experienced in
flow [324, 326]. When in flow, it has also been shown that elongated nanopar-
ticles align to flow and drift laterally toward vessel walls, aiding their endothelial
interactions [324]. Particles of tube like morphology thus possess a number of
properties advantageous to targeting the BBB by ligand functionalisation.
1.2.1.4 Nanoparticle ligand functionalisation
Within systemic circulation, it is possible to enhance the specificity of nanopar-
ticle accumulation by decorating their surface with ligands known to interact
with molecules specific to- or enriched in- given tissue types [332, 333]. These
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may be molecules found on the cell surface, or the surrounding extracellular-
matrix. Targeting may simply enhance a particles tissue affinity, or directly
target them into the cell via receptor mediated endocytosis (discussed further
bellow) . Particle functionalisation has shown success in targeting solid neo-
plasm, both when functionalised against tumour endothelia [334–336], and the
tumour itself as direct extravasation through their leaky endothelia is possible
[334, 336, 337]. A cautionary note should be taken regarding the effects recep-
tor activated processes may have, ranging from receptor mediated endocytosis
to receptor induced cell death [338].
Ligand decoration maybe rendered unnecessary where a polymers chemistry
demonstrates an inherent affinity for certain receptor interactions. For instance,
despite PMPC’s highly non-fouling nature, polymersomes composed of the di-
block co-polymer PMPC-PDPA have been found to enter cells much more read-
ily than PEG-PDPA polymersomes of similar size [339, 340]. Recently, a major
role for Class B scavenger receptors in mediating the uptake of PMPC-PDPA
was identified [341], receptors known to recognise phosphorylcholine moieties
such as found in PMPC [342]. Though widely expressed, Class B scavenger
receptors are particularly concentrated in immune cells, adipocytes and a num-
ber of cancer cells; PMPC-PDPA nanoparticles may be well suited to targeting
these.
1.2.1.5 Targeting the CNS
To treat diseases of the brain such as PD, nanoparticles must be able to deliver
their cargo to the interstitial fluid of the brain, if not to individual cells of the
CNS. As mentioned before, the BBB is a continuous endothelia that prevents
the passage of all but selective material to and from the CNS, presenting a major
hurdle the greater number of potential CNS therapeutics fail to cross [263, 267].
However, as systemic circulation perfuses rapidly and fully throughout the CNS,
with neurons being no further than an estimated 8-20µm distant from a capillary
[264], drug delivery from blood would provide the greatest accessibility to the
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brain, and in many cases the most direct route to disease affected regions.
Numerous endogenous ligands, unable to directly penetrate the BBB, cross into
the CNS via receptor mediated transcytosis (discussed further below) through
the BBB endothelium, and there are multiple examples where nanoparticles
have been able to hijack this mechanism [296].
Poly(ethylene glycol)-poly(caprolactone) methyl ether (PEG-PCL) polymersomes
decorated with a monoclonal antibody (OX26-PO) against a transferrin recep-
tor (CD71), were able to enhance the brain accumulation and therapeutic effect
of a poorly brain penetrant therapeutic (NC-1900, a vasopressin fragment pep-
tide) in rats with toxin induced brain damage [343]. Notably, this study found
an optimal ligand density, above or below which brain accumulation was detri-
mented. Transferrin receptors are responsible for the transcytosis of iron to
the CNS and advantageously are highly expressed along the BBB [344, 345].
Using antibodies against epitopes of transferrin receptor distinct from the trans-
ferrin binding region circumvents the issue of competitive antagonism with the
high blood concentrations of transferrin [345, 346]. Notably, work has shown
that nano-rods decorated with monoclonal transferrin demonstrate a ∼7 fold
improvement in targeting brain endothelia relative to spheres [330]. Liposomes
have also employed this strategy, though the improved stability and circulation
times of polymersomes present a distinct advantage over these [345, 346].
Lactoferrin (Lf), another receptor involved in the transcytosis of iron, is of partic-
ular interest to Parkinson’s Disease (PD). Lf-PEG-PLA nanoparticles with flu-
orescent cargo have demonstrated marked distribution to the cortex, SN, third
ventricle and periventricular region [347]. When loaded with therapeutics, such
particles have shown therapeutic effects over free drug in toxin induced mod-
els of PD (6-OHDA rats) [348]. Therapeutic Lf-poly(ethylene glycol)poly(lactic
acid) (PEG-PLA) polymersomes have also been used to effectively treat mouse
models of Alzheimer’s Disease [349] and Lf nanoparticles to treat glioma [350].
However like transferrin receptors, lactoferrin receptors are expressed more
widely than at the BBB alone.
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Recently polymersomes decorated with des-octanyl ghrelin showed improved
accumulation in mouse brain, as well as decreased liver and spleen accumula-
tion relative to unadorned polymersomes [351]. These successfully delivered
soluble cargoes to the brain, and therapeutic actions related to these were
seen. Des-octanyl ghrelin blood concentration is much lower than lactoferrin
and transferrin, and has been observed to move from blood to CNS and not the
reverse [351].
LDL receptor-related protein (LRP) is a scavenger receptor expressed highly
expressed in both the BBB and the cells of the CNS, and is involved in receptor
activated bidirectional transcytosis to and from the brain [352]. Angiopep-2 is a
small peptide able to bind and induce LRP-1 mediated transcytosis [353, 354],
and has been used to functionalise drug loaded nanoparticles targeting gliomas,
which showed enhanced specific accumulation and tumour reduction [355]. Re-
cently, Angiopep-2-poly(oligo(ethylene glycol) monomethyl ether methacrylate)-
poly(2 -(diisopropyl -amino)ethyl methacrylate) (POEGMA-PDPA) copolymers
have been synthesised and blended into POEGMA-PDPA polymersomes. These
were found to successfully cross a 3D BBB model, with relatively little accumu-
lation in the endothelial cells themselves [356, in preparation]. They and their
antibody cargoes if present, were also found to accumulate within mouse brain
in significantly higher concentration than unadorned polymersomes, and found
to accumulate at numerous locations distant to fluorescently labelled capillaries
again indicative of true penetrance into brain parenchyma. Interestingly, LRP-1
was found to be associated with a form of endothelial transcytosis in which no
compartmental acidification takes place, evident by the presence of intact poly-
mersomes within the brain ISF; PDPA possessing assemblies disassemble at
pHs <6.3 (discussed further below) [357, 358].
Another mechanism by which nanoparticles may induce transcytosis to the CNS
is by adsorption to the negatively charged surface of the BBB, as achieved by
a number of positively charged serum proteins [263]. As cationic nanoparti-
cles generally induce a higher level of toxicity, this method seems a poor op-
tion [359]. However one study relevant to the work here used chitostatin-PLGA
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nanoparticles loaded with the highly hydrophobic antioxidant co-enzyme Q10,
and administered them to a transgenic mouse model of AD where a therapeu-
tic effect was seen [360]. Thus where orally administered co-enzyme Q10 has
previously failed to evoke a disease modifying effect, carriers that increase its
concentration within the brain are still promising [167].
It is however notable that none of the above nanoparticles have or are likely to
show brain specific accumulation. Further, though improvements in brain distri-
bution are noted, total brain concentrations achieved are typically less that 1%
of the injected dose per unit weight of the in vivo model, and a large amount
of off-target distribution still is occurs. A number of studies have indicated that
inter-nasal administration of large molecules allowed them to pass through the
nasal mucosa and into the brain, particularly the olfactory bulb, and medical ef-
fects have been demonstrated in animal models of disease as well as humans
[361]. Transport to the brain can occur by one of three potential mechanism; by
diffusion between or within axons from the olfactory bulb both resulting in ac-
cumulation in the olfactory bulb, or along the trigeminal nerve projecting to the
midbrain. A meta-analysis in 2007 found only two of approximately one hun-
dred publications presented data indicative of feasible distribution of molecules
from the nose to the deep regions of the human brain, highlighting the difficulty
in translating therapies from animal studies, and the need for highly efficient
delivery in this mode [362]. Since, a number of nanoparticles functionalised
with lectins that interact with the nasal mucosa’s highly glycosylated surface
have been developed [296]. Wheat germ aglutin decorated nanoparticles have
shown successful accumulation in the brain along olfactory and trigeminal nerve
paths following intranasal but not intravenous administration [363, 364]. Nasal
administration of lectin decorated poly(ethylene glycol)-poly(lactic-co-glycolic
acid) (PEG-PLGA) nanoparticles loaded with therapeutics showed improved
therapeutic effects in a toxin induced rat model of PD [363, 365], suggestive of
the therapeutic potential for this route of administration as well as the improved
efficiency of deliver lectins impart. However the feasibility of this approach in
humans is still questionable.
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Nanoparticles targeting the BBB’s transcytotic machinery may be able to achieve
one of two things. They may release their cargo within the BBB, greatly increas-
ing their proximity to the brain, or, they may be able to traverse through to the
brains ISF intact. In the latter case, it may be possible for nanoparticles to exert
a second level of targeting, delivering their cargo directly into certain cells, or to
release their cargo directly into the ISF, allowing it to diffuse to its targets. Once
robust brain delivery with a system has been established, it will be essential
to establish the safety of this system with regard to cell viability and potential
microglial activation, the CNS primary immune cell, among other factors.
1.2.1.6 Penetrating the cell membrane
For many delivery vectors, it is essential that their cargo is delivered into their
target cell, either to produce enhanced therapeutic effects associated with the
delivery of large drug loads [341, 366], or to yield a therapeutic effects in the
first instance. Nanoparticles are of a scale that allows them to enter cells along
those routes used to import materials essential to cell physiology. Cells utilise
a number of mechanisms, collectively termed endocytosis, to internalise and
appropriately process materials of various sizes (summarised in figure 1.6)
[367, 368]. Materials bound or proximate to the cell surface are engulfed by
the plasma membrane, which is then pinched off into the cytosol. The resulting
vesicles are trafficked within the cell, typically to endosomes for further process-
ing and distribution, lysosomes for degradation or the adjacent cell membrane
in a process termed transcytosis5.
Phagocytosis (greek; cell eating) is a receptor activated internalisation mecha-
nism that occurs predominantly within phagocytes [367]. Actin re-organisations
extend membrane collars around and over >1µm bodies such as bacteria and
cell debris until enclosed [369]. The resulting phagosome typically fuses with
lysosomes/late endosome. Macro-pinocytosis (greek; large cell drinking) also
re-organises actin to indiscriminately extend the cell membrane around large
5Transcytosis is also known to occur from endosomal compartments
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volumes of extracellular fluid, producing cytosolic vesicles up to several µm in
diameter [369]. Though not directly cargo-receptor activated, macropinocyto-
sis is inducible by for instance growth factors [370]. Once formed, the inter-
nalised macropinosome matures along cell specific paths. Typically, they un-
dergo shrinkage and develop an elongated/tube like morphology before tran-
sitioning to smaller spheres, whilst taking on late endosomal markers and/or
merging with the late endosome or lysosome.
Micro-pinocytosis (greek; small cell drinking), is a continual process in which
small sections of plasma membrane are invaginated and internalised, drawing
both lipids and extracellular fluids/materials into ∼40-300nm  vesicles [367].
Pits/invaginations in the plasma membrane that result from high concentrations
of certain structurally ordering proteins, lipids or cytoskeletal reorganisations
are pinched off into the cytosol, and typically trafficked to endosomal compart-
ments or the adjacent cell membrane. This process is matched by a homeo-
static addition of lipid to the plasma membrane from exocytotic vesicles, main-
taining cell volume. The rate of pinocytosis varies with cell type, macrophages
internalising 25% of their own volume per hour, where fibroblasts internalise
just 1% [367]. Receptor activated endocytosis allows for specific extracellu-
lar molecules to be actively internalised along a bespoke route, dramatically
increasing their accumulation within the cell despite possibly low extracellular
concentration.
A classic example of receptor mediated endocytosis is the uptake of cholesterol
containing LDLs. LDL receptors are found either in pits or dispersed across the
cell membrane. In the latter case, pit formation is induced on LDL binding. Pits
are formed by coating the cytosolic face of the cell membrane with the mem-
brane deforming protein, clathrin. On receiving a cargo these pits bud inwards
and are cut from the plasma membrane by the catalysed actions of multiple pro-
teins, and the resulting vesicle is trafficked to early endosomal compartments.
Interestingly, clathrin coated pits can vary in size, ∼10-300nm  having been
observed [371, 372]. Links have been drawn between cargo size and the size of
clathrin coated vesicle, wherein membrane deformations induced by the cargo
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are proposed to guide the ordering of clathrin cages around the membrane
[372]. Currently, 200nm  is the reported upper limit of cargo size admissible
by clathrin mediated endocytosis. Larger entities are known to bind receptors
affiliated with clathrin mediated endocytosis, and to assemble the machinery
required of it, though whether their subsequent internalisation requires inputs
from further internalisation mechanisms is unknown, though probable [373].
Pinocytotic mechanisms independent of clathrin are also known of, the best
studied of which is caveolae mediated endocytosis. Caveolae (latin; little caves)
are 50-80nm  “flasks” enriched with cholesterol, glyco-sphingolipids and most
frequently calveolin proteins. Receptor mediated endocytosis through these is
linked to cargo trafficking to a number of intracellular locations including the
endosome, as well as a form of transcytosis [374, 375]. Despite their relatively
small size, caveolae have reportedly mediated the endocytosis of 100nm 
nanoparticles [376].
Whilst it is possible to target materials towards particular endocytic pathways
and subsequent intracellular locations by merit of their physical characteristics
and ability to bind receptors that activate endocytosis, the concurrent activity
of internalisation mechanisms likely means uptake occurs by multiple routes.
Indeed there is evidence that nanoparticles enter cells by more than one form
of endocytosis [377, 378].
1.2.1.7 Tuning nanoparticle for cellular uptake
A nanoparticle’s size, tensile strength, shape and adherence to biological sur-
faces dictate their cellular interactions. Particles of identical chemistry but dif-
fering diameter [379–381], shape [340, 378] and/or stiffness [377] show altered
cellular internalisation kinetics. This is a result of both the strength of attraction
between the particle and cell membrane, and the particles ability to deform the
cell membrane [382, 383]. It has been shown that solid spherical gold or silica
nanoparticles co-incubated with liposomes are found engulfed in phospholipid
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FIGURE 1.6: Endocytic pathways: Representations of (a) Phagocytosis, (b)
macropinocytosis, (c) caveolae mediated endocytois, (d) clathrin mediated en-
docytosis, (e) receptor mediated endocytosis independent of clathrin and cave-
olae. Typical cargo sizes are indicated. Taken from Petros and Desimone 2010,
with permission [313].
vesicles found within the lumen of the latter despite the absence of active endo-
cytosis [384, 385]. Other work has shown that mesoporous silica nanoparticles
∼600nm  are able to deform erythrocyte membranes and enter into these en-
docytically inactive cells [386]. Studies with spherical solid nanoparticles have
identified optimum sizes for cellular uptake [380, 381, 387] and in close agree-
ment numerous computer models have identified diameters of 40-60nm as the
most effective at inducing plasma membrane wrapping [325, 382, 388]. Be-
low the optimum, the high bending requirement of the plasma membrane slows
or prevents membrane deformation, and above greater cell-particle adhesion
must be developed for membrane wrapping, for instance by the diffusion of
more receptors to the site of particle adhesion. Strength of adhesion is also sig-
nificant, wherein increasing attraction theoretically increases the size optimum
for membrane wrapping, with the converse being true of increasing repulsion
[382, 383, 388]. For instance PMPC-PDPA polymersomes have been found to
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enter cells more readily than PEG-PDPA polymersomes likely due to the specific
interaction between PMPC and phosphorylcholine binding class B scavenger
receptors [341]. The uptake of both declines with diameters increasing from
100nm [339, 340]. Interestingly, polymersomes composed of both these diblock
copolymers were found to enter fibroblasts in a manner apparently independent
of vesicle diameter. Characterisation of these particles revealed the two copoly-
mers segregated into discrete regions of the membrane, creating patches. This
will establish regionalised interaction strengths between patchy polymersomes
and the cell membrane perhaps approaching the membrane wrapping ideals
noted above.
It is interesting to note that many naturally occurring delivery vectors, whose
design has been guided by billions of years evolution, display small protrusions
from their surface enriched with molecules that interact with the cell surface,
and arranged in a clear topological order. Many of these are also larger than
the ideal diameter noted above, spherical/icosohedral viruses for instance are
most commonly found with diameters of ∼60-150nm [389]. Theoretical work
has demonstrated that clustering of nanoparticle induced deformations on the
cell membrane lowers the energy threshold to membrane wrapping, meaning
such topologically arranged cell membrane deformations could be an effective
strategy to improve cell entry [388]. Enhancing the ability of larger vectors to en-
ter cells is significant, as the volume and subsequent payload contained within
these will be larger than in smaller particles. It is also important to reinforce that
whilst effective entry to the cell is important, entrance into a specific subset of
cells is often equally or more important for a medical molecular delivery vector,
thus particles should not necessarily be designed for effective entry into all cell
types.
As noted previously, particles of increased aspect ratio tend to show increased
circulation times, and enhanced ligand specific interactions in vivo. In keeping, a
number of studies have shown that shapes with increased aspect ratios, such as
nano-rods, are internalised less effectively by cells even where particle volumes
are matched [322, 378, 387]. This is also true of phagocytotic cells [327, 328].
Chapter 1. Introduction 45
Vector designs that carefully enhance certain cellular interactions may allow
for cell specific internalisation. One study, for instance, found apolipo-protein
peptides conjugated to lipid micelles selectively entered one type of endothe-
lial cell among a mixture endothelial cells, using clathrin mediated endocytosis
[390]. Liposomes or the peptide alone by contrast were internalised by all cells
through a number of routes. In another study, when incubated with both neu-
rons and glia, gold nano-rods preferentially entered endocytic neurons where
“spiky” gold nano-particles entered phagocytic glia [391].
1.2.1.8 Environmentally sensitive block co-polymers and intracellular cargo
release
Though many particles are able to enter into cells via receptor mediated endo-
cytosis, their sub-cellular locations are often limited initially to the endosome,
from which they are later trafficked to the lysosome. This has been known
to limit and/or prevent therapeutic actions of nanoparticles acting as therapeu-
tic vectors. Development has subsequently gone into discovering methods by
which nanoparticles can be released into the cytosol, either by altered entry to
the cell, or escape from the endosome.
PMPC-PDPA polymersomes have been shown to enter cells via an endocytic
route and localise within the endosome [392, 393]. In this regard it is interesting
to note that class B scavenger receptors, which play a major role in the internal-
isation of these particles [341], have been connected to both clathrin, and cave-
olae mediated endocytosis [394, 395]. On entering the endosome, these parti-
cles will experience environments of increasing acidity as they progress through
the endolysosomal pathway. Owing to the tertiary amine groups present in the
hydrophobic DPA block, PMPC-PDPA polymersomes are pH sensitive with a
pKa ∼6.3 [357, 396]. Below this, DPA units become protonated, causing both
units of the diblock copolymer to become water soluble and subsequently losing
the hydrophobicity that held the self assemblies together (figure 1.7) [358, 396].
This feature is of particular relevance to PMPC-PDPA polymersomes ∼ 100nm
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in diameter, which are internalised along an endocytic pathway in which they are
exposed to the mildly acidic environment of the early endosome. Here PMPC-
PDPA polymersomes disassemble rapidly, causing an osmotic shock that drives
the escape of soluble cargoes into they cytosol, and hydrophobic cargoes into
neighbouring apolar environments [339] (further details on endosomal escape
can be found in the introduction of Chapter 4). The eventual sub-cellular loca-
tions of the copolymer and its cargo, whether polar or apolar, will result from
their specific properties and the manner in which the cell interacts with them,
fluorescent cargoes having been observed both throughout the cell and con-
centrated within certain organelles such as the nucleus and mitochondria [392].
FIGURE 1.7: pH sensitivity of PMPC-PDPA: (a) PMPC-PDPA possesses
a pKa ∼ 6.3, PDPA’s tertiary amine group being protonated in mildly acidic
concentrations, allowing it to interact with water molecules. (b) intracellular
distribution of rhodamine B following delivery by polymersomes composed
of (i) PMPC-PDPA and (ii) PEG-PBG, a non pH sensitive diblock copolymer.
Adapted from Massignani et al. 2009, with permission [338].
Other examples of polymersomes that disassemble or degrade in reductive
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environments also show effective release of soluble cargoes from the endo-
lyosomal compartment and delivery to the cytosol [397, 398]. A number of envi-
ronmentally responsive copolymers beside these also show promise for medical
applications. Polymersome that degrade after fixed periods could allow for bet-
ter temporal control of drug dosing [399, 400]. Oxidation sensitive polymers
could permit cargo release only in tissues generating high ROS levels, both
for diagnostic and therapeutic reasons [401]. Temperature and light sensitive
copolymer have also been synthesised, the latter being perhaps of particular
interest as lasers could be focussed at points in which cargo release is de-
sired [402]. Certain copolymers show specific permeabilities [403], and others
have been used to incorporate proteins within their membranes, something that
would allow mimicry of specific cell properties and functions [295].
Some of the above possess biodegradable groups, such as reductively sensitive
disulfide bonds. Developing co-polymers that may be totally degraded, broken
down and incorporated into a cells chemistry, or that are safely expelled from
the body remains an important goal for medical delivery vectors. The long term
biological effects of PMPC-PDPA have yet to be fully addressed, though early
studies indicate it is biocompatible, non-immunogenic, and well tolerated in cells
for at least a week [339, 358, 404].
1.2.2 Controlling the shape and size of amphiphilic diblock
copolymer assemblies
So far, a number of properties that enhance the ability of nanoparticles to de-
liver therapeutic compounds within the body have been listed. Herein, methods
by which these properties can be achieved using diblock copolymers are dis-
cussed.
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1.2.2.1 Packing factor determines assembly structure
When hydrated, an amphiphile population of sufficient concentration will or-
der into structures due to the introduction of the hydrating forces and the hy-
drophobic effect, which overcome the ordering imparted by other weak forces
[405, 406]. Water molecules will attempt to orientate their dipoles away from
apolar molecules they immerse. However, such ordering is energetically un-
favourable in a liquid state, so water instead drives the association between
apolar groups to maximise entropy, producing interactions markedly stronger
than those imparted by other weak forces [406]. Hydrophilic molecules by con-
trast may interact with water molecules sufficiently to effectively dissolve within
them. Interactions with water are believed generate more disorder than with
other polar molecules, so hydrated polar entities will effectively “repel” one an-
other [406]. When polar water solubilities are combined in a single molecule in
an amphiphile, water will exert both attractive and “repulsive” forces that drive
their self assembly into higher order structures. The balance of forces can be
formalised using the dimensionless packing factor, p:
p =
v
a0l
Where “v” is the molecular volume of the hydrophobic chain, “l” is the amphiphile
length, and “a0” is the optimal area that is occupied by an amphiphile in an as-
sembly that has reached equilibrium [406]. This is also known as Israelachivili’s
parameter. Where p ≤ 1/3 micelles (solid spherical particles) are most typical,
1/3 ≤ p ≤ 1/2 worm like micelles (solid tubular particles) and 1/2 ≤ p ≤ 1 lamel-
lar membranes (planar sheets) (figure 1.8). Only the first of these can exist in
water without further modification, their size being determined purely by the am-
phiphile’s character. Worms must form energetically frustrated end caps to pre-
vent exposing their hydrophobic core to water, and will continue to lengthen until
they do so. In membranes, curvature is generated from the energetic frustration
of exposed hydrophobic edges plus local membrane fluctuations, wrapping this
sheet into closed structures, typically vesicles. Except at very small diameters,
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the energetic penalty for vesicle formation is mathematically equal at all sizes,
and so final diameter is determined by the local availability of copolymer and
thermodynamic state at the time of formation. Thus vesicle size varies with the
method of preparation, and may differ significantly between vesicles formed at
the same time. Material is not exchanged between vesicles due to the great
insolubility of amphiphilic copolymers, the number of molecules present within
the inner and outer leaflets being fixed at the time of membrane closure. The
formation of discs instead of vesicles is unfavourable owing to the large number
of molecules that must exist in an energetically frustrated state to cap the 360◦
of exposed membrane core.
FIGURE 1.8: Amphiphile packing parameter correlates assembly mor-
phology: Adapted from Smart et al. 2008, with permission [294].
1.2.2.2 Lyotropic phases
As water is the primary driver for amphiphile self assembly, another key deter-
minant of aggregate structure is the amphiphile concentration in water [407].
At very low concentrations, amphiphile chains remain separately dissolved in
water. Past a threshold, the Critical Aggregation Constant (CAC), amphiphile
chains are able to interact with one another, where the combination of the hy-
drophobic effect and hydration forces drive their self assembly. It is notable
that amphiphiles of high MW, such as block copolymers, have CACs close to
zero. Thanks to both this and their low membrane fluidity (discussed further
below) [408], copolymer assemblies will not readily disassemble on dilution as,
for instance, occurs on entry to human blood.
Membrane forming amphiphiles order into disperse isotropic structures such as
vesicles at low concentrations, and structures possessing long range order at
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high concentrations (figure 1.9). The latter are metastable lyotropic phases, as-
semblies which though locally stable, are capable of ordering into structures of
lower energy within a permissive environment. From a dry amphiphilic copoly-
mer, initial film hydration results in the formation and/or swelling of planar mem-
branous sheets known as lamellae [409]. There is evidence this occurs directly
from films possessing a semi-crystalline order, whilst disordered copolymer
films initially transition through a hexagonal rod phase prior to forming lamellae
[407] (figure 1.9). As copolymer concentration in water continues to decrease,
lamellae continue to swell until the changing balance of hydrating and hydropho-
bic forces results in membrane unbinding and the formation of “sponge” phases.
Further dilution results in the formation of further structures, ever more closely
approximating energetic equilibrium until the transitioning to isotropic/ergodic
morphologies. All these phases are encountered when forming polymersomes
by Thin Film Re-hydration (TFR), if only transiently [407, 409].
FIGURE 1.9: Phase diagram of a diblock copolymer: Phases formed by
membrane forming PEO-PBO with increasing MW and water content. Figure
taken from Battaglia and Ryan 2006, with permission [406].
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1.2.2.3 Copolymer size determines membrane properties
Another key component to the nature of amphiphilic assemblies is amphiphile
size (figure 1.10). Amphiphile membranes show increasing bending rigidity
and mechanical properties with increasing MW. For instance, polymersomes
composed from high molecular weight diblock copolymer have been shown
to resist rupture at forces greater than ten times that required to rupture lipo-
somes formed of low MW lipids [293]. Membrane thickness also scales with
MW, though past a threshold, interdigitation between the hydrophobic chains
of copolymers from opposing membrane leaflets can occur, resulting in an ap-
parent decrease in thickness [410]. Concordantly, membrane fluidity / chain
exchange kinetics decrease with amphiphile size. Relative membrane perme-
abilities also decrease with amphiphile size, though still remain specific to am-
phiphile chemistry. Membrane elasticity remains independent of MW, and is
comparable to that of liposomes [293, 411].
FIGURE 1.10: Diblock copolymer membrane properties scale with am-
phiphile size: *Relative position of PMPC25−PDPA65−78 is indicated along
the x axis. Adapted from Discher and Ahmed 2006, with permission [320].
1.2.2.4 Method of formation determines vesicle size
As mentioned earlier, for membrane forming amphiphiles, the method of forma-
tion is key to the size of vesicles produced. As amphiphilic diblock copolymers
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have CAC close to zero, once energetically stable closed structures are formed,
the copolymer chains within are fixed and only externally applied energy can
disrupt this. The specific constraints placed on the copolymer at the time of
formation will dictate the size and morphology of the particle they will assemble
into [409]. For instance, electro-formation, a process in which an electrical cur-
rent is passed through a thin film of, in this instance, membrane forming diblock
copolymer at the time of hydration, results in giant (µm scaled) unilamellar vesi-
cles. TFR by contrast, a method in which a thin film of the same membrane
forming diblock copolymer is exposed to water in the presence of mechani-
cal energy, will form nano-scaled vesicles, the mutual diffusion of copolymer
and water into one another being slower than with the more energetic electro-
formation [412]. Applying exogenous energy can further transform vesicle size
post formation. Sonication for instance is routinely used to reduce average vesi-
cle size and narrow size distribution. TFR and electro-formation are examples
of top down nanoparticle formation, in which a bulk amphiphile transitions to
dispersed particles. Bottom up approaches, in which particles are formed from
molecularly dissolved amphiphile chains, tend to form smaller particles. Bottom
up approaches typically utilise a switch in amphiphile solubility. PMPC-PDPA
may for instance be dissolved in acidic water, which when raised to a neutral pH
will cause this pH sensitive copolymer to precipitate as the PDPA block loses its
charge and gains a hydrophobic nature, resulting typically in vesicle and micelle
formation [357, 358]. Figure 1.11 lists some common methods of formation and
post processing, along with the range of vesicles sizes expected from them.
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FIGURE 1.11: Vesicle size varies with methods of polymersome forma-
tion: DLS determined size distributions of E16B22 vesicle produced by different
methods of formation and post formation processing. Adapted from Battaglia
2006, Amphiphilic polymeric membranes (thesis), with permission.
The specific structural character of nanoparticles self assembled from diblock
copolymers can be controlled by determining block lengths, overall molecular
weight, concentration and the method of formation. As a thermodynamic pro-
cess, temperature will also be a key determinant. Further customisation, such
as ligand functionalisation, can be achieved either at the point of copolymer
synthesis, or following particle formation.
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1.3 Project aims and objectives
UA, UCA and UDCA have been shown to improve the mitochondrial function
of parkin mutant fibroblasts [198]. In these experiments, fibroblasts were incu-
bated with serum supplemented media, to which DMSO formulated compounds
were added (final concentration of 0.1% DMSO). As UA, UCA and UDCA are all
highly hydrophobic, they risk adsorption to serum proteins and cell culture plas-
tic. Previous work has shown encapsulation of hydrophobic therapeutic com-
pounds within non-fouling PMPC-PDPA polymersomes produces enhanced in
vitro drug efficacy relative to “free” drug [341]. This is believed to result from
the high concentration polymersomes can house, and the resulting high drug
“pay loads” delivered to a cell by each polymersome [341, 366]. PMPC-PDPA
polymersomes have also been shown to encapsulate large loads of hydropho-
bic compounds with high efficiency [341, 413]. Further, they are known to enter
into fibroblasts more rapidly than other copolymer chemistries [340, 341].
Thus one could hypothesise delivery of hydrophobic compounds such as UA,
UCA and UDCA by PMPC-PDPA nanoparticles could improve the drugs ther-
apeutic efficacy in fibroblasts. This project aims to create PMPC-PDPA loaded
nanoparticles loaded with UA, UCA or UDCA of biologically relevant size and
morphology, the suitability of PMPC-PDPA polymersomes to use in parkin mu-
tant fibroblasts, and the therapeutic potential of drug loaded PMPC-PDPA nanopar-
ticles relative to “naked” drug.
1.3.1 Objectives of Chapter 3: Drug Loaded Polymersomes
 Create empty PMPC-PDPA polymersomes by TFR, and characterise their
shape and morphology over time with continuing formation.
 Assess the ability of centrifugation to separate out the unique particle mor-
phologies formed by TFR.
Chapter 1. Introduction 55
 Create UA, UCA and UDCA loaded as well as unloaded polymersomes by
thin film rehydration, and characterise their morphology and encapsulation
efficiencies before and after hollow fibre filtration purification.
 Isolate “tubular” and “spherical” drug loaded nanoparticle fractions, and
assess their stability after long term storage.
 Assess the effect of drug load on nanoparticle formation and final mor-
phology.
1.3.2 Objectives of Chapter 4: Suitability of PMPC-PDPA poly-
mersome use in parkin mutant fibroblasts
 Investigate the kinetics of polymersome uptake in parkin mutant fibrob-
lasts under different bioenergetic conditions, relative to wild type (wt) fi-
broblasts.
 Assess the effect of concentration on the uptake of TFR formed nanopar-
ticles, and the relation between initial particle binding kinetics (over min-
utes), and later nanoparticle accumulation (over days).
 Determine the effect of PMPC-PDPA nanoparticle concentration on the vi-
ability and mitochondrial function of parkin mutant fibroblasts and controls,
using reproducible high content plate reader assays.
1.3.3 Objectives of Chapter 5: Polymersome mediated de-
livery of mitochondrial therapeutics to parkin mutant
fibroblasts
 Assess the therapeutic potential of UA and UCA loaded nanoparticles of
“polymersome” or “tubular” morphology in parkin mutant fibroblasts, rel-
ative to drug formulation within DMSO. The effect of concentration and
incubation time are to be investigated.
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 Assess the ability of DMSO, “Polymersomes” and “Tubes” to deliver sterol
like compounds into parkin mutant fibroblasts and controls, with increasing
concentration and incubation times.
Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Block Co-Polymer
Block co-polymer PMPC-PDPA was synthesised by Dr. J. Madsen using Atom
Transfer Radical Polymerisation (ATRP) and by Dr. N. Warren using Reversible
Addition-Fragmentation chain Transfer (RAFT). Co-polymers were characterised
by gel permeation chromatography (GPC) and 13C Nuclear Magnetic Reso-
nance (NMR) as previously described [357, 414]. Rhodamine-6G labelled PMPC-
PDPA was synthesised by Dr. J. Madsen as previously described [415]. Details
of all polymers used can be found in table 2.1.
TABLE 2.1: PMPC-PDPA batches
Copolymer Polymerisation MW
PMPC25-PDPA70 ATRP 22.3kDa
PMPC25-PDPA72 ATRP 22.7kDa
PMPC25-PDPA76 RAFT 23.5kDa
PMPC25-PDPA65 RAFT 21.2kDa
R.6G-PMPC25-PDPA70 ATRP 22.7kDa
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Limited polymer supplies required that several batches of PMPC-PDPA be utilised
during this project. However, the great majority of work reported here was per-
formed using PMPC25-PDPA65, and where appropriate R.6G-PMPC25-PDPA70.
This work includes characterisation of nanoparticle formation with and without
hydrophobic cargoes, measurement of empty and DHE loaded nanoparticle en-
try into fibroblasts, and assessment of cell viability and mitochondrial physiology
following incubation with empty and drug loaded nanoparticles over a range of
concentrations. The consistent use of PMPC25-PDPA65 throughout these key
experiments allows conclusions to be drawn over the affects nanoparticles com-
posed of this polymer produce. Work with other polymers comprise early pilot
and validation studies only; corresponding figures are listed below:
• Figure 3.5; Cholesterol incorporation alters PMPC25−PDPA72 nanoparticle
morphology
• Figure 4.1; Rhodamine labelled nanoparticle characterisation
• Figure 4.2; Polymersome uptake in fibroblasts cultured in different sugar
substrates
• Figure 4.4; Effect of Polymersome concentration on internalisation
• Figure 4.1; Percentage of fibroblasts demonstrating Rhodamine 6G labelled
PMPC-PDPA (R.6G-PMPC-PDPA) fluorescence
• Figure 4.5; DNA content of fibroblasts incubated with polymersomes
• Figure 4.9; Inter-experimental comparison of TFR and pH switch formed
polymersomes uptake in fibroblasts
• Figure 4.10; PMPC-PDPA polymersomes characterisation
• Figure 4.12; Effect of Polymersome incubation on fibroblast LDH release
• Figure 4.15; Cellular ATP assay pilot
2.1.2 Organic Solvents
Analytical grade chloroform (99.8% purity) and absolute ethanol (99.8% pu-
rity) were purchased from Fisher Scientific UK ltd. HPLC grade chromasolv R©
methanol (99.9% purity) was purchased from Sigma-Aldrich ltd.
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2.1.3 Small Molecules
UA, UDCA, UCA and cholesterol were all purchased from Sigma-Aldrich ltd.
at the highest available purity. Dehydroergosterol (DHE) was purchased from
Avanti polar lipids inc. at the at the highest available purity. Compounds were
dissolved, without further purification in ethanol or DMSO Dimethyl Sulfoxide
(DMSO), for polymersome encapsulation and cell culture purposes respectively.
FIGURE 2.1: Small molecules LogPs estimated using ACD labs Physchem
suite. Information taken from “chemspider.com”
2.1.4 Primary Human Dermal Fibroblasts
Human dermal fibroblasts were derived from punch skin biopsies of PD patients
possessing compound heterozygous mutations in parkin, (initial biopsies were
taken by Dr S. Klaffke and cell culture established by the Sheffield Children’s
Hospital cell culture service headed by Dr S. Olpin) [95]. Healthy fibroblasts
possessing wt parkin were purchased from the Coriell Cell Repository (Camb-
den, New Jersey). Mutant and wild type fibroblasts were paired by sex and age
(± 3 years age at time of biopsy).
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TABLE 2.2: Human Dermal Fibroblasts
Name Age Gender 1st parkin muation 2nd parkin muation
Ctrl1 37 F wt -
PD1 38 F het202-203delAG(exon2) hetExon2del
Ctrl2 45 F wt -
PD2 48 F het202-203delAG(exon2) hetExon4del
Ctrl3 32 M wt -
PD3 33 M het255delA(exon1) hetExon5del
Ctrl4 36 M wt -
PD4 39 M c.101-102delAG(exon1) c.1289G>A(exon11)
Ctrl5 12 M wt -
2.1.5 Cell Culture
Cells were cultured in 75cm2 flasks made of tissue culture treated polystyrene
(NuncTM). Minimum Essential Media (MEM) and Foetal Bovine Serum (FBS)
gold were purchased from PAA Laboratories GmbH (now a subsidiary of GE
healthcare). Dulbeccos Modied Eagle’s Medium (DMEM) without glucose was
purchased from Gibco R© (Life technologiesTM). MEM vitamins, non-essential
amino acids, and Penicillin-Streptomycin were purchased from Lonza. Sodium
pyruvate was purchased from Sigma-Aldrich. Uridine was purchased from Alfa
Aesar R©.
2.1.6 Physiological Assays
Flat bottomed clear and white walled well plates were purchased from greiner
bio-one. CyQUANT R©-NF cell profliferation assay kit was purchased from invitrogenTM
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(Eugene, OR, USA). CytoTox-ONETM Homogeneous Membrane Integrity As-
say was purchased from Promega (Madison, WI, USA). ATPLiteTM kit was pur-
chased from Perkin Elmer (Boston, MA, USA). MycoAlertTM Mycoplasma De-
tection Kit was purchased from Lonza Walkersville, inc. (MD, USA). Tetram-
ethyl rhodamine methyl ester perchlorate (TMRM), carbonyl cyanide 4-(triflu-
oromethoxy)phenyl-hydrazone (CCCP) was purchased from Sigma-Aldrich ltd.
at the highest purity and respectively dissolved in DMSO and ethanol with no
further purification.
2.2 Methods
2.2.1 Formation of Polymersomes by pH switch
PMPC-PDPA was dissolved in PBS [pH2-4] at 10mg/mL. The solution was
slowly titrated to pH7-7.5 by drop-wise addition of 0.1M NaOH. Turbidity con-
firmed the formation of polymersomes.
2.2.2 Formation of loaded and unloaded Polymersomes by
Thin Film Rehydration
In glass, PMPC-PDPA was dissolved in a mixture of chloroform and methanol
(2:1). Hydrophobic small molecules dissolved in a miscible solvent (ethanol)
were added at this point. Where sterility was required, the solution was filtered
through 0.2µm nylon filters into a sterile glass vial in a class II laminar flow
hood, and a 0.2µm nylon membrane secured over the vials opening. Solvents
were evaporated under vacuum for 24hrs, leaving a thin film of polymer and hy-
drophobic small molecule(s). This was then rehydrated with Dulbecco’s Phos-
phate Buffered Saline (PBS) - made up to a concentraion of 10mg/mL - and
left to stir by magnetic bar for 4 - 8 weeks. Following this, a 20 minute sonica-
tion was performed at ambient temperature (Water-bath Sonicator, S-100 from
Chapter 2. Methods 62
Sonicor Instrument Corporation; 3 litre capacity, 100W output, pulse frequency
40kHz). The process is referred as TFR.
2.2.3 Centrifugal Fractionation of PMPC-PDPA nanoparticles
Polymersomes were centrifugated at 2000 Relative Centrifugal Force (RCF) for
20 minutes, the supernatant removed by pipette, and the resulting pellet resus-
pended in a volume of PBS equivalent to the original volume. The procedure
was then repeated at 15,000RCF. Separation was confirmed by DLS.
2.2.4 Nanoparticle characterisation
2.2.4.1 Dynamic Light Scattering
DLS measures the scattering of monochromatic light within an equilibrated sus-
pension of particles over time, which can be used to assess particle size. Fluc-
tuations in light scattering result from the brownian motion of particles, where
the larger a particle, the slower its movement and ergo the slow scattered light
signal fluctuates. By recording the intensity of scattered light at a fixed point
and plotting the decay of this signal normalised to total photon count over time,
a samples auto-correlation function is acquired. The larger a particle the longer
it will take for its DLS correlation function to decay. For a mono-disperse sample
of spherical objects that do not interact with one another, a single exponential
decay will be seen. By contrast polydisperse samples will produce variable
exponents. Multi-modal samples may also be measured, these being suspen-
sions of particles in which there are two or more particulate populations whose
size centre around two distinct means, and which are discontinuous with one
another. These will produce auto-correlation functions with a stepped appear-
ance, in which at least two patterns of signal decay are superimposed onto one
another.
Chapter 2. Methods 63
Assuming a mono-disperse sample, a diffusion co-efficient that is proportional
to the duration of exponential decay can be calculated, and particle spherical
hydrodynamic diameter derived using the ‘Stokes-Einstein equation’, for diffu-
sion of spherical particles through a liquid with low Reynolds number [416]:
D =
kBT
6piηr
Where D is the diffusion constant, kB is Boltzmann’s constant, T is absolute
temperature, η is viscosity and r is radius of spherical particle. For polydisperse
samples, the measured correlation function will be the sum of intensity corre-
lations measured - meaning the auto-correlations of larger particles will pre-
dominate in these measurements - and data fitting models are required to esti-
mate the variance between multiple measurements. Data fitting of this kind is a
so called an ”ill posed” problem, being a mathematical problem to which there
are multiple valid solutions that subsequently require certain assumptions to be
made to give the most valid data fit. The Constrained Regularisation Method
for Inverting Data (CONTIN method), developed by Stephen Provencher [417],
is commonly used to estimate size variance in multimodal nano-particle popu-
lations. This technique aims to reveal “the least amount of detail or information
that was not already known or assumed, providing smooth distributions between
multiple centres of variance” and is routinely used to estimate the size distribu-
tion of polydisperse nanoparticle suspensions.
DLS measurements were performed on a Zetasizer nano zs (Malvern Ltd.) at
copolymer concentration of 0.25mg/mL. Unless otherwise stated, 3 measure-
ments at 25◦C were taken - each consisting of 12 subruns - and averaged to
give correlation functions, Z-averages achieved through cumulants analysis and
size intensity distributions and Polydispersity Index (PDI) following the CONTIN
method of analysis. A 633nm HeNe laser was used at a scattering angle of
173◦. Using both a low concentration of nanoparticles and a highly acute angle
of detection helps to reduce the effect of multiple scattering, this being the scat-
tering of light, already scattered by one particle, by further particles. Multiple
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scattering increases the probability that light will encounter larger particles in a
suspension, so decreasing measurements of multiply scattered light increases
the signal received from smaller particles.
2.2.4.2 Transmission Electron Microscopy
In Transmission Electron Microscopy (TEM), a beam of electrons is emitted by
an electron gun and focussed onto a camera detector by magnetic fields. As the
beam passes through a sample placed within its path, electron dense regions
will prevent electrons passing, creating regions of absent signal on the camera,
and from which a two dimensional image of electron dense material can be
resolved.
Copper grids (Agar Scientific) were carbon coated and glow discharged. 5 µL
of PMPC-PDPA nanoparticles at 1mg/mL were then applied to these and left to
adsorb for 60 seconds. Unattached polymersomes and PBS were removed by
blot. Grids were then exposed to 0.75% (w/w) Phosphotungstic acid (PTA)(aq)
(pH corrected to 7.4 and sterile filtered through a 0.2µm membrane for 5 sec-
onds, and again blotted dry. Excess liquid was removed by vacuum. Stained
Electron Micrographs (EM) were then imaged using a FEI Tecnai G2 Spirit elec-
tron microscope. EM were captured at 120 keV and analysed using Gatan Dig-
ital Micrograph and Image J (version 1.44o) software packages.
2.2.4.3 Fluorescence emission spectrophotometry
Fluorescence emission spectrophotometry excites fluorescent materials with
defined wavelengths of light, and measures the magnitude of fluorescent light
subsequently emitted. Where the amplitude of emitted fluorescent light remains
linear to a materials mass, standard curves can be created to determine the
mass of an unquantified sample.
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R.6G-PMPC-PDPA plus PMPC-PDPA, in the same proportions as found in rho-
damine labelled polymersomes, was dissolved in acidified PBS [pH4] and serial
dilutions performed to create a standard curve. Samples of rhodamine labelled
polymersomes were then taken, and their R.6G-PMPC-PDPA concentration cal-
culated by interpolation from standard curve.
FIGURE 2.2: R.6G-PMPC-PDPA fluorescence standard curves: Standard
curves produced by serial dilution of R.6G-PMPC-PDPA plus PMPC-PDPA in
acidified PBS [pH4].
2.2.4.4 High Performance Liquid Chromatography
In reverse-phase High Performance Liquid Chromatography (HPLC), solubilised
samples are injected into a mobile phase, typically a mixture of organic and in-
organic solvents. This passes through a column packed with modified silica
beads that eluted compounds within a sample will adsorb to with varying avidi-
ties. Compounds are subsequently retained within the column for durations
dependent on their charge, solubility and where MW is great enough to retard
passage between packed beads, size. Mixtures of compounds can thus be
separated from one another. The mobile phase can then carry the temporally
separated materials to a detectors which are used to measure the magnitude
of compound present. Coupled with standard curves, this technique is used to
quantify the mass of compounds within samples of a known volume.
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Samples of PMPC-PDPA nanoparticles suspended in PBS were taken and
dried under vacuum over night. Compounds were then re-solubilised in a mix-
ture of acidified MeOH and water (4:1 plus 0.1% Trifluoroacetic Acid (TFA))
equal to one and half times their original volume, so as to solubilise the copoly-
mer, hydrophobic encapsulates and the salts found within PBS. This was most
effective where MeOH was added prior to water. Samples were left at 37◦C
for 30 minutes to assure solubilisation. Where turbidity was seen, the sample
was diluted in half its own volume again until clarity was acheived. Only clear
solutions were used for HPLC analysis.
Reverse-phase HPLC of samples containing UA, DHE, or cholesterol was per-
formed on a Dionex ultimate 3000 system, using a C18 analytical column (pheno-
menex R© Jupiter; octadecylsilyl ultrapure silica, C18, 300A˚, 150 x 4.6 mm, 5µm).
Samples Ultra Violet (UV) absorbance and 205nm was measured using a UV
detector. Data was analysed using Dionex Chromeleon software. Reverse-
phase HPLC of samples containing UCA, or UDCA was performed on a Shi-
madzu UFLC XR system, using a C18 analytical column (phenomenex
R© Jupiter;
octadecylsilyl ultrapure silica, C18, 300A˚, 150 x 4.6 mm, 5µm). PMPC-PDPA
UV absorbance was measured at 205nm on a diode array detector, and small
molecules light scattering measured using a Evaporative Light Scattering De-
tection (ELSD). Data was analysed using Shimadzu Labsolutions LCSolution
software. Column temperature was set to 30◦C in both sets of equipment.
UA and UDCA containing samples were injected into an initial mobile phase
of 60% MilliQ filtered water (MQ) and 40% [0.1% TFA] (eluent A) Methanol
(MeOH) [0.1% TFA] (eluent B). The following multistep gradient was then used
at a flow rate of 1mL/min; 0 minutes 30% eluent B, 5 minutes 30% eluent B, 12
minutes 100% eluent B, 20 minutes 100% eluent B, 21 minutes 30 % eluent B,
26 minutes 30 % eluent B. The column was cleaned with 20 column volumes
(1mL/min flow for 30 minutes) of 100% methanol and 5% methanol.
UCA, DHE and cholesterol containing samples were injected into an initial mo-
bile phase of 60% MQ and 40% [0.1% TFA] (eluent A) MeOH [0.1% TFA] (eluent
Chapter 2. Methods 67
B). The following multistep gradient was then used at a flow rate of 1mL/min; 0
minutes 30% eluent B, 5 minutes 30% eluent B, 12 minutes 100% eluent B, 22
minutes 100% eluent B, 23 minutes 30 % eluent B, 28 minutes 30 % eluent B.
The column was cleaned with 20 column volumes (1mL/min flow for 30 minutes)
of 100% methanol and 5% methanol.
FIGURE 2.3: Calibration curves of known standards: Calibration curves
of known standards following HPLC. Sample UV absorption at 205nm of light
scattering was measured, and area under curves (AUC) calculated, from which
calibration curves were constructed.
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FIGURE 2.4: Example HPLC traces: HPLC traces of solubilised PMPC-PDPA
plus compounds. (a) UV detection (205nm) and (b) ELSD detection.
2.2.5 Purification by Hollow Fibre Filtration
In Hollow Fibre Filtration (HFF), solutions are passed through hollow fibres pos-
sessing pores of distinct size / Molecular Weight Cut Off (MWCO), tangental
to the direction of flow (figure 2.5a). This allows particles and/or molecules
of low enough size to pass out whilst continuously moving larger particles on-
wards, preventing their lodging within these pores, retarding the filtration pro-
cess. The extent of flow required for complete filtration of TFR formed poly-
mersomes from unencapsulated material was assessed using Bovine Serum
Albumin (BSA). 1mM BSA (69.3kDa) was added to a 10mg/mL solution of
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TFR formed PMPC-PDPA nanoparticles and dilute either 50, 100 or 150 times.
These were passed through porous hollow fibres (MWCO 500kDa, ∼20-50nm
) at 15mL/min, until the original volume was reached. For comparison, BSA
nanoparticle solutions were also purified by Gel Permeation Chromatography
(GPC). Sepharose-4B beads (45-165µm , 35-50kDa pores) were packed into
a 10mm  column to 75mm in height, and to which 200µL of nanoparticle plus
BSA solution was added from the top. As BSA molecules are close in size, they
will in part enter sepharose pores were they will temporarily be retained, and so
will exit the column after larger nanoparticles which pass between beads without
retention (figure 2.6b). Fractions were collected in a 96 well plate, each ∼100uL
in volume (two drops), and turbid fractions combined. A second round of GPC
was used to confirm full separation. UV-HPLC was used to determine BSA and
copolymer concentrations of samples before and after purifaction steps (figure
2.5c).
FIGURE 2.5: Validation of purification techniques for PMPC-PDPA
nanoparticles: Cartoons of (a) HFF and (b) GPC. (c) BSA : PMPC-PDPA ra-
tios (w/w) of polymersome plus BSA suspension, following purification by HFF,
or GPC Images adapted from the Wikimedia Commons with permission
The ability of HFF to remove micellar UA was also validated. An UA thin film
was solvent cast from a 1mM stock (ethanol), rehydrated to 1mM in PBS and
agitated by magnetic stirrer (700rpm) for 4 weeks. The resulting solution was
added to TFR formed polymersomes (10mg/mL), which were then diluted 1 in
100, and purified by HFF using ∼20nm/500kDa pores until the original volume
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was re-established. Quantification by UV-HPLC reveals a decrease in UA con-
centration following HFF (figure 2.6).
FIGURE 2.6: Purification of micellar UA by HFF: HPLC traces of polymer-
some plus micellar UA before and after HFF at a 1 in 100 dilution. UA to
PMPC-PDPA ratios (mol/mol) are indicated.
2.2.6 Primary Fibroblast Culture
Fibroblasts were kept at 37◦C and 5% CO2, and fed three times a week in
MEM supplemented with; 10% FBS, L-glutamine (2 mM), sodium pyruvate
(1mM), penicillin (100 IU/mL), streptomycin (100µg/mL), uridine (50µg/mL), and
1x MEM vitamins. Cells were subcultured at 80-90% confluence by chemical
detachment (1x Trypsin plus EDTA or versene). Mycoplasma testing was per-
formed fortnightly using the MycoAlertTM Mycoplasma Detection Kit (assay per-
formed by Mrs. H. Crewe)
2.2.7 Physiological Assays
For physiological assays, cells were seeded into well plates at the required
number and left to grow in media for 24 hours. 48 hours prior to physiologi-
cal assays, cells were washed and left in galactose media consisting of; MEM
(without glucose), supplemented with 10% FBS, sodium pyruvate (1mM), peni-
cillin (100 IU/mL), streptomycin (100µg/mL) and 0.9 mg/mL galactose, as de-
scribed before. 24 hours prior to physiological assays cells were changed into
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fresh galactose media containing desired testable conditions (small molecules,
polymersomes or appropriate controls). Testable conditions were applied in trip-
licate unless otherwise specified. Physiological assays comparing healthy and
parkin mutant fibroblasts utilised cells matched by sex and subject age to within
three years at time of biopsy. Cells were matched to within one passage of one
another, and no fibroblasts were assayed passed passage 14.
2.2.7.1 Lactate Dehydrogenase release assay
Lactate Dehydrogenase (LDH) is a ubiquitous and highly stable cytosolic pro-
tein. An increased presence in extracellular LDH is good indication of increased
membrane permeability, itself a sign of cellular toxicity. LDH release was as-
sessed in fibroblasts using the CytoTox-ONETM Homogeneous Membrane In-
tegrity Assay kit (Promega, Madison, WI) according to the manufacturers in-
structions. Briefly, fibroblasts were seeded in a clear 96 well plate at 5000 cells
per well and cultured as described abovel, except that conditions were applied
to six wells instead of three. Cells were equilibrated to room temperature, and a
100% lysis solution was added to three of the six wells assigned to each tested
condition. 100µL of ”assay buffer” was applied to all wells containing cells plus
media only ”blanks”, and shaken at 700rpm for 10minutes. The presence of
LDH linearly catalyses the process leading to resazurins - present in the ”assay
buffer” - conversion to the fluorescent resorufin . 50µL of ”stop solution” was
then added to all wells, and shaken at 700rpm for 10 seconds. Resorufin fluo-
rescence (excitation = 560nm, emission = 590nm) was then measured was then
measure on a plate reader (Omega Fluostar, bottom reading). LDH release was
expressed as:
(
MeanF luorescence−Blank
Mean F luorescence 100% Lysis−Blank
)
× 100 = LDH Release (%)
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2.2.7.2 Mitochondrial Membrane Potential assay
In order to produce ATP, the mitochondria must establish a proton gradient
across its inner membrane. Decreases in the electrochemical potential are a
good indicator of a dysfunctional ETC. MMP was assessed as previously de-
scribed [95, 418]. Briefly, cells were seeded in clear 96 well plates at 5000 cells
per well and cultured as described above , except that conditions were applied
to six wells instead of three. CCCP - a chemical uncoupler of the mitochondrial
respiratory chain - was applied to half the wells of each experimental condition
1.5 hours prior to the assay (final concentration 10µM). One hour later, media
is removed from all cell and blank wells, and replaced with 100µL of 150nM
TMRM made up in standard assay buffer (80mM NaCL, 75mM KCl, 25mM d-
glucose, 25mM HEPES, solution corrected to pH7.4) and left to incubate for 30
minutes at 37◦ C. TMRM, a ”Nernstian dye”, is known to accumulate within cells
and organelles in a membrane potential dependent manner [419], though also
strongly adsorbs to the polystyrene of 96 well plates. Thus TMRM is removed
and wells are washed 3 times with 150µL PBS - to remove excess TMRM - and
left in 100µL PBS. TMRM fluorescence (excitation = 530, emission = 580) is
then read on a plate reader (Omega Fluostar, bottom reading). Mean TMRM
fluorescence of cells in the prescence of CCCP (i.e. lacking the MMP) and
without (i.e. whole cell membrane potential) can then be calculated for each
condition. 50µL of CyQUANT R©-NF solution, made up as per the manufactur-
ers instructions, is then added to all wells and left to incubate at 37◦C for 1
hour. CyQUANT R©-NF fluorescence (excitation = 485nm, emission = 530nm)
was read on a plate reader(Omega Fluostar, bottom reading), and is used as
an inference of cell number:
Mean TMRM Fluorescence− TMRM Blank
Mean CyQUANT R©Fluorescence− CyQUANT R© Blank = MMP /DNA (a.u.)
Membrane Potential−Membrane Potential with CCCP = MMP/DNA (a.u.)
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The MMP assay has previously been performed using 10 minute TMRM incu-
bation periods, however this was found to produce weak signal to noise ratios.
Incubation of 150nM TMRM over 30 minutes was selected as reliable follow-
ing optimisation studies (figure 2.7a). Confocal microscopy at consistent laser
exposure and gain settings confirmed loss of mitochondrial TMRM staining in
cells pretreated with 10µM CCCP persisted after 30 minutes (figure 2.7b).
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FIGURE 2.7: Optimisation of TMRM incubation periods: Ctrl1 and Ctrl5
were incubated with 150nM TMRM in standard assay buffer for 10, 20, 30, 40
and 50 minutes. Matched conditions including 1 hour incubation with 10µM
CCCP were included. (a) Fibroblast TMRM fluorescence minus TMRM plus
CCCP fluorescence (n = 3). (b) Confocal microscopy images of fibroblasts and
fibroblasts pretreated with CCCP following 30 minute incubation with TMRM
(taken with Zeiss 510 LSM confocal microscope; 60x objective, scale bars =
50µm).
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2.2.7.3 Cellular ATP Levels
Cellular Adenosine Triphosphate (ATP) levels were measured using the the
Perkin ElmerTM ATPlite kitTM according to the manufacturers instructions. Briefly,
fibroblasts were seeded in a white walled 96 well plate at 5000 cells per well
and cultured as described above. Cells and blank wells were then equilibrated
to room temperature, and their media was removed and replaced by 50µL of
lysis buffer. Plates were shaken at 700rpm for 5 minutes on an orbital shaker,
following which 50µL of ATP substrate - containing luciferin and luciferase - was
added to each well, and shaken for a further 5 minutes. 100µL of PBS was
added to every well, and the plate removed from all sources of light to dark
adapt for 10 minutes. In the presence of ATP and O2, luciferase catalyses the
conversion of luciferin to oxyluciferin and a number of other products including
light. Luminescence was measured on a plate reader (Omega Fluostar, bottom
reading). Plates were then removed and 50µL of CyQUANT-NF R© - made up
as per manufacturers instructions - was added to all wells, and left to incubate
at 37◦C for 1 hour. The CyQUANT R©-NF solution contains a cell permeabilisa-
tion agent and a DNA binding dye whose fluorescence greatly increases when
bound. CyQUANT R© fluorescence (excitation = 485nm, emission = 530nm) was
read on a plate reader(Omega Fluostar, bottom reading), and is used as an
inference of cell number. Cellular ATP levels calculated as follows:
Mean ATPlite R© Luminescence−Blank
Mean CyQUANT R© Fluorescence−Blank = ATP/DNA (a.u.)
Cellular ATP and DNA assays produce signals independent of one another, and
both of which show good linearity over a wide range of cell number [420–422].
However as assays are performed sequentially on the same lysed fibroblast
population, it is possible that aspects of the ATP assay may interfere with the
linearity of the DNA assay. To test this, healthy and parkin mutant fibroblasts
were detached and aliquoted in PBS at 500, 1000, 5000, 10,000 and 20,000
cells per well. Both assays were then performed sequentially as before. A
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linear positive correlation between cell number,ATP and DNA signal was seen
in all fibroblasts tested (figure 2.8 a,b,c).
FIGURE 2.8: Linearity of DNA quantification after ATP bioluminescence
assay: Fibroblasts were detached, resuspended in PBS and aliquoted into a
96 well plate at 500, 5000, 10,000 and 20,000 cells per well. (a) CyQuant and
(b) ATP assays were then performed sequentially and linearity between cell
number, and (c) each over tested (error bars = SD derived from three technical
repeat within a single experiment i.e. n = 1).
2.2.7.4 Polymersome uptake assays
Cells were seeded in 12 well plates at 33,000 cells per well and cultured as
described above with some exceptions. 24 hours prior to the application of
polymersomes, wells were changed into galactose media. Fluorescent poly-
mersomes were then applied directly to cell wells at the desired concentration,
and left to incubate for the desired time. Application of polymersomes was stag-
gered so that the varied incubation times would be reached concurrently, and
so polymersome uptake could be assayed in parallel. A control population incu-
bated with no polymersomes was also included and one technical repeat was
performed for each condition per assay. Following polymersome incubation,
cells were washed five times and detached (1% trypsin). Cells were centrifuged
at 1000RCF in 1.5mL eppendorfs for 5 minutes and resuspended in 400µL cold
PBS (4◦C). Flow cytometry was then performed using either a BD FACSArrayTM
Bioanalyzer, a Life technologies Attune R© autosampler or a BDTM LSRII as in-
dicated. Forward scatter, side scatter fluorescence lasers were calibrated be-
fore each experiment according to the manufacturers instructions. Size gating
was determined using a control population of fibroblasts, one for each fibroblast
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set. The fluorescent emissions of Rhodamine 6G labelled PMPC-PDPA fluores-
cence (excitation = 538nm, emission = 575nm) and where present DHE (exci-
tation = 325nm, emission = 375nm) were measured in 10,000 size gated cells.
Laser intensity was calibrated to produce a signal for the weakest signal/short-
est incubation time, and kept constant within all experiments in a series. Data
was analysed using the software local to the equipment in use.
2.2.8 Statistical analysis
All statistics were calculated using Graphpad Prism R© version 5. Where appro-
priate, statistical significance was determined using p values as follows; p ≤
0.05 = * , p ≤ 0.01 = ** p ≤ 0.001 = ***, p ≤ 0.0001 = ****.
• Student’s t-test was used to assess the probability that the mean of two popu-
lations was different where data did not, or could not be assumed to possess a
normal distribution.
• The Mann-Whitney test was used to assess the probability that the mean of two
large data sets (n >100) was different, where data did not fit a Gaussian distribu-
tion according to the “D’Agostino and Pearson omnibus normality test”.
• One-way Analysis Of Variance (ANOVA) was used to assess the probability that
the mean outputs from varied instances of the same treatment group (e.g. poly-
mersome concentrations) within a single cell line were different.
• Two Way Analysis Of Variance (ANOVA) was used to assess the probability that
the mean outputs produced by two categorically independent conditions (e.g.
polymersome concentration and cell type) were different and to what extent these
two conditions interacted with one another. Multiple comparisons were made
following the Bonferoni correction, to assess for specific statistical differences
between two groups within the same condition.
• Regression analysis was used to assess the correlation between a measured
output and a scalable variable, as well as the linearity of any relationship.
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Except where stated, results constitute three independent experiments, in each
of which three measurements were taken.
Chapter 3
Results: Drug Loaded
Polymersomes
3.1 Aims
To form and purify cePMPC25-PDPA65 nanoparticles encapsulating UA, UCA,
UDCA, cholesterol, or nothing. The size, shape and encapsulation efficiencies
of these are to be characterised, and the nature of their pathway to formation
investigated.
3.2 Background
PMPC-PDPA, a pH sensitive diblock co-polymer self-assembles into nano- and
micro-scaled structures on hydration owing to hydrophobic and hydrating forces.
PMPC–25 PDPA70 is a membrane forming diblock copolymer that tends to assem-
ble into energetically stable isotropic vesicles known as polymersomes [358].
The membranes of these are able to retain hydrophobic compounds, allowing
polymersomes to act as water soluble vectors to insoluble molecules [341, 404].
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Polymersomes are also capable of delivering hydrophobic compounds into en-
docytically active cells [402, 404].
The hydrophobic small molecules UA, UCA and UDCA1 were recently identified
as potential PD disease modifying agents (figure 2.1) [198]. UCA and UDCA
are both tetracyclic triterpenes and bile acid derivatives [423], whilst UA is a
pentacyclic triterpene found in a number of plants [271]. They bear similari-
ties to cholesterol, a compound that in mammals is packaged into nanoscopic
lipoproteins so it may be effectively transported through systemic circulation
to numerous locations [287, 288]. Due to their hydrophobicity, UA, UCA and
UDCA have previously been conjugated to water soluble compounds where
they acted as the hydrophobic component of amphiphilic molecules designed
to self assemble into nanoscopic micelles [424–426]. UA and UDCA have also
been packaged within liposomal membranes, which demonstrated enhanced
mechanical properties over empty liposomes [427–429].
Here UA, UCA and UDCA loaded polymersomes are formed by TFR of pre-
mixed polymer-drug films at a final concentration of 10mg/mL in PBS. These
were purified by tangental flow filtration, following which cargo encapsulation
efficiencies, particle morphologies and particle size distributions were charac-
terised. Encapsulation of these compounds was found to alter the morphol-
ogy of polymersomes in a fashion akin to previous observations with NBD-
Cholesterol encapsulation. The nature of these morphological changes is in-
vestigated further with UA, UCA, UDCA and Cholesterol by morphological frac-
tionation and mass quantification.
3.3 Thin film rehydration of PMCP25−PDPA65
In TFR, nanoparticles are formed from a thin film of amphiphile and the de-
sired encapsulate. Hydration of this film in the presence mechanical energy
results in the formation of nanoparticles and the highly efficient encapsulation
1Predicted logPs; UA = 7.3, UCA = 8 and UDCA = 4.9
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of hydrophobic compounds [341, 413]. Use of high MW diblock copolymer has
proven particularly effective in this regard, likely owing to the large membrane
cores and robust nature of the nanoparticles they form [321, 341].
A PMPC25−PDPA65 film was solvent cast and rehydrated in PBS to a concentra-
tion of 1% w/w. Agitation by magnetic stirrer was applied over four weeks and
the resulting particulate suspension was sonicated for 20 minutes. This pro-
duced dispersed particles of heterogenous morphology, ranging from isotropic
particles resembling typical polymersomes to large lyotropic and high genus
2 structures with tube like protrusions (figure 3.1a,c). No multi-lamellar as-
semblies were apparent. This contrasts with the isotropic dispersed particles
that would be expected at this concentration when using similar copolymers
[409, 412], and indeed, which particles formed using the pH switch method of
formation possessed (figure 3.1 b). Concordantly, those particles produced by
pH switch were of smaller average size and size distribution compared to those
particles formed by TFR (figure 3.1 c). Small particles <50nm were seen with
both methods of formation, either representing micelles formed during TFR or
more probably the result of vesicles that ”burst” during drying steps required of
the staining procedure (figure 3.1 a,b)[430].
During TFR, water and membrane forming amphiphile films diffuse into one
another developing a concentration gradient of water [412]. At the interface,
hydrophilic blocks hydrate and begin to effectively ”repulse” one another, whilst
the insoluble blocks are pushed away from water and driven together. Stud-
ies with large MW poly(ethylene oxide)copoly(butylene oxide) (EB) have shown
membrane forming copolymers arrange themselves into planar sheets known
as lamellae or long rods that later transition to lamellae [407, 409]. As the lamel-
lae continue to swell with water, the effects of hydrophobic and hydrating forces
become stronger, eventually resulting in membrane unbinding events that occur
with thermodynamic fluctuations, and from which “sponge phases” are formed
[407, 409]. As water continues to diffuse into these and alter the balance of
2“Genus” is used in its topological sense, and refers to particles possessing holes within their
bulk that do not break the membrane
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forces holding such assemblies together, copolymer amphiphiles continue to
unbind into more energetically favourable structures, until particles of energetic
uniformity are created. TFR subsequently generates a wide “spectrum” of initial
metastable and stable morphologies, which all typically transition into isotropic
structures with the addition of further external energy, such as ongoing stirring
or sonication (figure 3.1e) [412, 431].
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FIGURE 3.1: Thin film rehydration of PMPC25−PDPA65 produces mixed
particle morphologies: EMs of PMPC25−PDPA65 nanoparticles formed by
(a) TFR over 4 weeks and (b) pH switch methods of formation, both following 20
minutes sonication (scale bar = 500nm, magnified sections indicated by boxed
selection). (c) DLS determined auto-correlation functions (left) and calculated
size distributions by intensity (CONTIN algorithm) (right) for both nanoparticle
suspensions. (d) DLS auto-correlation functions of TFR formed nanoparticles
over 8 weeks formation. (e) Proposed transitional pathway of from bulk film to
isotropic dispersed particles during TFR; images taken from multiple fields of
view of the same electron micrograph
(scale bar = 200nm).
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The presence of “lyotropic structures” after four weeks stirring that were resilient
to sonication was unexpected. Diblock copolymers possess CACs close to zero,
so once an assembly is closed, the number of amphiphile chains within is es-
sentially fixed and non exchangeable [408, 432]. Thus morphological changes
must occur by membrane fission/unbinding. The long lived nature of large,
metastable particles here may be due to the high viscosity large MW copolymer
membranes possess, and the formation of surprisingly stable initial metastable
assemblies owing perhaps to unique polymer chain arrangements in bulk film
[410, 433]. None the less, DLS over time reveals a particulate population tend-
ing towards smaller and more uniform sizes over weeks (figure 3.1d), indicating
the presence of metastable assemblies slowly re-arranging into smaller, more
energetically favourable structures. Arranging particle morphologies by order of
size reveals a possible transitional pathway (figure 3.1e). Large intact planar
structures are visible throughout the nanoparticle suspension. As open ended
membrane sheets cannot exist in water, and end capping of discs only occurs
only at great energetic cost with diblock copolymers, these are likely enclosed
structures [434]. It is also notable that they possess irregular/non-uniform mor-
phologies, another indication of the surprising stability presumably metastable
structures in this particle population demonstrate. These planar structures ap-
pear to evolve holes that expand to form large interconnected tubular networks,
which break from the bulk to form dispersed tubes and high genus structures.
Tubes, branched tubes and tori of smaller scale are observed, and evidence
of “pearling” is seen within these, instabilities which can result in budding and
the formation of smaller tubes and/or vesicles. The absence of multi-lamellar
structures is notable, and suggests bulk PMPC25−PDPA65 may evolve directly
into the large suspended structures seen here.
By contrast, when PMPC25−PDPA65 were formed by a bottom up approach, the
pH switch method, the great majority of particles produced were vesicles (fig-
ure 3.1b). This utilises the rapid switch in PMPC25−PDPA65 solubility above and
below its acid dissociation constant (pKa), allowing molecularly dissolved am-
phiphile chains to freely assemble without prior ordering. That only vesicles and
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micelles form underlines the energetic and entropic favourability these struc-
tures possess, and that PMPC25−PDPA65 assemblies will ideally tend towards
arrangements of energetic uniformity. Vesicles produced by both methods are
of similar size (figure 3.1a,b).
Work in collaboration with James Robertson [435] showed PMPC−PDPA nanopar-
ticles could be separated on the basis of size and density using stepwise cen-
trifugal fractionation, without marked morphological changes. Centrifugation at
2000RCF, separation of supernatant and pellet, and further centrifugation of this
supernatant at 15000RCF was found to reliably produce fractions enriched with
larger “lyotropic aggregates”, “tubular” and high genus assemblies or smaller
tubular and spherical “polymersomes” (figure 3.2a). Polymersomes were cre-
ated by TFR, and samples taken and sonicated at weekly intervals up to four
weeks, and a final sample taken after 8 weeks formation. These were split into
the described morphological fractions and their relative masses determined us-
ing UV-HPLC (figure 3.2b, validation of HPLC method in Chapter 2). An initial
transition from larger “lyotropic aggregates” to “tubes” and “polymersomes” is
seen over the first 4 weeks, after which the presence of “polymersomes” over-
takes the predominance of “tubes” indicating a transition of the former into the
latter. This further supports the presence of long lived large metastable struc-
tures within the nanoparticle suspension.
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FIGURE 3.2: Centrifugal fractionation of nanoparticles: TFR of
PMPC25−PDPA65 proceeded for 8 weeks under continuous agitation by mag-
netic stirrer. Samples were taken at weekly intervals, sonicated, and centrifu-
gally fractionated. (a) DLS auto-correllation profiles and CONTIN calculated
size distribution for of each centrifugal fraction, plus un-fractionated particles
after 8 weeks formation. (b) The relative masses of each fraction during con-
tinuing agitation were determined by UV-HPLC (mean 3 separately prepared
samples; error bars = SD). (c) Two separate fields of veiw from EM supporting
nanoparticles from “Polymersome”, “Tube” or “Lyotropic Structure” fractions,
following 8 weeks formation (scale bar = 500nm).
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3.4 Formation, purification and characterisation of
PMPC25−PDPA65 nanoparticles encapsulating
tetracyclic and pentacyclic compounds
PMPC-PDPA polymersomes encapsulating hydrophobic compounds have pre-
viously been prepared by TFR, with high resulting encapsulation efficiencies fol-
lowing purification by GPC [341]. Encapsulation of UA, UCA and UDCA within
PMPC25−PDPA65 nanoparticles was trialled with films designed to produce a
10µM (low concentrations) or 1mM (high concentration) drug solution, at copoly-
mer concentrations of 10mg/mL. Following 4 weeks formation, nanoparticles
were characterised by DLS, TEM and drug/copolymer concentrations quanti-
fied by UV-HPLC (figure 3.3 and table 3.1). Nanoparticles were then purified by
HFF, following which drug and polymer concentrations were re-quantified (table
3.1).
TABLE 3.1: Copolymer and drug concentrations (mean of 3 measurements
± SD), drug encapsulation efficiency (EE, % initial drug present) and drug :
copolymer ratios (mol/mol) of nanoparticles after formation and HFF. Post HFF
values are corrected for differences in volume.
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FIGURE 3.3: Drug loaded PMPC25−PDPA65nanoparticles: (Top) Electron
micrographs and DLS auto-correlation functions, and size distributions by in-
tensity of drug loaded nanoparticles are shown for each compound in rows.
Light grey = 10nmol/mL drug per 10mg/mL copolymer, Dark grey = 1µmol/mL
drug per 10mg/mL copolymer, and for reference dotted lines = 10mg/mL
copolymer alone.
Drug loaded nanoparticles took on a spectrum of morphologies similar to those
seen with unloaded nanoparticles, though possessed larger size distributions
(figure 3.3). Drug and copolymer quantification after formation revealed neither
drug loaded or pristine copolymer films formed into nanoparticles with 100%
efficiency (table 3.1), reflected by a visible unsuspended / insoluble mass within
these samples. Following purification by HFF, the proportion of drug encap-
sulated is essentially unchanged at the low concentration, indicating almost all
drug is present within co-polymer particles (table 3.1). At the high drug con-
centration, a slight though marked drop in % drug and drug:copolymer ratio is
seen. It is unknown whether this results from the loss unencapsulated material
or as a result of the purification, between ∼20-30% of copolymer being lost by
the HFF process.
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Nanoparticles were next centrifugally fractionated, and separation confirmed by
DLS (figure 3.5). ELSD/UV-HPLC revealed a greater proportion of drug within
the “tube” fraction, relative to copolymer. The “polymersome” and “tube” frac-
tions were stored at 4◦C for 6 months and size distributions re-assessed. Drug
loads were also re-characterised following purification by GPC to remove any
freed drug (figure 3.5). Little deviation was seen in particle size distribution,
indicating good long term stability. The appearance of slight bimodal distribu-
tions in some particles indicates that some larger particles were present after
6 months storage, though notably the particle suspensions still had not visibly
precipitated. Similarly, drug loads did not significantly alter between the two
time-points, again indicating all the compounds readily sit within the PMPC-
PDPA membranes.
FIGURE 3.4: Long term stability of drug loaded “Polymersomes” and
“Tubes”: Size distributions for nanoparticles after 8 weeks formation (solid
lines) and 6 months storage at 4◦C (dashed lines) are shown. The drug con-
centration within copolymer (w/w% from 3 measurements) at each time point
is listed.
Chapter 3. Results: Drug Loaded Polymersomes 90
In earlier work aiming to assess the delivery of sterol like compounds into fi-
broblasts (not presented in this thesis), PMPC25−PDPA72 nanoparticles encap-
sulating the fluorescent NBD-cholesterol were formed by TFR. It was noted the
presence of “tubular” morphologies increased with cholesterol loads (figure 3.5).
Like NBD-cholesterol, UA, UCA and UDCA possess rigid cyclic backbones and
high hydrophobicities. Thus it was of interest to assess whether these too would
affect the morphologies of nanoparticles formed of PMPC25−PDPA65, the block
copolymer used throughout this thesis. The affects of cholesterol encapsulation
on nanoparticle morphology were also of interest, both for it’s similar structure
and the extensive works conducted on this molecules affects in both lipid and
copolymer membranes [436, 437]. As cholesterol is used widely in many fields,
this work may also have greater relevance to other research.
FIGURE 3.5: Cholesterol incorporation alters PMPC25−PDPA72 nanopar-
ticle morphology: TFR formed nanoparticles formed from ATRP synthesised
PMPC25−PDPA72 with target concentrations of 10mg/mL copolymer plus (a,
blue border) 0, (b, light grey border) 10nmols/mL and (c), 1µmols/mL NBD-
Cholesterol (dark grey border). (d) DLS determined size distributions by in-
tenisty. (e) Structure of NBD cholesterol.
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The effect of encapsulating tetra- and penta- cyclic compounds within PMPC–25
PDPA65 nanoparticles was assessed by centrifugal fractionation and quantifica-
tion of each fractions relative mass. Copolymer films with 0, 0.05, 0.5 and 5%
(w/w) cholesterol were solvent cast, and rehydrated under the TFR protocol.
Samples of the resulting polymer/drug suspensions were taken at 1, 2, 3, 4, and
8 weeks and sonicated for 20 minutes. Centrifugal fractionation was performed,
separation confirmed by DLS and copolymer/encapsulate concentrations quan-
tified by UV-HPLC. It is worth noting that during centrifugal fractionation the
supernatant and pellet were separated by hand, something that will have intro-
duced a level of variability. The experiment was later repeated with UA, UCA
and UDCA at the same concentrations, and with samples taken at 1, 4 and 8
weeks formation. In a concentration dependent manner all compounds tested
increased the prevalence of “tube” structures, both increasing their initial preva-
lence and apparently stabilising them against transitions into smaller “polymer-
somes” (figure 3.6) when compared to empty PMPC25−PDPA65 nanoparticles
(figure 3.2b).
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FIGURE 3.6: Relative masses of morphological fractions present within
populations of drug loaded PMCP25−PDPA65 nanoparticles during forma-
tion: Drug loaded nanoparticles were made by TFR for fixed durations, soni-
cated, centrifugally fractionated and total volumes plus drug polymer concen-
trations quantified. Line graphs show the relative % of “polymersomes” (green),
“tubes” (yellow) and “lyotropic aggregates” (red) fractions at given drug loads,
and bar charts compare relative masses between the drug loads after 8 weeks
of formation (error bars = SD from 3 individual nanoparticle populations).
If the load of tetra- / penta- cyclic encapsulate does increase the presence of
tubular particles, one would might expect to find morphological differences. In-
deed, DLS analysis suggests the unfractionated, drug loaded nanoparticles
possess wider size distributions and greater average sizes when compared
with unloaded nanoparticles. However, DLS analysis can only provide accu-
rate estimation of particle hydrodynamic diameter for relatively mono-disperse
populations, where the presence of larger particles will skew size distribution to-
ward larger average diameters. The size distribution calculations also assume
spherical particle morphology. Thus, DLS calculated size distributions for highly
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heterogenous particle can only be considered qualitative. Image analysis was
undertaken to provide a more accurate measurement of particle size and mor-
phology. Unfractionated empty and cholesterol loaded (5% w/w) nanoparticles
PMPC25−PDPA65 were imaged by TEM (29000x magnification). One full field
of view possessing an even spread of all observable particle morphologies was
selected as representative of the particle population. Particle two dimensional
perimeter, area, persistent length and branch number were measured. All par-
ticles in a field of view were measured to limit selection bias.
FIGURE 3.7: Image analysis of empty and 5% cholesterol loaded
PMPC25−PDPA65 nanoparticles: (a) EM fields of view used for particle anal-
ysis. (b) Histogram of measured persistent lengths. (c) Histogram of particle
branch numbers. (d) Histogram of particle perimeter divided by area. (statistic
performed by unpaired, two tailed Mann-Whitney test).
Mean persistent length was greater in the cholesterol loaded nanoparticles (p =
<0.0001) (figure 3.7b). Though the greater majority of structures in both sam-
ples were single branched a non-significant increase in branch number was
seen in the cholesterol loaded nanoparticles (p = 0.1465) (figure 3.7c). Choles-
terol loaded particles also possessed a significantly larger perimeter to surface
area ratio, indicative of longer tubular morphologies (p = 0.0482) (figure 3.7d).
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Taken together, this data corroborates the notion that cholesterol increases the
relative presence of tubular structures. However, the relatively small sample
size here is of note, as is the analysis of only one field of view for each sample.
To increase the throughput of this technique, attempts were made to automate
image analysis. This however was hampered by the mixture of positive and
negative particle staining, and particle clustering, both of which made it harder
to discern individual particles in quantitive terms. Progress in the image anal-
ysis of particles captured by electron microscopy have been made elsewhere
[438].
3.5 Discussion
At 1% in water (w/w),TFR of PMPC25−PDPA65 produced a range of co-existing
nanoparticle morphologies, including dispersed polymersomes, large lyotropic
structures, and branched tubular assemblies intermediate of the two (figure
3.1a). This contrasts the purely spherical morphologies seen at the same con-
centrations when formed by pH-switch (figure 3.1b) [358, 430], and the TFR of
other membrane forming diblock copolymers which too readily form into vesi-
cles from film [407, 409]. Continued agitation by magnetic stirrer resulted in de-
clining nanoparticle size, size distribution and particle density over the course
of weeks, indicating the presence of metastable entities, slowly transitioning
into smaller, more energetically favourable assemblies. Work conducted by
James Robertson used confocal laser scanning microscopy to image the ini-
tial phases of thin PMPC25−PDPA65 film decomposition on hydration in PBS at
the micron scale [435]. Consistent with other amphiphiles, the copolymer film
swelled and wrinkled, extending finger like protrusions and developing holes
which expand to create micron scaled bicontinuous networks [407, 439, 440].
However, unlike previous studies, large intact sections of these networks broke
off directly into solution. This is most likely the origin of the large, flat, irregular
lyotropic structures found in suspension, from which it is probable the observed,
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nm scaled bicontinuous tubular networks and high genus assemblies evolved.
Membrane unbinding within these would produce the smaller genus, and tubu-
lar structures. In turn, evidence is seen of pearling instabilities within tubular
assemblies, from which smaller tubes and vesicles should bud. The presence
of small spherical particles ≤ 50nm , possibly micelles, is notable [430], as is
the absence of multi-lamellar assemblies despite the persistence of other large
lyotropic phases.
The long lived nature of the lyotropic particles seen here, and their resistance
to sonication indicates that, though metastable, they possess a high degree of
stability, likely at least in part due to the high viscosity of copolymer membranes
[410, 411, 433]. As PMPC25−PDPA65 is a diblock copolymer from which discs
of a non-uniform shape are very unlikely to form, the observed large irregular
structures are likely enclosed. Their irregular geometries might result from ei-
ther interactions between the opposing membranes, or an uneven distribution
of polymer chains between the inner- and outer- leaflet, either of which could
limit membrane re-arrangements into more uniform shapes. If the latter is true,
as the number of copolymer chains present within a membrane leaflet is essen-
tially fixed at the time of membrane closure, the structures these evolve/unbind
into will also possess fewer amphiphiles within their inner leaflet. In this re-
gard it is notable that unequal distribution of amphiphile chains between mem-
brane leaflets have previously been shown to produce outwardly curving, tubu-
lar and/or branched stable vesicles [441]. Whilst other long lived, metastable as-
semblies have been seen following a TFR of diblock copolymers, these rapidly
broke into vesicles on addition external force [431]. It is also interesting to
note that genus, non-uniform structures similar to those seen here have also
been generated by pH switch, using PMPC25−PDPA94 at room temperature
and PMPC25−PDPA77 at ≤15◦C, a condition found to lengthen the PDPA77
chain [430]. As greater hydrophobic volumes increase an amphiphile’s pack-
ing factor, these assemblies are unlikely to be the result of worm like micellar
assembly. Future work may aim to look at the affect of copolymer block length,
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thin film thickness and temperature on the formation of particular nanoparticle
morphologies by TFR.
Thin films of PMPC25−PDPA65 plus UA, UCA or UDCA successfully formed into
nanoparticles on rehydration. At the lower/10µM drug concentrations, purifi-
cation by HFF did not markedly lower the drug to polymer ratios of particles,
indicating the majority of drug existed within PMPC-PDPA nanoparticles. At the
higher/1mM concentration, a small though more marked decrease is seen, indi-
cating drug enriched particles were removed either by filtration through 500kDa
pores, or entrapment within the HFF system. Though these drugs are highly
hydrophobic, limited solubility in water is seen particularly for UDCA as the
least hydrophobic of the compounds [442, 443]. It is possible that during the
TFR process, drug concentrations high enough to permit micellarisation may be
achieved, resulting in the loss of compound from the bulk film. However, TEM
of un-purified polymersomes did not reveal a discrete morphological population
of micelles or crystal like structures under 500kDa (approximately 20nm ) as
might be expected if this were the case (figure 3.3) [444, 445]. Also, drug loss
from nanoparticle suspensions does not appear to correlate with compound hy-
drophobicty, the difference between drug:copolymer concentrations before and
after HFF being approximately equal. This might indicate that particularly drug
rich particles demonstrate an increased propensity to become entrapped within
the HFF system, to which it is notable that a correlation between drug load and
particle size was also noted (3.6). However, the possibility that a fraction of
drug is lost as micelles or drug polymer micelles, of sizes unresolvable by TEM,
cannot be excluded.
Characterisation of drug loaded polymersomes and tubular nanoparticle frac-
tions before and after six months storage revealed little deviation in copoly-
mer to drug ratios, indicating an absence of freed drug. The size distribu-
tions of these particles was also relatively undisturbed indicating good long
term stability. This could be taken as indication the compounds readily inte-
grate with PMPC-PDPA membranes, as poor compound miscibility within mem-
branes is known to lead to phase separations between the membrane forming
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amphiphiles and their hydrophobic cargo, resulting in loss of particle stability
[437, 446]. As a hydrophobic poly-base [357], PDPA should be able to in-
teract with hydrophobic acids UA, UCA and UDCA, hypothetically permitting
their presence throughout the membrane core. Differential scanning calorime-
try, nuclear magnetic resonance, and/or X-ray scattering experiments would
however be necessary to confirm this. Other studies have also indicated good
miscibility between copolymer membranes, and sterol like compounds. For in-
stance, high encapsulation efficiencies have been reported of UA loaded, high
MW methoxy poly(ethylene glycol)poly(caprolactone) (mPEG-PCL) nanoparti-
cles [447, 448]. Similarly, dual fluorescence cross correlation spectrometry has
been used to show that TFR of cholesterol plus poly(dimethylsiloxane)-poly(2-
methyl-oxazoline) (PDMS60−PMOXA21) copolymer films (1:1 mol/mol) produce
polymersomes composed exclusively of both substances [436]. No evidence of
micro-domains was seen within these, and the particles remained stable for at
least four weeks.
In a non-linear, concentration dependent manner, encapsulation of cholesterol
was found increase the persistence of small genus, and tubular PMPC25−PDPA65
nanoparticles, apparently limiting their transition into smaller tubular and spher-
ical “polymersomes”. Image analysis of cholesterol loaded particles (5% w/w)
suggested nanoparticles were longer and more branched than control, again
suggesting larger more heterogenous structures were stabilised. Concordantly,
a separate image analysis in which tubular polymersomes alone were sampled
found a small increase the persistent length and a clear increase in the branch
number of cholesterol loaded nanoparticles relative to empty ones [435]. UA,
UCA and UDCA encapsulation produced similar increases in the prevalence of
the tubular fraction of TFR formed PMPC25−PDPA65 nanoparticles. UA, UCA,
UDCA and cholesterol, all possess rigid cyclic backbones, and were all found
to concentrate within the tubular fraction, indicative of a stabilising role within
these particle morphologies. Precisely how this might be achieved is however
unclear.
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Previous work has investigated the effect of chloroform, a water immiscible or-
ganic solvent, on the TFR poly(ethylene oxide)copoly(butylene oxide) (E16B22),
a membrane forming diblock copolymer [449]. As chloroform is soluble within
E16B22 and not water, it will readily incorporate into E16B22 membranes, where it
acts both to decrease water permeability and increase the free-volume between
copolymer chains as well as decreasing entanglement, from which improved
fluidity results. Indeed the presence of chloroform decreased the rate at which
the E16B22 films swelled, and increased the speed and frequency with which
tubular protrusions were extended. These protrusions possessed a smaller di-
ameter, and showed signs of eased transition into µm scaled uni- and multi-
lamellar vesicles. Assuming they are freely dissolved within the membrane, the
compounds tested here may produce similar effects within PMPC25−PDPA65
membranes, easing initial transitions from bulk film to more stable assemblies.
However one might then also expect eased transitions to nm scaled vesicles
with improved membrane fluidity. One possible reason why this does not occur
would be the increased hydrophobic membrane volume produced by the incor-
poration of hydrophobic compounds in the absence of a concomitant increase
in hydrophilic volume. This could shift the balance of hydrating and hydrophobic
forces, and produce re-arrangements effectively decreasing membrane curva-
ture to accommodate them [450].
An alternative explanation by which tubular structures might be stabilised is
altered membrane packing. Winzen et al. [436] showed using static- and
dynamic- light scattering, that incorporation of 5 and 50% (mol/mol) choles-
terol increased MW of isotropic PDMS60−PMOXA21 polymersomes in a con-
centration dependent manner whilst producing particles of slightly smaller di-
ameter, indicating increased membrane density. It was speculated that this may
be achieved in a fashion analogous to cholesterols role in phospholipid mem-
branes. Cholesterol possesses a rigid cyclic backbone, which when aligned
with disordered hydrophobic phospholipid tails, acts to straighten these, reduc-
ing their free volume and producing lipid membranes of increased density in
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their liquid crystalline phase [437, 451]. In their gel phase by contrast, choles-
terol acts to increase the free volume between closely packed phospholipids,
increasing membrane fluidity. Despite their more polar nature, incorporation
of UA [260, 427] and UDCA [429] have been shown to produce analogous ef-
fects in lipid membranes, as have other hydrophobic bile acids similar to UCA
[452]. A similar phenomena is harnessed in plastics. The incorporation of small
molecules know as plasticisers, into bulk polymers, acts to reduce the entan-
glement between neighbouring polymer chains and increasing their freedom of
movement. This results in the reduction of the materials glass transition tem-
perature, the temperature at which plastics transition from a brittle- to a more
malleable- state.
Large MW copolymer membranes are highly entangled within their hydrophobic
core [410]. Hypothetically, the incorporation of small rigid cyclic compounds like
UA, UCA, UDCA and cholesterol within and throughout the membrane core may
interfere with this entanglement, resulting in somewhat straightened polymer
chains, and increased polymer-polymer packing. It is also, again, notable that
polymersomes formed by pH switch from PMPC25−PDPA94 formed high genus
structures at room temperature, as did PMPC25−PDPA70 when the PDPA chain
was stretched [430]. Again the increase in the membranes hydrophobic volume
would also likely be an important factor. In the future it will be important to
determine where these compounds sit in the membrane, how they interact with
it, and how the alter its properties using techniques such as differential scanning
calorimetry, nuclear magnetic resonance and X-ray scattering.
3.6 Conclusion
UA, UCA and UDCA were successfully encapsulated within purified PMPC25–
PDPA65 nanoparticles with high efficiency and are subsequently promising as
therapeutic vectors. Distinct spherical, tubular and large lyotropic morphologies
were successfully fractionated into enriched populations. UA, UCA and UDCA
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were found to favour segregation into the tubular fraction, and there incorpora-
tion into PMPC25−PDPA65 nanoparticles increased the proportion of these tubu-
lar and genus particles. As nanoparticle of different morphologies are known to
have distinct biological interactions (Chapter 1), and given the different drug
loading efficiencies seen in the morphological fractions, later work has aimed to
compare the therapeutic effects spherical “polymersome” and “tube” fractions
(Chapter 5).
Chapter 4
Results: Suitability of PMPC-PDPA
polymersome use in parkin mutant
fibroblasts
4.1 Aim
To demonstrate the ability of PMPC-PDPA polymersomes to enter parkin mutant
fibroblasts, and to assess their suitability as a drug vector to treat the mitochon-
drial dysfunction of parkin mutant fibroblasts.
4.2 Background
For PMPC-PDPA nanoparticles to be effective as a therapeutic vector, they
must both enter the target cell and cause no adverse effects therein. Whilst
PMPC-PDPA polymersomes are known to enter many healthy cell types without
loss of viability [339, 358, 404], their entry into cells with a known mitochondrial
defect has not yet been investigated. In this chapter, the uptake of fluorescently
labelled polymersomes by healthy and parkin mutant fibroblasts is assessed
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using flow cytometry and fluorescence microscopy. In addition, fibroblast via-
bility following incubation with empty polymersomes are assessed by assays of
cytotoxicity, intracellular ATP and MMP.
Massignani et al. [339] demonstrated PMPC-PDPA polymersomes of ∼100nm
 are able to enter a large range of endocytically active primary and immor-
talised cells. In human dermal fibroblasts, internalisation was prevented by
pre-incubation with chloroquine or cooling cells to 4◦C both known to prevent
or limit endocytotic processes [453, 454]. Pre-incubation with nocodazole, an
agent known to disrupt microtubule assembly and interfere with intracellular
trafficking[455], limited accumulation of polymersomes to the surface mem-
brane only. Similarly, cell fixation prior to polymersome exposure also limited
accumulation to the cell surface [393, pg.138]. Taken together, this suggests
polymersomes are endocytosed by the cell. Recent work from Colley et al. [341]
has shown antagonisation of class B scavenger receptors significantly reduces
the uptake of PMPC-PDPA polymersomes in fibroblasts. Class B scavenger
receptors are known to bind and mediate the internalisation of a wide range
of ligands, including those bearing phosphorylcholine motifs such as PMPC
[342, 456] and have been linked to both calveolae- and clathrin- mediated en-
docytosis [394, 395]. Though polymersomes appear to accumulate on the cell
surface in abundance, they do not limit endosomal function, as demonstrated by
the effective uptake of transferrin - a known cargo of clathrin mediated endocyto-
sis - after pre-incubation with 50nM PMPC-PDPA polymersomes (aproximately
1.15mg/mL) in serum containing media [393, pg.136].
Following internalisation, evidence shows PMPC-PDPA polymersomes enter
the endolysosomal pathway [392? , 393, pg.139,141]. Here, polymersomes
are exposed to a progressively more acidic environment, as H+ pumps work to
acidify the endosomal compartments, the early endosome being typically pH
6.2-5.4, and the late endosome typically pH 5.6-5.4, depending on cell type
[457, 458]. PDPA, possessing an pKa of around 6.2-6.4 [357, 430] accepts
protons at its tertiary amine groups whilst in mildly acidic conditions. Thus
PMPC-PDPA becomes positively charged in the early endosome, increasing its
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water solubility and initiating polymersome disassembly with subsequent cargo
release.
Unlike non-pH sensitive analogues, PMPC-PDPA and its cargoes distribute
widely throughout the cell, indicating both polymersome disassembly and en-
dosomal escape [339, 404, 459]. The latter is believed to occur by transient os-
molytic disruptions within the endosomal membrane. Below its pKa, nanoscopic
PMPC-PDPA polymersomes have been shown to disassemble within millisec-
onds, wherein the number of water soluble entities sharply increases. For in-
stance, a 200nm  PMPC25−PDPA70 polymersome formed in 100mM PBS
is estimated to be formed from 1.7 × 103 copolymer chains, and encapsulate
∼ 5× 105 ionic species [404]. The rapid release of both on particle disassembly
will dramatically increase the osmotic potential of the endosomal compartment,
the pressure of which is believed to result in localised destabilisations and the
rapid flux of materials across the endosomal membrane [358, 404]. Other poly-
mersomes known to disassemble within the endosomal environment also show
cytosolic delivery of hydrophilic cargoes [397, 398]. The gain of cationic charge,
a property that can induce phospholipid membrane disruptions, may also con-
tribute to endosomal escape of PMPC-PDPA, as suggested in other systems
[460, 461]. PMPC-PDPA polymersome disassembly and escape from the early
endosome is believed to underly its apparent lack of toxicity relative to other
vectors which escape from later, and more acidic endosomal locations.
At 1.15mg/mL, PMPC-PDPA polymersomes are able to enter a wide range of
cell types without significant loss of cell viability [339]. Further, they fail to ac-
tivate immune responses in fibroblasts or immune cells [358, 392, pg.135]. Fi-
broblasts have been shown to tolerate 48 hours incubation with polymersomes,
and concentrations up to 5mg/mL without more than a 10% loss in metabolic
viability [358, 393, 404, pg.129]. Fibroblasts exposed to rhodamine loaded poly-
mersomes daily show now apparent decline in cell number after one week, fur-
ther demonstrating the biocompatibility of this chemistry [339].
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4.2.1 Exacerbation of mitochondrial defects in fibroblasts
Except where stated, experiments were undertaken with fibroblasts cultured
in glucose free media supplemented with galactose, 24 hours prior to exper-
imental conditions. Fibroblasts normally produce the majority of their ATP by
cytosolic glycolysis when cultured in glucose media, utilising little mitochondrial
OXPHOS [107]. However in galactose media, a sugar that is entered into the
glycolytic pathway at a much slower rate, mitochondrial OXPHOS is relied on
to a much greater extent to meet the energetic demands of fibroblasts [107].
It has previously been shown that cells possessing mitochondrial deficiencies
demonstrate reduced growth and loss of viability when grown in galactose me-
dia as a consequence of their increased reliance on mitochondrial OXPHOS
[462–464]. The mitochondrial defects in parkin mutant fibroblasts are also en-
hanced in galactose media [95]. Thus by using galactose media will exacerbate
phenotypes related to mitochondrial defects in fibroblasts.
4.3 Uptake of PMPC-PDPA polymersomes by parkin
mutant fibroblasts
4.3.1 Characterisation of rhodamine labelled polymersomes
Uptake of polymersomes in firboblasts was assessed using polymersomes com-
posed of PMPC-PDPA and R.6G-PMPC-PDPA (1% or 5% w/w), formed by ei-
ther pH switch or TFR methodologies [339, 415]. Figure 4.1 details the con-
centrations, morphologies and size distributions of the Rhodamine 6G (R.6G)
labelled polymersome batches used in this section. Rhodamine labelled poly-
mersomes attained morphologies and size distributions typical to the method of
formation [358, 435] (Chapter 3). Batches 1 and 2 were composed of an ATRP
synthesised copolymer whilst batch 3 was composed predominantly of RAFT
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synthesised PMPC25−PDPA65. The pH switch formed Batch 1 showed the nar-
rowest size distribution and smallest average particle size. Batch 3 initially pos-
sessed a much greater size distribution relative to Batch 2, both of which were
formed by TFR. Batch 3 was subsequently centrifuged at 10,000RCF, and the
resulting supernatant was found to have a smaller size distribution more akin to
Batch 2.
FIGURE 4.1: Rhodamine labelled nanoparticle characterisation: Batch de-
tails, two separate fields of view from EMs supporting nanoparticles, and DLS
auto-correlation functions and size distributions for each batch of rhodamine
labelled nanoparticles used in uptake studies. Batch details list; batch num-
ber, copolymers used, their proportions, method of nanoparticle formation plus
purification step, and copolymer concentration. Polymer concentrations calcu-
lated using fluorometry and known standards of matching polymer composition
(1 or 5% R.6G-PMPC-PDPA w/w; see methods 2). *Batch 3 possessed a very
large size distribution after formation, so was centrifuged at 10,000RCF and the result-
ing supernatant used for experiments.
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4.3.2 Uptake of polymersomes formed by pH switch and the
effect of fibroblast metabolic state
To assess the ability of fibroblasts to internalise polymersomes, rhodamine la-
belled polymersomes formed by pH switch (1% w/w; figure Rh. BATCH 1
4.1) were incubated with parkin mutant fibroblasts plus controls (Ctrl1 plus
PD1) for 1, 3, 12, 24 and 48 hours, in either glucose or galactose media.
Cells were washed, detached and passed through a flow cytometer to mea-
sure R.6G-PMPC-PDPA fluorescence from individual cells. Results were gated
firstly by size and granularity to include only intact fibroblasts (red ”P1”; For-
ward Scatter vs Side Scatter), and secondly by endogenous fluorescence, to
demarcate those cells that have certainly received polymersomes from those
that have not (green ”P2”; R.6G-PMPC-PDPA fluorescence)(figure 4.2a) [341].
Following 24 hours incubation, all fibroblasts tested demonstrate R.6G-PMPC-
PDPA fluorescence greater than maximal endogenous levels, in either media
(figure 4.2b). This indicates that at 1mg/mL, the polymersome to cell ratio
is great enough to ensure all cells are able to receive a measurable number
of polymersomes. Median R.6G-PMPC-PDPA fluorescence in fibroblasts in-
creases with time for all cells tested, though to a significantly greater extent in
Ctrl1 relative to PD1 (figure 4.2c; Ctrl1 gal vs PD1 gal, p <0.0001; Ctrl1 glu vs
PD1 glu, p = 0.0007). Where accumulation continues with approximate linear-
ity to 48 hours in glucose media, a threshold is reached between 24 and 48
hours in galactose media. This might be due a depletion of polymersomes from
the media, however that uptake is greater and remains linear in glucose media
suggests otherwise. Further, fibroblasts have been shown to grow slower in
galactose media both here (figure 4.3) and elsewhere [107, 464], suggesting a
less favourable nanoparticle to cell ratio, or dilution of R.6G-PMPC-PDPA signal
on cell division, are not reasonable explanations. Though galactose media re-
duces ATP levels in parkin mutant fibroblasts, it has no effect in healthy control’s
[95]. The effect of altered fibroblast physiology in galactose media on endocytic
processes thus warrants further consideration.
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FIGURE 4.2: Polymersome uptake in fibroblasts cultured in different
sugar substrates: Rhodamine labelled polymersomes were incubated with
parkin mutant fibroblasts (pink; PD1) or healthy controls (blue; Ctrl1) for 1, 3,
12, 24 and 48 hours in either a glucose or galactose based media (dashed and
solid lines respectively), and their fluorescence assessed by flow cytometry. (a)
Representative dot plots and gates used in flow cytometry experiments (SSC-
A = Side Scattering; FSC-A = Forward Scatering; Yellow-A = fluorescent light
intensity, ex. 532nm, em. 564-606nm) (b) Percentage of R.6G-PMPC-PDPA
positive cells as assessed by the p2 gate. (c) Magnitude of R.6G-PMPC-PDPA
absorption in fibroblasts, as assessed by median P1 gate fluorescence (n=4;
error bars = SD; two-way anova performed for glucose and galactose condi-
tions separately, ** = p <0.01, *** = p <0.001, **** = p <0.0001).
FIGURE 4.3: Growth curves of parkin mutant and control fibroblast: Fi-
broblasts were seeded at 5000 cells in 6 well plates in glucose, then switched
into fresh glucose or galactose medias 6 hours later. (a) Fibroblast cellular
DNA content as assessed by a DNA binding fluorophore (CyQuant
TM
) and (b)
cell number as assessed by cell counting on a haemocytometer were mea-
sured in parallel following 1, 3, 5, and 7 days incubation. (n = 1)
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4.3.3 Uptake of PMPC-PDPA nanoparticles formed by thin
film rehydration
PMPC-PDPA polymersomes encapsulating hydrophobic compounds such as
UA, UCA and UDCA, are formed by TFR, a method found to produce poly-
mersomes more tubular and genus1 in nature when compared to pH switch
method of formation (chapter 3 and figure 4.1). As size and shape are known to
affect the cellular uptake of polymersomes, the uptake of TFR formed polymer-
somes was investigated. Also, as earlier data indicated parkin mutant fibrob-
lasts may possess a deficient ability to accumulate polymersomes, a second
patient derived parkin mutant fibroblast was studied. Healthy and parkin mutant
fibroblasts (Ctrl1 plus PD1, and Ctrl2 plus PD2) were incubated with 0.1, 0.5
and 1mg/mL rhodamine labelled polymersomes (5% R.6G-PMPC-PDPA w/w;
Rh.BATCH 2 figure, 4.1) for 1, 3, 12, 24 and 48 hours in galactose media. Me-
dian fluorescence was again assessed by flow cytometry (figure 4.4).
1“Genus” is used in its topological sense, and refers to particles possessing holes within their
bulk that do not break the membrane
Chapter 4. Suitability of polymersome use in parkin mutant fibroblasts 109
FIGURE 4.4: Effect of Polymersome concentration on internalisation:
parkin mutant fibroblasts plus controls (PD1 + Ctrl1; PD2 + Ctrl2) were incu-
bated with 0.1, 0.5 and 1mg/mL rhodamine labelled polymersomes (Rh.BATCH
2 4.1) for 1, 3, 12, 24 and 48 hours in galactose media. Fluorescence was as-
sessed by flow cytometry. (a-e) The effect of polymersome concentration on
median cell fluorescence at each time-point, with linear regressions (R2 indi-
cated). (f-k) Time course of polymersome uptake at concentrations of 0.1, 0.5
and 1mg/mL (f-h, Ctrl1 vs PD1; i-k, Ctrl2 vs PD2). (n=3; error bars=SD; statis-
tics performed by two way anova, * = p <0.05, ** = p <0.01, *** = p <0.001,
**** = p <0.0001).
TABLE 4.1: Percentage of cells exhibiting fluorescence greater than maximal
endogenous levels (P2 gate). Percentages higher than 95% are indicated in
blue (data supplemental to figure 4.4)
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R6.G-PMPC-PDPA fluorescence increased linearly with polymersome concen-
tration at all time points studied (4.4a-e). Following 48 hour incubation, approxi-
mately all cells incubated with either 0.5 or 1mg/mL polymersome demonstrated
R.6G-PMPC-PDPA fluorescence greater than maximal endogenous levels (P2
gate). A substantial shift was also seen with 0.1mg/mL concentrations though
levels greater than 95% were not achieved (table 4.1). It is worth noting only
5% of the PMPC-PDPA possesses a Rh.6G conjugate, thus fluorescence signal
represents only a proportion of polymer accumulated in fibroblasts.
The time-course of polymersome internalisation reveals a rapid increase in flu-
orescence at one hour, after which R.6G-PMPC-PDPA accumulates within the
cell more slowly (4.4 f-k), something not seen, or at least not as apparent
with pH switch formed polymersomes. This might depict the rapid binding of
nanoparticles to the surface of the cell, followed by slower internalisation. Be-
tween 1 and 48 hours, internalisation is linear, suggesting an excess of nanopar-
ticle is still available for internalisation, though there are some slight signs of
saturating uptake. It is notable that accumulation of pH switch formed polymer-
somes had saturated by this time-point under identical conditions (figure 4.2c).
Where PD1 was significantly less able to accumulate R.6G-PMPC-PDPA than
its control, PD2 was significantly more able (figure 4.4), implying the mutant
parkin phenotype does not directly effect uptake. A possible explanation for
these differences would be different growth rates however, quantification of cel-
lular DNA content, a measure closely tied to cell number, demonstrates controls
consistently have greater cell numbers than parkin mutant firboblasts at the time
of assay (Two way anova, Ctrl1 vs PD1, p <0.0015; Ctrl2 vs PD2, p = 0.0015)
(figure 4.5). Differences in uptake may possibly arise from variance of polymer-
some receptors number at the cell surface.
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FIGURE 4.5: DNA content of fibroblasts incubated with polymersomes:
parkin mutant fibroblasts plus controls (PD1 + Ctrl1; PD2 + Ctrl2) seeded at
30,000 cells a well in a 12 well plate. Cells were washed, placed in galactose
media for 24 hours, then incubated with 1mg/mL rhodamine labelled polymer-
somes (Rh.BATCH 2 4.1) for an additional 1, 3, 12, 24 or 48 hours. (a,b)
Fibroblasts were washed, incubated with a cell membrane perforant DNA stain
(CyQuantTM), and fluorescence read using a plate reader. (n=3; error bars =
SD).
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4.3.4 Uptake of polymersomes formed by thin film rehydra-
tion of PMPC25−PDPA65 synthesised by RAFT
The majority of work performed for this thesis utilised polymersomes formed
by TFR of a RAFT synthesised PMPC25−PDPA65, which was found to produce
polymersomes more heterogeneous and tubular than seen with other polymer
batches (Rh.BATCH 3, figure 4.1, Chapter 3). Uptake of rhodamine labelled
PMPC-PDPA nanoparticles (5% w/w) was again assessed in three parkin mu-
tant fibroblasts plus controls. Two previously untested parkin mutant fibroblasts
were introduced to further investigate whether alterations in polymersome up-
take are associated with this phenotype. Availability of equipment required that
these experiments were performed on a different flow cytometer to that used
previously (population gating used shown in 4.6l). Fibroblasts were incubated
with 0.1, 0.5 and 1mg/mL nanoparticle concentrations. Early binding of poly-
mersomes was assessed with 1, 10 and 60 minute time points, whilst later
uptake was determined at 24 and 48 hours (figure 4.6a-j).
Chapter 4. Suitability of polymersome use in parkin mutant fibroblasts 113
FIGURE 4.6: Rapid binding, but slow internalisation of TFR formed
PMPC-PDPA nanoparticles: Rhodamine labelled polymersomes (Rh.BATCH
3 4.1) were incubated with parkin mutant fibroblasts plus controls for 1 and
10 minutes, 1, 24 and 48 hours. They were then washed, detached and
passed through a flow cytometer (BD Attune R© Autosampler). (a-j) Median
R.6G-PMPC-PDPA fluorescence of fibroblast population with increasing incu-
bation time. (k) R.6G-PMPC-PDPA accumulation at 48 hours normalised by
accumulation after 1 minute. (l) Representative dot plots from flow cytometry
experiments (SSC-A = Side Scattering; FSC-A = Forward Scattering; BL2-A =
fluorescent light intensity, ex. 488, em. 561587) (n=3; error bars = SD; statistics
performed by two way anova, ** = p <0.01, *** = p <0.001, **** = p <0.0001)
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TABLE 4.2: Linearity of polymersome concentration on magnitude of uptake.
For each fibroblast biopsy, R.6G-PMPC-PDPA fluorescence at 1 minute, 24
and 48 hours was plotted as a function of polymersome concentration, from
which linear regressions and R2 values were calculated.
After one minute, there is a dramatic accumulation of R.6G-PMPC-PDPA in
fibroblasts, the magnitude of which scales with polymer concentration (figure
4.6a-j, table 4.2). No apparent increase is seen up to one hour later. This
likely represents the rapid binding of nanoparticles to scavenger receptors on
the cell surface, followed by slow particle endocytosis. Though not seen with
spherical polymersomes (figure 4.2 c), long cell surface dwelling times have
also been observed with purified tubular polymersomes in other cell types [435].
From 1 to 10 minutes, a decrease in R.6G-PMPC-PDPA signal is notable at 0.1
and 0.5mg/mL concentrations, possibly the result of fluorescence quenching
as polymersomes are enveloped/wrapped by phospholipid membrane prior to
endocytosis [325, 326].
Following the initial binding step, a linear increase in signal is seen between
1 and 48 hours, also in a concentration dependent manner (table 4.2). At
0.1mg/mL, the increase in R.6G-PMPC-PDPA signal following the initial bind-
ing step is slight, most notably in Ctrl4 and PD4. This might suggest that very
few polymersomes actually enter the cell. However other factors must also be
considered; loss of signal through cell growth and polymer excretion, the possi-
bility that R.6G-PMPC-PDPA fluorescence is quenched on internalisation, and
the low percentage of polymer possessing a Rh.6G conjugate (5% w/w) . Flu-
orescent microscopy provides further evidence that these polymersomes are
internalised and distribute within the cell (figure 4.7). Here there is evidence of
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fluorescence throughout the cell, as well as contained within distinct puncta per-
haps reminiscent of the tubular morphologies macro-pinosomes assume during
their maturation [370].
FIGURE 4.7: Fibroblast internalisation of Rhodamine labelled polymer-
somes: Healthy fibroblast incubated with polymersomes (RhBATCH 3) at
0.5mg/mL for 48 hours in galactose media. Cells were washed and imaged
using the InCell Analyzer (60x objective; scale bar = 50µm).
Though, as in experiments with other polymersome batches (figures 4.2 and
4.6), a significant deficiency is seen in the ability of PD1 to accumulate poly-
mersomes relative to Ctrl1 (p = 0.0011, <0.0001 and <0.0001 at 0.1, 0.5 and
1mg/mL concentrations respectively), this is not replicated in the other parkin
mutant fibroblasts (4.6a-j). PD1 accumulates a notably smaller R.6G-PMPC-PDPA
signal after one minutes incubation, relative to Ctrl1 . As no apparent increase
in R.6G-PMPC-PDPA signal is seen between 1 and 60 minutes, the one minute
time point could be taken as an approximate gauge of a fibroblast’s ability to bind
polymersomes, and would suggest PD1 has fewer polymersome receptors. In
figure 4.6l, the R.6G-PMPC-PDPA signal accumulated after 24 and 48 hours
has been divided by signal after one minute to give a hypothetical normalisation
of polymer internalisation per bound receptor (i.e. the rate of internalisation it-
self). Here, there is no significant difference between parkin mutants or controls
at any of the concentrations tested (p = 0.6622).
The effect of cell number on polymersome uptake was also investigated. Fibrob-
lasts were plated at 7,500, 15,000, 30,000 and 60,000 cells a well, and grown
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for 24 hours. They were then incubated with rhodamine labelled polymersomes
(Rh.BATCH 3, figure 4.1) for 48 hours in galactose media. Cells were washed,
detached, and the population was split in two. R.6G-PMPC-PDPA accumulation
was assessed by flow cytometry with one half, and the DNA content quantified
with the other (figure 4.8). If nanoparticle number were a limiting factor, a nega-
tive correlation between uptake and cell number would be expected, as greater
cell numbers would effectively decrease the number of nanoparticles available
to each cell for internalisation. A slight negative correlation between polymer-
some accumulation and cell number is seen at lower concentrations, though the
impact is not great, suggesting overall cell number had little impact, and that a
saturation of nanoparticles bound to the fibroblast surface is achieved through-
out the 48 hour experiment.
FIGURE 4.8: Effect of cell number on nanoparticle internalisation: Fibrob-
lasts were seeded at 7,500, 15,000, 30,000 and 60,000 cells a well, grown in
glucose media for 24 hours, then in galctose media for a further 24 hours, and
then incubated with rhodamine labelled polymersomes for 48 hours. Cells were
washed, detached and resuspended. Half the population was passed through
a flow cytometer where R.6G-PMPC-PDPA fluorescence was assessed, and
the other’s cell number estimated using a cell perforant fluorescent DNA stain
(CyQuant
TM
NF). Median Rh-PMPC-PDPA fluorescence is plotted against cel-
lular DNA content for individual repeats, and lines of regression shown. Poly-
mersome concentrations are indicated (n = 3).
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4.3.5 Inter-experimental comparison
To compare the cellular uptake of each batch of rhodamine labelled polymer-
some, an inter-experimental normalisation was performed. Polymersome up-
take in Ctrl1 and PD1 following 1, 24 and 48 hour incubation with 1mg/mL
polymersomes in galactose media has been tested in all uptake experiments
described. Median fibroblast R.6G-PMPC-PDPA fluorescence at 24 and 48
hours incubation was normalised by signal at 1 hour (figure 4.9). This corrects
for differences in the gain settings of fluorescence measurements, and varied
composition of R.6G-PMPC-PDPA in polymersomes. It also assumes that the
accumulation of polymersomes on cell surface is similar between nanoparticle
batches at one hour, which is unlikely, with pH switch polymersomes demon-
strating signs of early internalisation. Therefore this normalisation must be con-
sidered qualitative only. Accumulation of polymersomes formed by pH switch
is more than two fold greater than that of TFR formed nanoparticles in both fi-
broblasts after 24 hours incubation (figure 4.9a), the point at which pH switch
polymersome uptake reached saturation (figure 4.2c). After 48 hours incuba-
tion, uptake of TFR formed polymersomes is still markedly less than pH switch
polymersomes (figure 4.9b). If pH switch polymersomes have begun entering
fibroblasts by the 1 hour time-point, then the difference in uptake between the
two methods of formation is likely greater than even shown here. This reinforces
other work which shows particles of larger sizes, and larger aspect ratios enter
into cells more slowly [322, 340, 378].
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FIGURE 4.9: Inter-experimental comparison of TFR and pH switch formed
polymersomes uptake in fibroblasts: Median R.6G-PMPC-PDPA fluores-
cence of Ctrl1 and PD1 following 24 (a) and 48 (b) hour incubation with rho-
damine labelled polymersomes was divided by median R.6G-PMPC-PDPA flu-
orescence at 1 hour. Method of polymersome formation and primary polymer
batch they were formed from are indicated along the x axis. (error bars = SD)
4.4 Effects of PMPC-PDPA polymersomes on
fibroblast viability and mitochondrial
physiology
4.4.1 Polymersome characterisation
The experiments described in this section used polymersomes formed by Thin
Film Re-hydration (TFR). Assay pilots used polymersomes made from ATRP
synthesised polymer (Batch 1 and 2, figure 4.10) and the polymersome dose re-
sponse experiments used polymersomes formed from RAFT synthesised poly-
mer (Batch 3, figure 4.10). Each batch demonstrated similar size distributions
and polymersome morphologies.
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FIGURE 4.10: PMPC-PDPA polymersomes characterisation: All polymer-
somes used to assess potential toxicity in fibroblasts were formed by TFR.
Batch details list batch number, polymer used, method of formation and con-
centration (determined by UV-HPLC). Two separate fields of view from EMs of
polymersomes, plus their DLS auto-correlation functions and size distribution
by intensity are shown.
4.4.2 Assessment of potential polymersome induced
toxicity
Potential polymersome induced cytotoxicity to fibroblasts was assessed by mea-
suring extracellular levels of LDH, a highly stable cytosolic enzyme. Increased
levels of cytosolic components outside the cell are a good indication that plasma
membrane integrity may be compromised, something known to result from cell
necrosis, apoptosis and other forms of cell death [465]. Fibroblasts from healthy
controls were incubated with 1mg/mL polymersomes (polymersomes used; fig-
ure 4.10a) for 24 hours in either glucose or galactose media, and the LDH
release assay performed in a 96 well plate according to previous protocol [95]
(Chapter 2). (figure 4.11).
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FIGURE 4.11: LDH release assay pilot: Fibroblasts from healthy controls
were incubated in either a glucose (grey bars) or galactose (blue bars) me-
dias in the absence (solid bars) or presence of 1mg/mL polymersomes (lined
bars). The top graphs (a,b) show the background subtracted resofurin emitted
fluorescence of intact and lysed cells, where the bottom graphs (c,d) show the
show the signal from intact cells as a percentage of that from lysed cells (n=3;
error bars = SD; individual data points shown).
No significant differences were found in % LDH release between conditions
(Ctrl1 p = 0.446, Ctrl5 p = 0.175), suggesting neither incubation in galactose
media for 48 hours, nor incubation with polymersomes for 24 hours induces de-
viation from baseline cell membrane integrity. As shown in figure 4.4, at 1mg/mL
polymersomes accumulate into fibroblasts linearly over 24 hour and are inter-
nalised by ≈100% of cells, so is a suitable point at which to assay for loss of
membrane integrity caused by nanoparticle uptake. Though the half-life of LDH
is approximately nine hours [466], the lack of even small deviations from base-
line LDH release during continuous accumulation of polymersomes suggest lit-
tle or no toxic insult has taken place and that signal loss due to LDH degradation
is negligible. Also, the well matched 100% lysis signals between conditions with
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and without polymersomes indicates that cell number is also unaffected. Visual
inspection by light microscopy prior to the assay confirmed similar cell mor-
phologies between conditions. It is interesting to note the apparent decrease
in the 100% lysis levels between the glucose and galactose conditions in Ctrl1
(37 year old female), indicating a smaller amount of LDH present in cells grown
in galactose media and perhaps reflecting a down-regulation of glycolysis or a
reduction in cell growth, which indeed was seen previously (figure 4.3). This
was not apparent in Ctrl5 (12 year old male).
The effect of polymersome concentration (polymersomes used; figure4.10c)
on LDH release from two parkin mutant fibroblast lines and their controls was
tested (4.12). No apparent cytotoxicity was seen at polymersome concentra-
tions up to 2mg/mL after 24 hours incubation (Ctrl1 vs PD1, p=0.4102; Ctrl2 vs
PD2, p=0.9968) (figure 4.12).
FIGURE 4.12: Effect of Polymersome incubation on fibroblast LDH re-
lease: LDH release from Ctrl1 and PD1 (a), plus Ctrl2 and PD2 (b) was as-
sessed following 24hr incubation with PMPC-PDPA polymersomes at 0.1, 0.5,
1 and 2 mg/mL in galactose media. (n=3; error bars = SD; statistics performed
by two way anova)
4.4.3 Fibroblast Mitochondrial Membrane Potential
To produce ATP by OXPHOS, mitochondria must generate a large electrochem-
ical gradient across the inner mitochondrial membrane by translocating protons
from the matrix to the IMS, something achieved by the ETC. This Mitochondrial
Membrane Potential (MMP) can be perturbed at almost any point along the ETC
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and is subsequently a useful indicator of mitochondrial health. Loss of MMP is
also one of the first steps seen in apoptosis [465]. MMP has previously been as-
sessed in intact fibroblasts using a TMRM based plate reader assay [95, 418].
It relies on three factors. First is the accumulation of a cationic and lipophilic
fluorescent dye, TMRM , within cellular compartments of electrochemical po-
tential difference, the most charged of which is the mitochondria [467]. Second
is the specific disruption of the MMP using an ETC uncoupler, CCCP. Finally,
a measure of cell number is necessary to normalise per cell the difference be-
tween whole cell membrane potential with and without the MMP. It is noteworthy
that the rigorous washing regime this assay employs to remove noise causing
excess TMRM, causes some fibroblast to detach, making normalisation by cell
number essential. All assay reagents are cell penetrant.
Using optimised incubation times (see Chapter 2), the TMRM assay was piloted
in two sets of apparently healthy fibroblasts (figure 4.13). The addition of poly-
mersomes (polymersomes used; figure 4.10c) caused no significant alteration
to MMP in either. It is interesting to note Ctrl5 demonstrated a higher MMP than
Ctrl1.
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FIGURE 4.13: Mitochondrial membrane potential assay pilot: Fibroblasts
derived from two separate healthy biopsies were incubated in either a glu-
cose (grey bars) or galactose media (blue bars) in the absence (solid bars)
or presence of 1mg/mL polymersomes (lined bars). Cells were incubated with
TMRM in standard assay buffer (150nM) and washed three times with PBS.
Additionally, replicates of each condition were incubated with CCCP (10nM)
for 1hour prior. TMRM fluorescence was read on a plate reader (ex. 544nm
em. 590nm). (a,b) Background subtracted TMRM signals normalised by back-
ground corrected CyQuant R© signal. (c,d) MMP, calculated as TMRM signal per
cellular DNA minus TMRM signal per cellular DNA in the presence of CCCP,
normalised by glucose only condition. (n=4; error bars = SD; individual data
points shown)
Next the MMP of two parkin mutant fibroblasts plus controls was assessed fol-
lowing 24 hour incubation with PMPC-PDPA polymersomes (0-2mg/mL) (poly-
mersomes used; figure 4.10c) was assessed.
No significant deviation from baseline levels were seen with increasing polymer-
some concentration (unpaired one-way ANOVA; Ctrl1, p=0.9721; PD1 p=0.9212;
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Ctrl2, p=0.9721; PD2, p=0.9212). A significant deficiency in MMP was seen rel-
ative to age-sex matched controls (Ctrl1 vs PD1 p = 0.0058; Ctrl2 vs PD2 p =
0.0027) [95].
FIGURE 4.14: The effect of Polymersomes on fibroblast MMP: MMP of
Ctrl1 and PD1 (a,b) plus Ctrl2 and PD2 (c,d), was assessed following 24hr in-
cubation with polymersomes at 0.1, 0.5, 1 and 2 mg/mL. a,c) parkin mutant
fibroblast MMP normalised to age-sex matched control. (b,c) MMP normalised
to fibroblast matched untreated controls (n = 3; error bars = SD; Statistics per-
formed by unpaired two-tailed t-test, ** = p <0.01).
4.4.4 Assessment of fibroblast ATP levels in the presence of
polymersomes
Intracellular ATP levels are routinely used to assess cell viability as they closely
correlate to cell number and metabolic capacity [468]. As the great majority of
ATP anabolism occurs by mitochondrial OXPHOS when fibroblasts are cultured
in galactose media, ATP levels per cell give a good indication of mitochondrial
function [95, 107]. Here, intracellular ATP levels of lysed fibroblast populations
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are assessed by the luciferin luciferase assay, which produces bioluminescence
proportional to ATP, and normalised by intracellular DNA content, a close corre-
late of cell number [420, 421](Chapter 2).
Fibroblasts from healthy controls were incubated with 1mg/mL polymersomes
(Batch 2, figure 4.10) for 24 hours in either glucose or galactose media. Cell
lysis was confirmed by light microscopy, and the intracellular ATP and DNA
quantification assays performed sequentially on the same fibroblast popula-
tions (figure 4.15a,b). Cellular ATP levels were normalised by cellular DNA
content to give ATP level per cell. This was then further normalised against the
ATP per fibroblast incubated in glucose media alone, so as to compensate for
inter-experimental variation and reduce variance within the conditions (figure
4.15c,d). It is interesting to note the higher ATP levels of Ctrl5 relative to Ctrl1
(figure 4.15a,b).
FIGURE 4.15: Cellular ATP assay pilot: Fibroblasts derived from two sepa-
rate healthy biopsies were incubated in either a glucose (grey bars) or galac-
tose (blue bars) medias in the absence (solid bars) or presence of 1mg/mL
polymersomes (lined bars). Cells were then washed twice in PBS and lysed.
(a,b) Background subtracted bioluminescence derived from ATP content (white
filled bars) and background subtracted fluorescence derived from DNA content
(dotted bars). (c,d) Cellular ATP per DNA content, normalised by glucose only
condition (n=4; error bars = SD; individual data points shown).
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Next, the effect of polymersome concentration (polymersomes used; figure 4.10c)
on intracellular ATP levels was tested in two parkin mutant fibroblasts plus con-
trols. As previously reported, a deficiency parkin mutant fibroblasts relative to
controls was observed in the absence of polymersomes (figure 4.16, a, Ctrl1
vs PD1, p=0.0004; c, Ctrl2 vs PD2, p=0.0049) [95, 96]. Polymersome concen-
trations of 0.1, 0.5, 1 and 2mg/mL caused no significant deviation from base-
line intracellular ATP levels in any fibroblasts tested (unpaired one-way ANOVA;
Ctrl1, p=0.9529; PD1, p=0.7213; Ctrl2, p=0.9301; PD2, p=0.8257).
FIGURE 4.16: The effect of Polymersomes on fibroblast ATP levels: Cellu-
lar ATP levels were determined in Ctrl1 and PD1 (a,b), plus Ctrl2 and PD2 (c,d)
following 24hr incubation with PMPC-PDPA polymersomes at 0.1, 0.5, 1 and
2 mg/mL in galactose media. (a,c) parkin mutant fibroblast cellular ATP levels
normalised to age-sex matched control. (b,c) Cellular ATP levels normalised
to fibroblast matched untreated controls (n = 3; error bars = SD; statistics per-
formed by unpaired two-tailed t-test, ** = p <0.01, *** = p <0.001)
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4.5 Discussion:
PMPC-PDPA polymersomes made by pH switch and TFR have been shown to
accumulate on and within parkin mutant fibroblast in galactose media, which
forces fibroblasts to rely more heavily on mitochondrial OXPHOS for ATP an-
abolism. Variation was seen between all fibroblasts tested and appeared in-
dependent of mutant parkin or wild type phenotypes. It was determined with
polymersomes made by TFR of RAFT synthesised polymer (RhBATCH3, figure
4.1) that faster fibroblast growth rate did not significantly contribute to individual
fibroblasts ability to accumulate polymersomes at the concentrations studied. A
correlation between ability to bind polymersomes after one minute and ability to
accumulate polymersomes at 24 and 48 hours was seen (figure 4.6). This ratio
was similar between all fibroblasts studied suggesting the rate at which control
and parkin mutant fibroblasts endocytose PMPC-PDPA nanoparticles is approx-
imately the same, and that differences in uptake might mostly depend on varied
nanoparticle receptor levels. There is evidence that class B scavenger receptor
protein levels are altered in the brain and liver of parkin knock-out mice, and that
this correlates with reduced lipid uptake [469]. However, much of this phenotype
requires a high fat diet to manifest. The galactose media used here exposed
fibroblasts only to those fats present in the FBS used, which though sadly a
“black box” regarding exact lipid content, is derived from bovine fed on a low fat
grass diet, thus plasma levels are perhaps unlikely to exceed a specific high fat
diet. Over-expression of parkin was shown to increase lipid uptake, something
also largely dependent on class B scavenger receptors, and this was mitigated
by deletion of the ubiquitin like region, primarily coded for in exon 2 of PARK2
[469]. Interestingly the fibroblast demonstrating lowest polymersome uptake rel-
evant to control was also the only to possess mutations effecting exon 2 in both
copies of PARK2 (table 2.2, PD1). Similarly, parkin mutant transformed B cells
possessing mutations on both PARK2 alleles effecting the ubiquitin like region
also showed reduced lipid uptake [469, 470]. Quantification of class B scav-
enger receptor protein levels in parkin mutant fibroblasts was piloted, however
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interpretable western blot or immuno-cytochemical data was difficult to acquire,
perhaps due to the relatively low expression of class B scavenger receptors in
fibroblasts and the low specificity of currently available commercial antibodies.
Work elsewhere has has successfully detected SRB1 and CD36 in fibroblasts
respectively using a commercially available and patent protected antibody [341].
Whilst parkin mutant fibroblasts possess deficient cellular ATP [95, 96], the ef-
fect this might have on receptor -mediated and -independent endocytosis is not
entirely clear. ATP depletion studies in cancerous cell lines have shown ATP
is required for true receptor mediated endocytosis, and that this inhibition is
fully reversible within minutes of partial ATP level recovery [471]. Somewhat
confoundingly, ATP depletion in fibroblasts was shown not to directly corre-
late their ability over one hour to internalise LDL [472] whose internalisation
is, like PMPC-PDPA polymersomes, mediated by class B scavenger receptors
[473, 474]. However, this study did not clearly distinguish deeply invaginated
but still exterior cargoes from those truly internalised, which may in part ex-
plain this disparity [471]. Macropinocytosis, being an actin regulated process
is also ATP dependent, and there is evidence that ATP depletion causes a re-
duction, though the correlation between the two at modest reductions in ATP
is not clearly documented [475, 476]. That healthy fibroblasts showed reduced
polymersome uptake in galactose media similar to that seen in parkin mutant
fibroblasts (figure 4.2), though only the latter’s cellular ATP is reduced in this
condition [95] suggests that in these conditions the ATP levels of both fibroblast
phenotypes are sufficient to maintain normal endocytosis and macropinocyto-
sis.
The uptake of TFR formed polymersomes in galactose media remained lin-
ear between the initial binding step and 48 hours at all concentrations tested,
suggesting an excess of polymersomes was present down to 0.1mg/mL. By
contrast, pH switch polymersomes saw an uptake plateau after 24 hours in
galactose media (figure 4.2). As uptake of pH switch formed polymersomes
remained linear up to 48 hours in glucose media, a condition which also pro-
duced faster cell growth, this is unlikely to have resulted from total polymersome
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depletion. Another possibility is antagonisation of polymersome uptake by com-
ponents of the galactose media not found in glucose media, though none of
these are known class B scavenger receptor ligands. It has been shown in
caco-2 cells cultured in high glucose or galactose that cholesterol uptake is
increased [477]. Glucose was more efficacious in this respect, and antagonisa-
tion of SRB1 mitigates the effect of both media types. Increasing concentrations
of glucose have also been found to increase protein levels of class B scavenger
receptors in dendritic cells, endothelial cells, caco-2/15 cells, vascular smooth
muscle, mesangial cells and macrophages [478–483]. Enhanced expression of
polymersome receptors in glucose media relative to galactose could explain the
increased uptake. Future work quantifying the presence of class B scavenger
receptors may shed light on this situation.
Work, currently in preparation, from the Battaglia group has also shown that
neutrophils both absorb polymersomes, and that reducing polymersome con-
centration results in a loss of polymer from the cell [484]. This indicates that
both polymer entry and exit from the cell happens concurrently, and explains
why saturated uptake might occur while there is still an excess of polymersomes
in solution, as seen in many cell types [404, 413, 435]. The reduced rate of up-
take seen in galactose media might thus result from decreased polymersome
entry or increased polymer secretion. It is therefore interesting to note that high
glucose concentration has also been found to reduce protein levels of choles-
terol exporters in caco-2/25 and mesangial cells [480, 482]. Again, future work
quantifying the presence of class B scavenger receptors and identification of
components involved in polymersome secretion may shed light on this situa-
tion.
TFR formed PMPC-PDPA nanoparticles were generally larger and more tubular
than pH switch formed polymersomes (figure 4.1). They also demonstrated a
reduced ability to enter fibroblasts (figure 4.9), in close keeping with previous
research demonstrating slower uptake of PMPC-PDPA particles with increasing
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size over 100nm  [339, 340], and of tubular morphologies relative to spher-
ical particles [435]. It is interesting that where uptake of pH switch polymer-
somes occurs linearly at early time-points, TFR polymersomes show a rapid
initial accumulation (1-60 minutes) then slow internalisation, reminiscent of the
long surface dwelling times seen with purified tubular polymersomes [435]. Ev-
idence that isolated tube like “intermediate” particles accumulate in healthy and
parkin mutant fibroblasts as a function of incubation time is shown in Chapter
5 (figure 5.5), suggesting these larger morphologies are also truly internalised.
Though the TFR formed nanoparticles used here are a mixture of quickly and
slowly internalised morphologies [387, 435], the longer receptor occupancy and
greater surface area of the more tubular morphologies will impede the uptake
of further nanoparticles more greatly than faster internalised particles. Further,
the slower wrapping of cell membrane around tubular particles may also im-
pede the uptake of spherical particles clustered closely to it on the cell surface
[325, 326, 388]. Thus the presence of even a small proportion of slowly in-
ternalised particles may have a disproportionately large impact on the uptake
of a nanoparticle population. Future experiments aiming to discern the endo-
and phago- cytic routes by which polymersomes of varying size and shape are
internalised by fibroblasts may shed light on the different uptake kinetics seen
here.
PMPC-PDPA nanoparticles formed by TFR demonstrated no noxious effects
towards healthy or parkin mutant fibroblasts as assessed by measures of cell
membrane integrity, metabolism, and mitochondrial function. TFR formed rho-
damine labelled nanoparticle have demonstrated effective binding and internali-
sation into fibroblasts at all concentrations tested here (figure 4.6 and 4.7), infer-
ring these results relate to the presence of PMPC-PDPA both on and within cell.
These are the first cells possessing a known mitochondrial defect to be tested
with PMPC-PDPA nanoparticles has. Whilst the mitochondrial dysfunction of
parkin mutant fibroblasts is mild relative to fibroblasts derived from patients of
mitochondrial syndromes such as MELAS and LHON [95, 96, 462], the lack of
obvious alteration to mitochondrial physiology or cytotoxic induction is promising
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for the use of PMPC-PDPA nanoparticles in more severe mitochondrial disor-
ders.
It must be noted that fibroblasts are known to show slow internalisation kinet-
ics relative to other cell types, and that cells which internalise polymersomes
more effectively tend to show larger reductions in viability at equivalent poly-
mersome concentrations [339, 341]. There is evidence that fibroblasts show a
loss of viability at concentrations greater than 2mg/mL, though never by more
than 10%, slight in comparison to many other delivery vectors [358, 393, 413,
pg. 129]. The nanoparticles used here are markedly more tubular than those
used previously and assessment of their viability in fibroblasts was conducted
in galactose media, both factors shown to decrease PMPC-PDPA nanoparticle
uptake (figure 4.9 and 4.2). Studies in which PMPC-PDPA nanoparticle ac-
cumulation is greater could possibly identify disparate concentrations of toxic
induction between cells with healthy and dysfunctional mitochondria.
As mitochondria are known to express class B scavenger receptors on their
OMM [485], and the amphiphilic nature of PMPC-PDPA at pHs >6.3 forces it
to associate with non-polar environments, as well as its overall cationic charge
under this, the possibility of an interaction between PMPC-PDPA and the mito-
chondria is feasible and merits further study.
4.6 Conclusions
The ability of parkin mutant fibroblasts and their controls to accumulate and
internalise PMPC-PDPA polymersomes whilst dependent on mitochondrial ATP
anabolism has been demonstrated at 0.1-1mg/mL concentrations. TFR formed
PMPC-PDPA polymersomes showed no significant noxious effect on cellular
ATP production, MMP, or membrane integrity at concentrations of 0.1-2mg/mL.
Together, the suitability of polymersomes as a therapeutic for parkin mutant
fibroblasts has been demonstrated.

Chapter 5
Results: Polymersome mediated
delivery of mitochondrial
therapeutics to parkin mutant
fibroblasts
5.1 Aim
To assess the therapeutic potential of UA, UCA, and UDCA loaded polymer-
somes on the mitochondrial function of parkin mutant fibroblasts, and investi-
gate the effectiveness with which steroid like compounds are delivered to fi-
broblasts when formulated in PMPC25−PDPA65 nanoparticles.
5.2 Background
Mortiboys et al. [198] recently identified a number of compounds capable of
improving the mitochondrial dysfunction seen in parkin mutant and LRRK2 mu-
tant fibroblasts, as well as parkin knock-down cortical neurons. These included
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UA, UDCA and UCA, respectively a naturally occurring triterpene found in many
plants [271] a secondary bile acid and a bile acid derivative (figure 2.1). These
all possess high hydrophobicity and molecular weights <500Da, indicating they
may penetrate the BBB [168, 262]. However brain penetrance is proportional
to plasma concentration, something that greater hydrophobicity will limit as the
compound rapidly accumulates within any non-polar environment encountered.
Dietary UA demonstrates relatively poor percentage distribution to the brain of
rats [271]. Though distribution to the CSF is reported, evidence of true brain
penetrance by UDCA is currently lacking [272, 275, 278].
Poor distribution to the brain would require increased dosage, creating an in-
creased possibility for adverse side effects. UA and UDCA for instance have
been studied extensively in other medical research fields for various therapeu-
tic effects. However, both have known adverse effects in vivo, and concerns
have been raised over their use at high doses or with prolonged use [210, 282].
Thus, though these compounds possess therapeutic potential in at least some
forms of PD, in vivo effects could benefit from formulations that improve their
brain specific distribution, something for which polymeric nanoparticles such as
polymersomes show potential.
Polymeric nanoparticle such as polymersomes have previously been used to
deliver hydrophobic cargoes in vitro, in vivo, and have recently entered into early
clinical testing [296]. Delivery of hydrophobic chemotherapeutics have shown
enhanced efficacy when encapsulated in polymersomes, attributed to improved
tumour penetration/targeting, and the simultaneous delivery of large drug “pay-
loads”, as opposed to the diffusion of single molecules into the cell [341, 366].
Progress has also been made in targeting polymersomes across the BBB. Intra-
venous administration of Poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles
(c.150nm ) coated with a cationic molecule known to enhance absorptive-
mediated BBB transcytosis successfully delivered the highly hydrophobic anti-
oxidant CoQ10 to the brains of transgenic mouse model of AD, where a dis-
ease modifying effect was seen [360]. Similar brain penetrance and therapeutic
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effects have also been described for nanoparticles decorated with ligands tar-
geting receptor mediated transcytosis across the BBB [351, 356], including
Lactoferrin (Lf) which led to accumulation of particles in the SN, the region of
midbrain particularly effected in PD [348](further details in Chapter 1).
UA has previously been formulated in lipid nanoparticles and administered top-
ically and intravenously, the former of which was recently tested clinically in
cancer patients [280, 282]. UA has also been encapsulated within PLGA poly-
meric nanoparticles and shown to enhance its anticancer properties, though
the empty nanoparticles were also shown to alter cell metabolism [447]. The
successful encapsulation of UA, UCA and UDCA in PMPC25−PDPA65 “poly-
mersomes” and “tubes” has been discussed in detail in Chapter 3, and the
innocuous effects of empty PMPC25−PDPA65 nanoparticles on parkin mutant
fibroblast viability and mitochondrial function in Chapter 4. PMPC25−PDPA65
polymersome have also demonstrated the delivery of hydrophobic dyes that
then distribute to multiple sub-cellular locations in fibroblasts [404]. Tubular
PMPC25−PDPA65 polymersomes have been investigated in less detail, though
their cellular uptake, slower relative to polymersome, has been demonstrated,
as has their ability to deliver hydrophilic proteins to a cell’s intracellular space
[435]. Thus PMPC-PDPA nanoparticles appear an appropriate delivery vehicle
for UA, UCA and UDCA, to fibroblasts.
As PMPC-PDPA nanoparticles deliver their cargoes intracellularly, it is desirable
that encapsulated therapeutics are able to elicit their desired response from
inside the cell or cell membrane. Though precise targets have not yet been
described, inhibitor studies have revealed roles for GR activation and PI3K/Akt
signalling in mediating the mitochondrial effects of UCA and DUA, an analogue
of UA [198]. Increased Akt phosphorylation was also demonstrated in UCA
and UDCA treated parkin knock-down neurons. Thus the GR is a probable
molecular target. However a number of other possibilities exist by which these
compounds may exert their effects on the mitochondria, both intracellular and
on the cell surface (discussed further in Chapter 1). This includes TGR5, a cell
surface GPCR linked to increased mitochondrial activity [229]. Notably, both
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UA and UCA are known TGR5 activators [231, 232]. UDCA on the other hand
shows little efficacy for TGR5 activity [233, 234].
Herein the effect of UA- and UCA- loaded “polymersomes” and “tubes” on the
intracellular ATP levels of parkin mutant fibroblasts, and their ability to deliver
steroid like cargoes to these cells, is investigated.
5.3 Rescue of parkin mutant fibroblast ATP levels
using drug loaded polymersomes
5.3.1 Characterisation of drug loaded polymersomes
Drug loaded polymersomes where made by TFR of PMPC25−PDPA65 with the
addition of chosen drugs over one month. UA and UCA films were prepared
to produce 10µM (low drug load) and 1mM (high drug loads) concentrations in
PBS, should 100% of material form into drug loaded nanoparticles. Suspen-
sions were split into polymersome, tubular and large lyotropic structure frac-
tions using stepwise centrifugation. Drug plus polymer concentrations were
determined by UV-HPLC as previously described (Chapter 3). Successful frac-
tionation was confirmed by TEM and DLS studies (figure 5.1).
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FIGURE 5.1: Characterisation of UA and UCA loaded polymersomes for
therapeutic assays: (a) empty, (b) UA and (c) UCA loaded PMPC25−PDPA65
nanoparticles. Two separate fields of view from EM supporting either poly-
mersome and tubular fractions, encapsulating the high or low drug loads, are
shown (scale bars = 500nm). DLS correlation functions (right) and size distri-
butions (left) are shown (green indicates “polymersome” fractions, yellow “in-
termediate” fractions, solid lines high drug loads, and dashed lines low drug
loads). Tables indicate ELSD-HPLC determined drug and polymer concentra-
tions in PBS, and nanoparticles drug composition by percentage weight.
5.3.2 Therapeutic effect of drug loaded polymersomes
The ability of UA and UCA formulated within PMPC25−PDPA65 “polymersomes”
or “tubes”, at high or low concentrations (<3 or <0.1 drug:polymer (mol/mol) re-
spectively), to increase the intracellular ATP levels of parkin mutant fibroblasts
toward control levels was investigated relative to drug formulations in 0.1%DMSO.
Previous work has determined the EC50 of UCA to be 350nM, and both UA and
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UCA were shown to be competent of increasing parkin mutant fibroblast ATP
levels to control levels at 100nM [198]. Concentrations of 10, 100 and 1000nM
were chosen for investigation, allowing comparison of the polymer based for-
mulations of UCA against DMSO based formulations known respectively to be
“therapeutically” ineffective, effective and highly effective. It is notable that a
full dose-response in which the EC50 of UA is identified has not yet been per-
formed. Though the purpose of these experiments were to test if polymer based
formulations effected UA’s therapeutic efficacy, the possibility of loss of signal
due to close proximity to the EC100 would need to be considered if increased
dosing produced little apparent effect.
Fibroblasts were cultured for 24 hours in galactose media, and then incubated
with all five formulations of UA and UCA formulated in 0.1% DMSO for 24 and 48
hours, following which cellular ATP levels were measured (figure 4.16). DMSO
formulations were first diluted into galactose media, mixed and then applied to
fibroblasts at a final concentrations of 0.1% DMSO. Nanoparticle formulations
were diluted as appropriate into 10µL PBS, before application to fibroblasts so
that the mix constituted 10% of the cell media. The first two assay repeats
assessing fibroblast ATP levels following 24 hour incubation with UA and UCA
loaded nanoparticles were kindly performed by Dr. H.M. Mortiboys. Drug for-
mulations were applied to fibroblasts by Mr. G.M. Yealland in all instances.
UDCA loaded polymersomes were also characterised and tested in fibroblasts,
however no measurable effect on intracellular ATP levels was found at the con-
centrations tested, using PMPC25−PDPA65 nanoparticles or 0.1% DMSO for-
mulations. A third patient derived parkin mutant fibroblast (PD2) was also
tested, however this failed to demonstrate a deficiency in cellular ATP levels
relative to control. This is contrary to previous evidence and possibly the re-
sult of the late passages at which the fibroblasts and controls were available
(passage 11-13).
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FIGURE 5.2: Cellular ATP of healthy and parkin mutant fibroblasts follow-
ing incubation with drug loaded PMPC25−PDPA65 nanoparticles: Intracel-
lular ATP levels of parkin mutant fibroblasts plus matched controls were mea-
sured following incubation UCA (a) or UA (b) formulated in “polymersomes”
(green), “tubes” (yellow) or 0.1% DMSO (blue). High or low drug loads in
nanoparticles are indicated on the side, and incubation periods along the top.
The effect of empty nanoparticles at concentrations matched to drug loaded
nanoparticles are shown in accompanying bar graphs (graphs depict the mean
of two sets of parkin mutant fibroblast plus age and sex matched controls, PD1,
PD4, Ctrl1 and Ctrl4, n = 3 for each; error bars = SD)
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140TABLE 5.1: Intracellular ATP levels of PD1 and PD4 (expressed a % of untreated matched controls), following UA and UCA treatment
for 24 or 48 hours when formulated in PMPC25−PDPA65 “polymersomes” (green), “tubes” (yellow) or 0.1% DMSO (blue). Blue figures
indicate ATP levels significantly different from untreated controls (n=3; statistics performed by two way ANOVA with bonferoni corrected
multiple comparisons, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001)
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UA and UCA formulated within 0.1%DMSO demonstrated increases to parkin
mutant fibroblast ATP levels following 24 and 48 hours incubation (figure 5.2).
The dose response curve appears to be linear or just entering the linear phase,
in keeping with previous evidience [198]. Formulation within PMPC25−PDPA65
nanoparticles also elicited similar increases to parkin mutant fibroblast ATP lev-
els, though formulation in 0.1% DMSO consistently showed the strongest thera-
peutic effect. At 24 hours, the therapeutic effect of UA and UCA loaded “tubes”
is notably weaker than the other two formulations, particularly at low drug loads.
Longer incubation periods tended to yield improved therapeutic effects in parkin
mutant fibroblasts. High drug loads produced marginally greater, though non-
significant, gains in intracellular ATP levels relative to low drug loads. Significant
increases in the ATP levels relative to untreated parkin mutant fibroblasts were
seen at concentrations ≥ 100nM (indicated in blue in table 5.1).
5.4 Delivery efficiency of steroid like compounds
by PMPC25−PDPA65 polymersomes
5.4.1 Characterisation of DHE loaded polymersomes
Delivery efficiency of steroid like compound to fibroblasts was assessed using
rhodamine labelled polymersomes loaded with DHE, a naturally occurring fluo-
rescent steroid [486] (figure 5.3). DHE is a close analogue of cholesterol, and
reliably mimics the membrane altering properties of cholesterol within lipid bi-
layers [486]. It is used here as a representative steroid like compound, to model
their delivery to fibroblasts when formulated in PMPC25−PDPA65 nanoparticles
or DMSO. Fluorescent polymersomes were made from thin films of 5% (w/w)
R.6G-PMPC-PDPA (ex. 432-582nm, peak at 505nm; em. 532-682nm, peak
at 566nm) and DHE (ex. 250-360nm, peak at 325nm; em. 340-550nm, peak
at 375nm), the fluorescence spectra of which show no overlap in excitation or
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emission, allowing polymersome entry and cargo delivery to be measured inde-
pendently and simultaneously [415, 487].
FIGURE 5.3: DHE loaded nanoparticle characterisation: (a, b) From left
to right; two representative fields of view from EMs supporting DHE loaded
“polymersomes” or “tubes”, their DHE and PMPC25−PDPA65 concentrations in
PBS plus the ratio between these, and their DLS correlation functions and size
distributions for two separate DHE loaded nanoparticle batches.
5.4.2 Polymersome mediated DHE delivery to fibroblasts
The ability of DHE loaded polymersomes to accumulate and deliver DHE to
fibroblasts was assessed by flow cytometry. Pilot data indicated DHE and
R.6G-PMPC-PDPA signal was weak below 10µM DHE load (0.198 and 0.121mg/mL
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“polymersomes” and “tubes” respectively, figure 5.3a), likely due to the non-
optimal excitation of DHE at 355nm, close to its absorption extinction and un-
fortunately the lowest excitation wavelength available to the equipment used
[487]. Concentrations of 10, 25 and 50 µM were subsequently chosen for in-
vestigation (0.198, 0.495 and 0.99mg/mL ”Polymersomes”, and 0.121, 0.303,
0.605 mg/mL ”Tubes”). No fluorescence bleed through was seen between DHE
and R.6G-PMPC-PDPA fluorescence channels (figure 5.4a). Fibroblasts de-
rived from parkin mutant patients plus controls were incubated with polymer-
some and tubular fractions (figure 5.3a) for 24 and 48 hours in galactose media
(figure 5.5, 5.4b).
Fluorescence gating revealed that approximately all cells demonstrated R.6G-
PMPC25−PDPA70 and DHE fluorescence greater than maximal basal fluores-
cence, at all concentrations studied, following 24 hours incubation with “poly-
mersomes” or “tubes” (table 5.2). Both were delivered in a time and concen-
tration dependent manner (figure 5.5a-d). While polymer accumulation from
the tubular fraction is less than from “polymersomes”, both deliver an amount
of DHE comparable to 0.1% DMSO. At higher concentrations, “polymersomes”
deliver the highest DHE concentrations, followed by “tubes” and then DMSO,
a trend seen in all cells tested. This is less clear at 10µM DHE, and may be
a result of the low fluorescent signal drawn from the non-optimal excitation of
DHE. Both DHE and R.6G-PMPC-PDPA signal showed good linearity to con-
centration.
The DHE:R.6G-PMPC-PDPA ratio reveals that “tubes” deliver more DHE per
unit polymer, likely a reflection of the higher DHE loading in these particles. Nor-
malisation by the DHE load within nanoparticles (DHE:PMPC-PDPA ratio, figure
5.3) revealed “polymersomes” deliver slightly more DHE load once nanoparticle
cargo load is accounted for. However it should be noted that DHE quantification
accounts for its load within a polydisperse fraction of nanoparticles, and that
the tubular fraction possesses a greater size distribution, possibly explaining
this discrepancy. In all instances, the DHE:R.6G ratio declines with increasing
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nanoparticle/DHE concentration, indicating either decreasing DHE delivery or a
declining DHE signal.
FIGURE 5.4: Flow cytometry settings for DHE delivery experi-
ments: (a) DHE plus R.6G-PMPC-PDPA fluorescence (ex.355nm em.450nm
and ex.488nm em.575nm respectively) was measured by flow cytometry
(BD
TM
LSRII) following 72 hour incubation with galactose media alone (top),
50µM DHE (middle), or 1mg/mL R.6G polymersomes (bottom). Gating for fi-
broblasts (left, grey), DHE positive cells (middle, blue), and R.6G positive cells
(right, green) are indicated. DHE was excited by a (b) Dot plots from Ctrl1 fi-
broblasts following 24 hour incubation with 10, 25 and 50µM DHE formulated
in “polymersomes”, “intermediate structures” and 0.1% DMSO.
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FIGURE 5.5: Delivery efficiency of polymersome formulated DHE to fibroblasts following 24 and 48 incubation: Fibroblasts were
incubated for 24 and 48 hours with rhodamine labelled and DHE loaded “polymersomes” and “tubes” (figure 5.3a) in a galactose media.
Background subtracted Rh.6G-PMPC25−PDPA70 and DHE fluorescence was assessed by flow cytometry. Graphs are arranged by
fibroblasts in rows. From left to right, graphs represent; Rh.6G-PMPC25−PDPA70 fluorescence, DHE fluorescence, DHE fluorescence
per Rh.6G-PMPC-PDA fluorescence (DHE:R.6G), and DHE:R.6G in fibroblasts divided by DHE:PMPC-PDPA in relevant nanoparticles
(all error bars = SD).
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TABLE 5.2: Percentage of cells demonstrating R.6G-PMPC-PDPA and DHE
fluorescence greater than maximum endogenous levels, as assessed in
untreated controls, following 24 or 48 hour incubation with DHE loaded
PMPC25−PDPA65 nanoparticles. Blue indicates percentages greater than 90%
(n = 3).
A separate batch of DHE loaded polymersomes (figure 5.3 b) was used to
assess DHE delivery by “polymersomes” and “tubes” when PMPC25−PDPA65
concentrations were matched (figure 5.6). At matched polymer concentrations,
“tubes” delivered a greater DHE load than “polymersomes”, again showing greater
DHE delivery per unit R.6G-PMPC-PDPA in fibroblasts. While the accumu-
lation of polymer is linear with concentration, DHE accumulation saturates at
higher concentrations. This indicates either less DHE is delivered when there
are more “intermediate” nanoparticles, or DHE signal is decreasing due to cell
metabolism, efflux or quenching fluorescence signal.
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FIGURE 5.6: Comparison of “Polymersome” and “Tubular” fractions effi-
ciency in delivering DHE: Healthy and parkin mutant fibroblasts were incu-
bated with DHE loaded “polymersomes” and “tubes” (figure 5.3b) for 48 hours,
at matched polymer and DHE concentrations. Fibroblasts were passed through
a flow cytometer and median R.6G-PMPC-PDPA and DHE fluorescence per
cell assessed. Graphs are arranged by fibroblast in rows. From left to right
graphs show accumulation of R.6G-PMPC-PDPA with increasing polymer con-
centration, DHE accumulation with increasing polymer and DHE concentration,
and R.6G-PMPC-PDPA:DHE ratios with increasing polymer concentration (n =
3 ; error bars = SD).
5.4.3 Discussion
UA and UCA loaded “polymersomes” and “tubes” elicited dose dependent in-
creases in the intracellular ATP levels of parkin mutant fibroblasts. Their effect
was comparable to 0.1% DMSO formulations. In keeping PMPC25−PDPA65
nanoparticles and 0.1% DMSO showed similar delivery efficiencies of DHE, a
highly hydrophobic cholesterol analogue with strong structural similarities to UA
and UCA. It is notable that the therapeutic responses detailed here, whilst sim-
ilar in trend, are less potent than those previously reported [198], possibly a
consequence of the late passages at which fibroblasts were used. Drug de-
composition within nanoparticles is also a possibility given the long duration of
formation, however DMSO formulated drugs were prepared fresh prior to the
first experimental repeat. Increased incubation periods yielded both improved
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therapeutic effect and increased delivery of hydrophobic cargoes in all three
formulations. Similar increases in physiological action have previously been
reported for UA with increased incubation periods [488].
Though both UA and UCA are known to activate at least one extracellular recep-
tor, TGR5 [231, 232], the data here would suggest their therapeutic effects on
intracellular ATP can still be elicited following direct intracellular delivery, though
it is notable that DMSO consistently proved the most efficacious formulation.
Future work investigating the effect of polymersome encapsulation on the dis-
crete pleiotropic effects of UA and UCA would be of interest. This may also
hold some therapeutic relevance, as certain side effects may be connected to
activation of TGR5, gastrointestinal problems for instance [226, 282, 489].
PMPC25−PDPA65 nanoparticles did not show increased therapeutic effect over
DMSO formulated drugs. Other work has demonstrated increased in vitro effi-
cacy of compounds with typical dose responses when delivered by nanoparti-
cles, something believed to result from the simultaneous delivery of many drug
molecules, temporarily creating regions of high drug concentration within the
cell [341, 366]. A pertinent example would be UA loaded mPEG-PCL polymer-
somes, which showed greatly enhanced apoptotic induction in a gastric cancer
cell line over “free” UA, though it is of note the polymer itself evoked some al-
terations in cellular viability [447]. Comparisons with this study are difficult to
make due to differences in cell type, UA concentrations, and the physiologi-
cal effect studied. Perhaps of particular relevance, fibroblasts are known for
slow internalisation of PMPC-PDPA nanoparticles relative to other cell types,
so likely receive less therapeutic compound when delivered by these vectors
[339, 341]. Cells which are known to endocytose nanoparticles more rapidly
may demonstrate enhanced therapeutic effects compared with those seen here.
Another study showed moderately decreased hydrophobic drug efficacy when
formulated within polymersomes, which was speculated to result from reduced
intracellular concentrations relative to free drug [490].
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The DHE loaded PMPC25−PDPA65 nanoparticles used here possess similar
sizes, morphologies and cargo loads to UA and UCA loaded nanoparticles used
in experiments measuring ATP recovery (figures 5.1, 5.3). As DHE possesses
a hydrophobicity, structure and size close to UCA and similar to UA, it may be
considered a representative model for the delivery of high UA and UCA loads by
“polymersome” and “tubes”. In all cells, DHE was delivered most effectively by
“polymersomes”, then “tubes” and least effectively by 0.1% DMSO at matched
DHE concentrations (figures 5.5, 5.6). The higher DHE delivery by nanoparti-
cles may be a result of the non-fouling properties of PMPC-PDPA, wherein this
formulation shields DHE from adsorption to the polystyrene wells in which the
uptake assay was performed and serum proteins within the cell media [491].
In this regard it is notable that DHE formulated within DMSO shows increased
accumulation within the cell with increased incubation periods. It must however
also be noted that where DHE uptake assays were performed in 12 well plates,
ATP assays were performed in 96 well plates, and that the differences in sur-
face area may have affected the delivery efficiencies from all three formulations
between the two assay sets, though perhaps DMSO formulations in particular.
Drug formulated within “polymersomes” and DMSO produced greater therapeu-
tic effects than “tubes” following 24 hour incubation, though these were approxi-
mately equivalent by 48 hours. Where PMPC25−PDPA65 “polymersomes” enter
cells with a single saturating exponent (figure 4.2) [341, 435] “tubular” parti-
cles have been shown to enter cells only after an appreciable dwelling time
on the cell surface (figure 4.6) [435]. Following this, it is possible a significant
proportion of the drug delivered to fibroblasts by “tubes” remains sequestered
within nanoparticles bound to, but not yet internalised by the cell. Future exper-
iments that distinguish between bound and internalised polymersomes/cargo
would help resolve this point.
The ratio of DHE to R.6G-PMPC-PDPA delivered by DHE loaded nanoparti-
cles was approximately the same between all fibroblasts studied, where “tubes”
delivered more DHE per unit polymer than “polymersomes”. Though “tubes”
entered fibroblasts less readily than “polymersomes”, the higher drug load in
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the tubular fraction would require fewer particles to enter the cell to deliver an
equivalent DHE load (figure 5.3). Indeed, at matched polymer concentrations,
“intermediate particles” delivered more hydrophobic cargo than the more readily
internalised “polymersomes”. Normalisation of the DHE delivered to the cell per
unit R.6G-PMPC-PDPA, by the DHE load within the nanoparticles themselves
demonstrated the latter can account for the much of the difference in deliv-
ery efficiency between the two particle morphologies. “Polymersomes” were
slightly more effective in this, however this difference might be explained by the
tendency of larger oblate particles to less readily enter fibroblasts [340, 435]
(Chapter 4), and the greater size distribution seen in the “intermediate” frac-
tion. Cholesterol like molecules have been shown stabilise and concentrate in
larger PMPC25−PDPA65 assemblies during the TFR method of formation, so
it is probable the DHE:Polymer ratio increases with particle size (Chapter 3).
As particles of smaller size and lesser DHE loads are likely to enter fibroblasts
more rapidly, normalisation of DHE delivery by DHE load will be most accu-
rate where a nanoparticle size distribution is smaller, and DHE loads show less
deviation from the populations average, as quantified by UV-HPLC.
At high concentrations, the DHE delivered by “intermediate” nanoparticles be-
gan to saturate, while delivery of R.6G-PMPC-PDPA remained linear (figure
5.6). Again it is unlikely that particles with greater DHE loads enter into fi-
broblasts more rapidly, as they concentrate within larger tubular particles (figure
5.3). Loss of DHE fluorescence by cellular metabolisation and/or excretion are
possibilities, such as previously seen with polymersome mediated delivery of
Rhodamine B to fibroblasts [404]. However DHE:R.6G ratios in fibroblasts were
not greatly altered between 24 and 48 hours, which suggests this is not the
case unless DHE delivery and processing remains constant over this duration
(figure 5.5). The non-linearity of DHE fluorescence in the cell is another possi-
bility. DHE fluorescence is auto-quenched at high concentrations and dilution
within lipid or cell membranes is known to ameliorate this [492, 493]. DHE
fluorescence emission is also known to under go a blue-shift on incorporation
within lipid membranes [492]. Thus, saturation of DHE signal might occur due
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to heightened quenching or altered emission spectra whilst concentrated and
encapsulated within PMPC25−PDPA65 nanoparticles, compared to its relative
dilution on cellular distribution. This assumes a greater proportion of bound but
non-internalised particles are present at higher polymersome concentrations,
for which there is evidence (Chapter 4; figure 4.6).
A representative model of UA and UCA delivery to fibroblasts at low concentra-
tions within “polymersomes” and “tubes” was not investigated. Given the lower
drug to polymer ratios present in this formulation, a greater number of particles
must be internalised to deliver drug concentrations equivalent to nanoparticles
with higher drug loads. It has been demonstrated that uptake of mixed pop-
ulations of “polymersomes” and “tubes” is linear with concentration following
1 minute, 24 or 48 hour incubation up to 1 mg/mL in fibroblasts cultured in
galactose media (figure 4.2). This suggests both that polymersome receptor
occupancy is not saturated by PMPC25−PDPA65 nanoparticles below 1mg/mL,
and that subsequent internalisation is linear to this. Though drug concentration
was lower per particle, the increased particle number should lead to greater re-
ceptor occupancy and internalisation. Concordantly high and low drug loaded
PMPC25−PDPA65 nanoparticles produced approximately equivalent therapeu-
tic responses, though high loads were marginally more effective, suggesting a
possible effect of increased drug concentration per particle.
The uptake of empty and drug loaded polymersomes was not compared here,
though this may be of interest as there are lines of evidence that might suggest
UA interacts with class B scavenger receptors and alter PKC activity which in
turn affects endocytosis [477, 488, 494]. Further, alterations to PMPC-PDPA
membrane properties by blending with steroid like components may alter their
cellular interactions [436].
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5.5 Conclusions
UA and UCA loaded “polymersomes” and “tubes” increase parkin mutant fibrob-
last ATP levels in a dose dependent manner comparable to DMSO formulations.
Whilst the polymersome fraction enters fibroblasts more rapidly than the tubu-
lar fraction, and subsequently give faster therapeutic responses, the higher drug
loads present in “intermediates” elicit similar therapeutic effects at matched drug
concentrations following 48 hours incubation. At matched polymer concentra-
tions below 2mg/mL, the tubular fraction deliver more hydrophobic compound to
cell. This may be of particular interest, as ligand functionalised tubular particles
are known to show enhanced targeting specificity in vivo.
Chapter 6
Discussion & future directions
6.1 Project findings
PMPC-PDPA nanoparticles formed by TFR were shown to produce a mixture
of morphologies consisting of large planar structures, branched and high genus
morphologies, elongated tubes and vesicles. The average size of these mix-
tures decreased over time with the continuing application of exogenous en-
ergy, suggesting the large lyotropic structures were metastable. However these
metastable structures were also extremely long lived, failing to reach morpho-
logical uniformity after eight weeks of mechanical stirring and 30 minutes of
sonication. This is likely the result of the exceptionally slow chain kinetics within
the semi-fluid membranes of large MW block copolymer membranes [321, 410].
Particles were successfully separated on the basis of size and density by cen-
trifugation, producing fractions enriched with vesicles, tubes and larger lyotropic
aggregates. Quantification of their relative mass over time further demonstrated
the progression from larger to smaller structures over time.
PMPC-PDPA nanoparticles were able to successfully encapsulate UA, UCA and
UDCA with high efficiency, at low and high compound to copolymer ratios. The
particles proved stable over time, with no marked alteration to size distribution,
or apparent loss of encapsulated compound after six months. Fractionation and
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quantification of these and cholesterol loaded nanoparticles revealed encap-
sulation of hydrophobic sterol like compounds altered the formation pathway
of nanoparticles, apparently enhancing and/or stabilising the formation of the
tubular fraction. Morphological analysis indicated cholesterol loaded particles,
were of a larger average length, and more branched than unloaded particles.
The presence of sterol like compounds within large copolymer bulks may act
as plasticiser, easing their initial transition into genus and tubular structures.
However their presence within the membrane may also act to increase the hy-
drophobic volume without concomitant increases in the hydrophilic brush of the
nanoparticles, resulting in a modification to copolymer packing.
PMPC-PDPA nanoparticles of mixed morphologies were shown to enter into fi-
broblasts derived from patients possessing a form of PD caused by compound
heterozygous mutations in parkin. These have been shown to possess defec-
tive mitochondrial function akin to that seen in patient neurons [95, 96], a factor
believed to at least in part underly the disease pathogenesis [23, 71]. The
nanoparticles were able to enter fibroblasts without detriment to MMP, cellu-
lar ATP levels or viability under conditions of heavy mitochondrial activity. This
suggests PMPC-PDPA nanoparticles do not aggravate existing mitochondrial
dysfunction, and could also potentially also be used in cells with more marked
mitochondrial dependance, in particular neurons.
Nanoparticles entered into fibroblasts in a time- and concentration- dependent
fashion. Mixed vesicular and tubular morphologies demonstrated long initial
surface dwelling times, the magnitude of which correlated to their eventual in-
ternalisation kinetics, suggesting variation in nanoparticle uptake was related
to receptor expression. A possible uptake deficiency in fibroblasts possessing
homozygous mutations in parkin’s second exon was also highlighted, and ap-
peared to relate to receptor expression, in keeping with other research [469].
Uptake was also affected by the sugar substrate in which fibroblasts were cul-
tured, a clear saturation in the uptake of spherical particles being seen in galac-
tose, but not glucose media. Galactose media forces fibroblasts to utilise mito-
chondrial OXPHOS to a much greater degree [107]. However, the physiological
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relevance of saturating uptake is difficult to interpret as galactose may alter gene
expression and receptor signalling independently of its effect on mitochondrial
activity [477]. Spherical particles also entered fibroblasts more rapidly than par-
ticle populations of mixed spherical and tubular morphology.
UA and UCA loaded PMPC-PDPA nanoparticles taken from the polymersome
and tubular fraction demonstrated a therapeutic effect on parkin mutant fibrob-
lasts, similar though marginally weaker than drug administered in a co-solvent,
0.1% DMSO. This suggested that the mode of action by which these com-
pounds exert their mitochondrial effects was compatible with nanoparticle me-
diated delivery. Longer incubation with drug loaded nanoparticles or DMSO
formulated compounds resulted in higher efficacy. Higher drug to copolymer
ratio did not result in significantly improved therapeutic effect. Previous work
has shown improved therapeutic effects are associated with delivering drugs to
cells in large payloads relative to simple diffusion. The absence of this effect
here may result either from the mode of drug action, or slower drug delivery to
fibroblasts by nanoparticles.
Polymersome and tubular fractions of PMPC-PDPA nanoparticles loaded with
a fluorescent cholesterol analogue successfully entered into fibroblasts along
with their cargo. This was both time and concentration dependent. The tubu-
lar fraction accumulated on and in fibroblasts more slowly than polymersomes,
but delivered a similar amount of cargo at cargo matched concentrations, by
merit of their greater cargo loading efficiency. At polymer matched concentra-
tions, the tubular fraction delivered greater cargo loads at lower concentrations,
though this effect saturated toward higher concentrations, again likely due to
their slower internalisation. Both sets of nanoparticles delivered a greater con-
centration of cargo to the cell than when the cargo was formulated in 0.1%
DMSO. However a distinction between surface bound and truly internalised
nanoparticles was not made, making it difficult to interpret how this relates to
intracellular delivery and subsequent therapeutic effects.
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6.2 Implications for the treatment of Parkinson’s
Disease
6.2.1 Therapeutic effect in vitro
Highly hydrophobic sterol-like compounds were successfully delivered to fibrob-
lasts where they elicited therapeutic effects. UA and UCA’s therapeutic effect
on mitochondria thus seem to be elicited from a location accessible either from
within the cell membrane or elsewhere in the cell. The precise sub-cellular
location of these nanoparticles during internalisation was not investigated. Pre-
vious work has shown that purely spherical PMPC-PDPA enter into the endo-
some, where they rapidly disassemble permitting access to the rest of the cell
[339, 392]. Elsewhere tubular particles have been shown to enter the cell ap-
parently intact, at least initially suggesting a separate mechanism of internalisa-
tion. Both however appear compatible with the therapeutic effects of steroid like
compounds. It is also interesting that the tubular fraction also produced similar
therapeutic effects to polymersomes despite their slower entry. This was likely
due to the higher drug loading efficiency seen in the tubes. However it is also
notable that the polymersome fraction also possessed some particles of greater
aspect ratio which may have had a negative impact on overall particle uptake.
Whilst an enhanced therapeutic effect was not seen when the drugs were de-
livered as encapsulated “packets”, this may be due to do with the particularly
slow internalisation of PMPC-PDPA polymersomes seen in fibroblasts, some-
thing which will likely have been enhanced by the presence of particles of higher
aspect ratio, found in both the tubular and polymersome fractions [326]. This
may not be true of other less dormant cell types such as BBB endothelia and
neurons, where more rapid uptake of “drug packets” could yield enhanced effi-
cacy. It is however notable that UA at least has been shown to induce toxicity
at low µM concentrations in at least some cell types [258, 488, 495], possibly
by merit of its cell membrane altering properties [260]. It is therefore possible
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that delivery of large drug “packets” could enhance cellular toxicity at certain
concentrations. Similarly, very hydrophobic bile acids demonstrate cellular toxi-
city, again possibly attributable to their membrane altering properties [496]. This
may be of relevance for UCA given its very high hydrophobicity and structural
likeness to these. UDCA has been shown not to alter membrane ordering [496],
and is well tolerated in vitro up to 500µM [209].
That PMPC-PDPA nanoparticle alone prove innocuous to the viability and mito-
chondrial function of PD fibroblasts derived directly from PD patients is promis-
ing. It is also promising for their therapeutic use in other diseases with a mi-
tochondrially related pathology. As these cells are human and possess the
same, or at least highly similar extent of ageing and genetic background found
in the respective individual, these results are likely to be at last partially trans-
ferable. However fibroblasts are also a very different cell to those of the CNS
and BBB. Further, studies here only tested viability over a relatively short time.
Though previous work has indicated that PMPC-PDPA nanoparticles are well
tolerated in human fibroblasts for up to a week [404], the effect a PD causing
parkin mutant phenotype may have on this is unknown. It will also be essential
to assess the long term toxicological profile of copolymer particles in neurons
of the CNS prior to their potential therapeutic application here. In particular,
though requiring both in vitro and in vivo studies, consideration should be given
to the potential for microglial activation, the primary immune cells of the CNS.
Though rarely addressed in brain delivery studies to date, microglial activation
is associated with enhanced cell death, and indeed already implicated in the
pathogenesis of many neurodegenerative diseases.
It interesting that a deficiency in particle uptake may be present in certain parkin
mutant phenotypes [469]. If this were tissue specific, it may be that PMPC-
PDPA polymersomes show preferential entry to certain cells within this pheno-
type. It may also translate to decreased uptake in all cell types, from which
extended circulation times in vivo could result.
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6.2.2 Therapeutic effect in vivo
6.2.2.1 Potential of UA, UCA and UDCA in the treatment of Parkinson’s
Disease
UA, UCA and UDCA possess chemical characters which suggest they may be
able to cross the BBB to some extent [267, 497]. However as highly hydrophobic
compounds, they will also rapidly accumulate into many other non-polar envi-
ronments, meaning the use of formulations that enhance their distribution to the
brain are desirable. Further, strong accumulation into regions other than the
brain would require increasing dosage to deliver therapeutically effective doses
of these compounds to the brain, from which adverse systemic effects may re-
sult. Thus appropriate formulation may dictate whether UA, UCA and UDCA
are viable for use in PD. Whilst the therapeutic use of UCA has received little
attention, UA and UDCA have been extensively studied for use in a number of
conditions and some information is known of their toxicological profiles as well
as brain penetrance.
UA administered orally to mice has been shown to distribute to the brain in
small amounts relative to other tissues, in particular the liver, colon and kidneys
[271]. Neuroprotective actions have been ascribed to orally administered UA in
murine models, though it is difficult to discern whether this is a result of systemic
actions or brain delivery [216, 217, 279]. As a potential anti-cancer agent the
safety and tolerability of intravenously administered, liposomally formulated UA
was recently assessed in a phase I clinical study [282]. Whilst UA was generally
well tolerated, the duration of its use was relatively short, and hepatotoxicity and
diarrhoea were encountered in humans after single doses ≥ 74mg/mL, with a
maximum tolerable dose of 98mg/mL [281, 282]. As noted before, there is
evidence of UA induced toxicity at low µM concentrations in some [258, 488,
495], though not all cell types [216, 498]. Research has also shown UA is an
activator of the TGR5, an extracellular GPCR that in mice has been shown to
Chapter 6. Discussion & future directions 159
induce defecation, which could possibly underlie the occurrence of diarrhoea in
patients [231, 232, 489].
UDCA, as an endogenously synthesised bile acid, is better tolerated in hu-
mans, showing no toxicity up to 500µM in vitro [209]. Oral formulations such
as URDOX are known to accumulate well within the liver, and UDCA is cur-
rently approved by the FDA and MHRA for therapeutic use against primary bil-
iary cirrhosis [209]. There are however certain safety concerns with its use at
high and/or prolonged use including; increased incidence of colorectal cancer
and hepatocellular carcinoma, liver failure, digestive tract varices, diarrhoea,
and immune complications such as hepatitis and cholingitis [210, 283, 499].
These could result from the actions of UDCA, or its metabolites lithocholic acid
and chenodeoxycholic acid, which UDCA is converted to by intestinal bacteria
[209]. Both are more hydrophobic than UCDA and shows higher in vitro toxicity
[200]. Lithocholic acid can also be reabsorbed into blood flow. They also, unlike
UDCA, are TGR5 activators [230]. It is also notable that a fraction of UDCA is
conjugated to glycine or taurine in the liver. This increases its solubility but limits
its ability to permeate cell membranes and the BBB. True evidence of UDCAs
distribution to the brain in humans is presently lacking [272, 275]. Whilst there is
evidence of distribution to the brain of rat models of stroke following intravenous
administration [277, 278], BBB permeability is enhanced within this condition
[500].
Formulations of UA, UCA and UDCA that both limit their accumulation within
non-disease tissue, and increase their distribution to disease affected tissue
could make the difference in their clinical viability. Encapsulation within a nano-
particle may have further benefits such as preventing extracellular-drug inter-
actions, for instance with the TGR5 receptor, and limiting drug metabolisation
to toxic by-products as seen with UDCA. Drug loaded spherical and tubular
PMPC-PDPA nanoparticles were able to successfully deliver hydrophobic car-
goes into cells, and produce a therapeutic effect in parkin mutant fibroblasts.
However to elicit a therapeutic effect in PD, these must be able to deliver their
cargo to the brain ISF or effected cells directly. By attaching ligands targeting
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transcytotic receptors on the BBB to nanoparticles, improvements in brain de-
livery from intravenous administration have been reported [296, 343]. However
these improvements are still relatively modest in light of high nanoparticle distri-
bution elsewhere in the body. The use of particle designs may however be able
to resolve this [330].
6.2.2.2 Potential of tubular nanoparticles to enhance drug distribution to
the brain
Ligand functionalised nanoparticles have shown significantly enhanced target-
ing specificity when particle shape is elongated, both in static conditions [331]
and within blood- or blood like- flow [324, 329]. Notably, intravenous injection
of nano-rods functionalised with antibodies against the transferin receptor dis-
tributed to the brain of mice more than seven times as effectively as function-
alised nano-spheres [330]. Modelling studies have shown the increased sur-
face area of these particles provides a greater contact area over which spe-
cific ligand-receptor interactions can be made with target cells resulting in en-
hanced binding avidity [323]. Elongated particles have also demonstrated a
tendency for lateral drift within flow, resulting in the marginalisation of parti-
cles at the endothelial lining where they lie parallel, further enhancing their abil-
ity to interact with endothelial cells [323, 324]. At the same time, the shear
stress exerted on particles of longer aspect ratios is greater in flow, helping
to destabilise weak interactions. In keeping, intravenous administration of un-
functionalised, long copolymer filomicelles circulate within the blood for approx-
imately ten times longer than any currently used spherical particle, an effect
which scaled with particle length and improved with particle flexibility [322, 501].
Both the filomicelles and tubular PMPC-PDPA particles possess similar mean
diameters, ∼60nm and ∼65nm respectively [322, 502]. Functionalisation of
long filomicelles against endothelial receptors resulted in an enhancement to
specific in vivo binding, similar to that seen with functionalised spheres [329].
Though the latter accumulated to greater extents within the endothelia, this is in
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close keeping with the greater forces hydrodynamic flow exerts on longer parti-
cles, which itself is believed to at least in part underly there extended circulation
times.
Thus, the creation and separation of tubular particles produced by TFR of
PMPC-PDPA may be advantageous to the purposes of brain delivery. However,
whilst tube like particles may show enhanced targeting specificity, they also en-
ter cells less readily. Though greater interaction strengths between a particle
and a cell favours internalisation [382, 388], increasing aspect ratios result in
greater energetic cost to membrane wrapping [325, 326]. Subsequently, a vari-
ety of cells demonstrate reduced uptake of elongated particles [328, 387, 435].
Certain particle features may possibly be able to overcome this however. For
instance, spherical particles of increasing size show reduced cellular internali-
sation [339, 340]. However, there is evidence that incorporating “patches” of a
chemistry known to interact more strongly with the cell surface into the nanopar-
ticle surface can overcome the effect of size, resulting in uptake kinetics inde-
pendent of particle diameter [339, 340]. Careful design of particle shape, and
target interaction strength could thus be tailored to optimise adherence and in-
ternalisation within a given endothelial surface.
Though many lengths of unbranched tubes were seen among TFR formed
PMCP-PDPA nanoparticles, these were mixed among branched and high genus
morphologies as well. Optimisation of both formation method and separation
technique could help increase the prevalence and isolation of long or short sin-
gle branched tubes. For instance, optimisation of copolymer film thickness and
homogeneity prior TFR may improve the yield of tubes, as may pre-templating
techniques. Recent work from the Battaglia lab has made use of density gra-
dients to improve the resolution of separation by centrifugal fractionation and
from which tubes of specific lengths can be more effectively isolated. In design-
ing ligand functionalised tubular vectors to target the BBB endothelia, striking
a balance between particle length, which is shown to decrease binding to en-
dothelial surface, and strength of ligand receptor interaction, which enhances
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tissue specific interactions, could be used to greatly improve targeting fidelity
and limit off target accumulation [322, 329, 330].
The ability of cyclic molecules such as UA, UCA, UDCA and cholesterol to mod-
ulate membrane properties of copolymer self assemblies may be of future inter-
est. They are relatively cheap and here were shown to increase the proportion
of tubular, branched and high genus morphologies. Though their effects will un-
doubtedly vary with method of formation and copolymer used [436], the ability
to modulate particle morphology may be of benefit to the production of thera-
peutically relevant particle morphologies.
As PMPC-PDPA polymersomes have recently been shown to target class B
scavenger receptors, their therapeutic applications may be best suited to those
tissues that express these in relatively high amounts, such as immune cells,
adipocytes and a number of cancer cells [341]. Other copolymer chemistries
may thus be more suitable to BBB targeting, POEGMA-PDPA polymersomes
for instance possess a highly PEG’ylated surface chemistry known to circu-
late for long times and enter cells slowly [340, 356]. Further, POEGMA-PDPA
polymersomes functionalised with ligands against the BBB transcytotic receptor
LRP have also shown effective penetrance into the brain ISF from blood circula-
tion [356, in preparation]. However, it is presently unknown if this chemistry will,
like PMPC-PDPA, produce tubular assemblies from TFR. Both possess PDPA
blocks, and it has been hypothesised that tubes result from the unique ordering
of PMPC-PDPA within dry thin films. The presence of PDPA may be sufficient
to exert a similar effect in POEGMA-PDPA films. It is still possible that tubular
PMPC-PDPA assemblies may be more resistant to uptake than polymersomes,
and that appropriate functionalisation of the particle surface may be able to
displace PMPC-scavenger receptor interactions. However, use of a longer cir-
culating copolymer chemistry would seem the more logical first step. Another
option available to the delivery of hydrophobic compounds would be packag-
ing them within solid worm like micelles, which can readily be achieved use
particular ratios hydrophilic to hydrophobic block lengths in diblock copolymers
[322, 329].
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Packaging UA, UCA and UDCA within tubular nanoparticles functionalised against
transcytotic receptors could both improve brain delivery and reduce off target
effects and toxicity from intravenous administration, both by lowering the thera-
peutically effective dose, and limiting non-brain specific drug distribution. One
alternate consideration would be to use a route of administration that avoids
exposing the drugs to non-nervous tissue. For instance, some promising re-
sults for drug delivery to brain following an intra-nasal administration of wheat-
germ aglutin functionalised copolymer nanoparticles have been reported. In-
deed there is evidence this strategy can yield therapeutic effects at the SN of a
toxin induced rat models of PD [363–365]. Research in this area is still however
relatively new and the relevance to other intra-nasal therapies in humans has
previously been called into question [361, 362].
A mentionable advantage to packaging drugs within nanoparticles is their ap-
plicability to combination therapies. By packaging two or more compounds that
have complimentary therapeutic effects within a targeted nanoparticle, their si-
multaneous delivery to a destination can be assured. The hollow nature of both
polymersomes [358] and polymer tubes [435] allows them to encapsulate large
soluble entities. If such nanoparticles possessed the ability to cross into the
brain, therapeutic avenues would be opened for larger hydrophobic compounds
such as CoQ10 [167] and more soluble compounds such as neurotrophic pep-
tides [14].
Finally, though un-functionalised PMPC-PDPA nanoparticles loaded with UA,
UCA or UDCA may not be directly applicable to PD, they may have applica-
tions in other diseases. UA for instance has proposed used against colorec-
tal and skin cancer, diabetes, inflammation, forms of atherosclerosis, muscle
wasting and oxidant injury in heart tissue [252, 280, 503–506]. Similarly bile
acids and their derivatives are under investigation for therapeutic use in liver
diseases, cancer, metabolic disorders, and extrahepatic inflammatory disorders
[227]. Packaging these within PMPC-PDPA nanoparticles of particular size and
shape may alter their distribution within the body and subsequently enhance
and detriment particular tissue specific effects.
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6.3 Conclusion
Mitochondrial dysfunction has been identified as a major common feature within
the many forms of Parkinson’s [23], as well as other neurodegenerative dis-
eases [507]. Several mitochondrially related therapies have shown promising
results in early clinical trials [160, 161], whilst others have fallen short despite
promising pre-clinical results [160, 167]. One possible explanation for this is
the limited ability of certain therapeutics to reach the the brain at effective con-
centrations, owing to barriers between the CNS and its external environment
[267].
Ursolic acid, ursocholanic acid and ursodeoxycholic acid have all demonstrated
positive effects on the mitochondrial function of cell’s possessing deficient Parkin
activity, a known cause of Parkinson’s disease [198]. It is presently unknown
whether these can produce disease modifying effects within Parkinson’s suffer-
ers. It is probable that, to elicit a therapeutic effect in Parkinson’s, these com-
pounds must exert their effects in those cells affected within the patient brain.
It would follow that methods which enable, or improve, their ability to distribute
here will enhance in vivo efficacy, as well as reduce dosage and off-target ef-
fects.
Aqueous nanoparticles self assembled from PMPC-PDPA and other PDPA based
diblock copolymers are able to encapsulate hydrophobic, amphiphilic and solu-
ble compounds and retain them until they are exposed to mildly acidic environ-
ments. Many morphologies are able to enter the cell using endocytic pathways
and release their cargo therein, and enhanced therapeutic efficacies relative to
other forms of drug delivery have been reported [339, 341, 435]. Nanoparti-
cles functionalised with ligands against specific endothelial surfaces have been
used to improve the tissue specific delivery of drugs, and elongated morpholo-
gies have recently been shown to enhance these effects. Targeting transcytosis
mediating receptors of the blood brain barrier has shown increase brain pene-
trance of such nanoparticles and their cargo.
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Ursolic acid, ursocholanic and ursodeoxycholic acid loaded PMPC-PDPA nano-
particles formed by thin film rehydration possessed high loading efficiencies and
produced a range of vesicular, tubular, branched and high genus morphologies.
The tubular particles in particular would lend themselves well to ligand based
targeting of the blood brain barrier. Morphologies were successfully separated
using centrifugation, and were able to enter parkin mutant cells without adverse
effects. Drug loaded nanoparticles successfully delivered hydrophobic cargos
to parkin mutant cells and produced therapeutic effects. Given the high levels
of customisation available to copolymer based nanoparticles, drug formulation
within these presents an ideal platform from which drug specific drug distribution
to the brain may be enabled or enhanced towards that of clinical relevance.
Unique formulations of pre-existing drugs are patentable. This, and the strong
potential synthetic copolymers possess for large scale manufacture, would aid
in drawing attention from the pharmaceutical industry towards otherwise unprof-
itable naturally occurring compounds which could aid in bringing such therapies
to the clinic.
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